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ABSTRACT 
The identification of the causative mutation(s) in individuals with familial cancer syndromes 
informs their clinical management and allows cascade testing of family members, which 
informs their clinical management in turn. The advent of next generation sequencing (NGS) 
has revolutionised diagnostic genetic analysis, demonstrated by this thesis. Three novel NGS 
assays have been developed.  
The first two assays allowed more comprehensive analysis of two genetically heterogeneous 
tumours, phaeochromocytoma/parganglioma and renal cell carcinoma, by creation of NGS-
based gene panel tests. These assays allowed increased detection of germline mutations at a 
lower cost per gene and reduced processing time compared to previous methods of analysis.  
The third assay also uses NGS but, instead, to more thoroughly analyse a single gene. The full 
gene region for VHL was examined at mosaic detection level, with a clinically actionable 
mutation identified in 18% of patients with von Hippel-Lindau disease in whom a mutation 
could not be identified by conventional analysis. 
The difficulty of providing more comprehensive genetic analysis is the concurrent increase in 
identification of variants of uncertain significance (VUSs). In depth variant analysis was 
conducted for all VUSs identified during this research. The reassignment of 17% of these 
VUSs as pathogenic or benign was enabled.  
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Chapter 1 Introduction 
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1.1 A brief introduction to medical genetics 
During the last two centuries, understanding of genetics has increased exponentially. From 
the insights of Gregor Mendel in the 1800s regarding the inheritance of traits in peas via the 
discovery of the DNA double helix by Watson and Crick in 1953, the field of genetics has 
exploded. In humans, genetics is now known to be instrumental in everything from eye 
colour (1) to cancer predisposition (2). Genetics plays a fundamental role in almost every 
discipline of medicine, clinical genetics is a speciality in its own right and the diagnostic 
genetics laboratory has become an important part of healthcare systems in developed 
countries around the world. Figure 1.1 demonstrates some of the landmarks in the study of 
genetics. 
 
Figure 1.1 Landmarks in genetics 
(Adapted from (3)). 
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Huge leaps forward in the understanding of genetics have often been driven by the advent 
of new techniques. In 1977 two methods for sequencing the DNA molecule were published 
(4;5). The Sanger sequencing method was adopted by the genetics community and is still at 
the heart of diagnostic laboratories’ work (6). By 1983 the polymerase chain reaction (PCR) 
method was published (7), and together with sequencing, it transformed the study of DNA 
and human genetic disease. PCR and Sanger sequencing on an industrial scale allowed the 
full sequence of the human genome to be published in 2001 (6). This huge collaborative 
research effort took 13 years and cost in excess $2.7 billion (6). The sequence was 
immediately an invaluable tool for the research and diagnostic genetic communities alike. In 
2005 genetics was revolutionised again with the commercial launch of the first next 
generation sequencing (NGS) platform (6). By the time of the commencement of this project 
in October 2010, enhancement in NGS platforms had resulted in the cost of sequencing a 
human genome having fallen to under $10, 000, with a time frame of weeks. Vast numbers 
of genotypes could be generated with comparative ease. Although whole genome or exome 
sequencing was not yet provided by diagnostic laboratories, NGS technology was starting to 
be employed in a more targeted manner.  
This introduction aims to describe NGS technology, as at the start of this project in 2010, 
and its role in the diagnostic setting. The application of diagnostic genetics and NGS to 
cancer will be introduced. This will be followed by a brief introduction to the interpretive 
challenges presented by the large amounts of data produced by NGS. 
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1.2 NGS platforms and library preparation methods 
At the commencement of this study in 2010, there were three companies providing NGS 
platforms that were widely commercially available, Roche, Illumina and Applied Biosystems 
(ABI) (see Table 1.1). All these platforms allowed massively parallel sequencing of clonally 
amplified DNA molecules that were spatially separated in a flow cell (8). 
Table 1.1 Comparison of 3 main NGS platforms 
(Adapted from (9)). 
Company Roche  Illumina ABI  
Platform GS-FLX 454 
Genome 
Sequencer 
Genome 
Analyzer 
SOLiD 
Sequencer 
Amplification method Emulsion PCR Bridge PCR Emulsion PCR 
Sequencing method Pyrosequencing Sequencing by 
synthesis 
Sequencing by 
ligation 
Read length (bp) ~400 ~75 ~50 
Run Time/ Throughput 
(maximum)  
10 hours/ 
600Mb 
7days/17Gb 7days/15Gb 
Raw Accuracy >99.5% >98.5% >99.9% 
Cost/Mb $84.40 $6 $5.80 
 
Additional sequencing platforms were available, albeit not widely purchased, or in 
development; some of which were reported to be able to sequence unamplified single 
molecules either synchronously or in real time (10). 
Both Illumina and Roche had also invested in smaller scale or ‘bench-top’ NGS technology, 
developing the MiSeq and GS Junior respectively. The NGS work performed in the course of 
this research was carried out on the Roche GS Junior (Chapter 3) and the Illumina MiSeq 
(Chapter 4). The technology behind these platforms is described in more detail below. 
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1.2.1 Roche GS Junior 
The Roche GS Junior used the same chemistry as the larger Roche GS-FLX but had a smaller 
output of 70, 000 – 100, 000 reads per run as opposed to >1 million, and a throughput of 
~35 Mb per run compared to ~400 Mb. The GS Junior technology worked in exactly the 
same way as the FLX. A library of template DNA was prepared with adapter oligonucleotides 
attached. The subsequent clonal amplification, pyrosequencing and image recording 
processes are summarised in Figure 1.2. The images recorded were analysed for signal-to-
noise ratio, filtered according to quality criteria, and subsequently algorithmically translated 
into a linear sequence output (8;11). 
In October 2010, the advantages of using the GS Junior NGS methodology compared to 
other platforms included longer read lengths and the short run time of only 10 hours (8). 
The main disadvantage was that the data obtained from homopolymer tracts greater than 4 
base pairs in length could be highly unreliable because the luminescence yield was not 
reliably proportional to the number of bases incorporated (8). 
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Figure 1.2 Schematic of the Roche NGS workflow 
a) Amplification is performed by emulsion PCR whereby single molecules and single beads 
are separated into individual aqueous microvesicles in an oil-aqueous emulsion. PCR allows 
clonal expansion of each single molecule, the emulsion is broken, template dissociated and 
DNA beads enriched (11); b) Sequencing uses a pyrosequencing based methodology. DNA-
amplified beads are loaded into individual PicoTiterPlate (PTP) wells with enzyme beads that 
are coupled with sulphurylase and luciferase. The PTP is loaded onto the GS Junior where it 
acts as a flow cell. Iterative pyrosequencing is performed by 200 successive flow additions of 
the 4 dNTPs. In this example, cytosine is shown flowing across the PTP wells. A nucleotide-
incorporation event allows pyrophosphate (PPi) release localised to individual PTP wells, 
which is converted to light photons by the enzyme beads, ATP and luciferin. The light is 
transmitted through the fibre-optic plate and recorded on a charge-coupled device camera. 
An image is recorded every time a dNTP is flowed across the PTP (11). (Adapted from (11)). 
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1.2.2 Illumina MiSeq 
Like the Roche GS Junior, the Illumina MiSeq used the same chemistry as its sister machine. 
Again the capacity was much smaller with a maximum of 1.5Gb of data produced per run 
compared to up to 200 Gb (8). The main difference was that advances in the technology 
meant that 151 bp runs were obtainable on the MiSeq before the chemistry was available 
on the Genome Analyser (later known as the HiSeq), which allowed easier contig assembly 
(8). The Illumina method required the preparation of a library using template DNA with 
adapter oligonucleotides attached. This was followed by bridge amplification, sequencing by 
synthesis and image recording, as shown in Figure 1.4. The images recorded and clusters 
were identified; then bases were called using signal intensity profiles translated into a linear 
sequence output with quality criteria (8;11). 
The main advantage of using the Illumina NGS methodology, compared to other platforms, 
was its higher output and lower reagent costs (8;12). The main disadvantage was the higher 
error rate and the shorter reads compared to the GS Junior (8;12). 
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Figure 1.3 Schematic of the Illumina NGS workflow 
a) Amplification is performed by bridge PCR, which is a type of solid phase amplification. 
This process comprises the binding of a single stranded template molecule to a primer 
immobilised on a flow cell, the extension of the template and its amplification by bridge PCR 
with further immobilised primers that are in close physical proximity. This creates clusters of 
identical molecules (11); b) Sequencing by synthesis uses a four-colour cyclic reversible 
termination method. In each sequencing cycle, all four dNTPs (A,C,G and T), which are 
fluorescently labelled, are washed over the flow cell. Each dNTP is blocked by a reversible 
chain terminator which means only a single dNTP can be added to a nucleotide chain in each 
cycle. An image is then captured and the chain terminator is enzymatically cleaved to allow 
incorporation of the next dNTP. The clusters are shown as single molecules in the image for 
illustrative purposes (11). (Adapted from (11)).   
a) 
b) 
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1.2.3 NGS target barcoding 
If running more than one individual DNA sample on an NGS platform, it is imperative to have 
a method to differentiate products. Molecular barcodes consist of short runs of 
oligonucleotides which are included between the target sequence and the platform specific 
adaptor (13;14). Each DNA is assigned a different barcode, which is incorporated either by 
ligation or during amplification. Once NGS is completed each read can be bioinformatically 
assigned to its DNA of origin using the barcode (13;14). 
 
1.2.4 NGS target enrichment methods 
If whole genome sequencing is not being performed a method of target enrichment must be 
carried out prior to sequencing. Since neither the Roche GS Junior, nor the Illumina MiSeq, 
have the capacity for whole genome sequencing, target enrichment is vital. 
Target enrichment can be largely divided into target hybridisation and target amplification 
methods. Target hybridisation works on the principle of using probes to capture the DNA 
fragments of interest from a total genomic DNA. It can be performed either in solution or on 
array and in 2010 commercial examples of this methodology included Agilent SureSelect 
and Nimblegen. Target amplification methods rely on polymerase chain reaction (PCR) and 
include simple PCR, long PCR and multiplex PCR. Automated versions of these methods are 
available and benefit from being much less labour intensive; examples in 2010 included 
RainDance and Fluidigm. Two different target amplification methods were used during this 
research. In Chapter 3 the Fluidigm Access Array was used for multiplex PCR and in Chapter 
4 long PCR and the Illumina Nextera XT kit were used. The theory behind these 
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methodologies has been described below. Due to the fast pace of development of all NGS 
related technology the version of the technology used for this research is described. 
1.2.4.1 Fluidigm 
The Fluidigm Access Array (AA) was used for target enrichment in Chapter 3. In 2010, the 
Fluidigm Access Array system allowed the concurrent amplification of 2, 304 PCR reactions 
(15). The automated system worked using microchannels and valves to create 
microreactors, which allowed mixing of each of the 48 patient DNAs with each of the 48 
primers sets in nanolitre reaction volumes (15). The system also allowed incorporation of 
adaptor sequences and molecular barcodes (see section 1.2.3) using a four primer ‘step-out’ 
PCR (see Figure 1.4), which could also be performed as two independent rounds of PCR if 
required. The samples and the primers could be different on every set-up. Advantages of 
this method included its low cost, the low starting concentration of DNA required and high 
uniformity between amplicons. The main disadvantage was the rigid format, all samples had 
to be amplified for the same 48 targets and arrays could only be used once which meant the 
best value for money could only be achieved with a full array, which was not always 
practical. 
11 
 
 
Figure 1.4 Schematic of the Fluidigm four primer system used to allow amplicon-based 
multi-patient NGS 
Stage 1 and 2: the target specific primers bind and amplify the region of interest. These 
primers are at a low concentration and run out at an early stage of the PCR; Stage 3 and 4: 
the barcode primers take over the PCR in a ‘step-out’ reaction. The barcode primers anneal 
to the universal tag sequences to allow amplification. The final PCR product consists of the 
Roche specific A and B sequences (red), the individual patient barcode twice (yellow), the 
CS1 and CS2 universal sequences (orange) and the target region (blue) including target 
specific primer sequence (green). 
 
1.2.4.2 Long PCR and Illumina Nextera XT 
Long PCR and Nextera XT were used for target enrichment in Chapter 4 of the project. Long 
PCR simply uses a DNA polymerase with both processivity and proof reading abilities to 
amplify larger regions of DNA. In this project the SequalPrep™ Long PCR Kit was used. The 
= Target specific primer comprising:
Target specific sequence
Universal tag sequences(CS1 sequence on forward primer and 
CS2 sequence on reverse primer)
= Barcode primer comprising:
Universal tag sequences (CS1 sequence on forward primer and 
CS2 sequence on reverse primer)
Barcode sequence (6 base pairs individual to each patient)
Roche specific sequences (A sequence on forward primer and B 
sequence on reverse primer)
STAGE 1
STAGE 2
STAGE 3
STAGE 4
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Illumina Nextera XT system allowed the processing of the long PCR products into barcoded 
fragmented molecules which included the required adaptor for sequencing on the MiSeq. 
First, a ‘tagmentation’ was performed, during which a sample was fragmented and tagged 
with adapters (16). The fragmentation used a proprietary enzyme named a transposome, 
which is a derivative of the Tn5 transposase with hyperactivity (17). It cut the DNA and then 
covalently tagged the 5’ end with the Illumina sequencing adapters, as shown in Figure 1.5 
(16). Sample indexes and the p5 and p7 sequences, which allowed binding to the flow cell, 
were then added by a 12 cycle PCR (16). Next, magnetic beads were used to select the DNA 
molecules at the optimum size of around 300 bp (16). Finally the concentration of the 
indexed libraries was normalised in order to make sure they were all equally represented 
(16). Following this the libraries could be pooled and sequenced (16). 
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Figure 1.5 Illumina Nextera XT process 
DNA is fragmented at an average of 300 bp intervals and tagged with sequencing adaptors 
(blue and green) using a ‘transposome’ in a process named tagmentation. A reduced cycle 
PCR uses tailed primers to bind to the common sequencing primer DNA sequences and add 
sample specific indexes (purple) with flow cell binding adapters/amplification primers 
(orange P5; red p7). (Adapted from (16)). 
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1.2.5  NGS in the diagnostic lab 
In 2010 , the field of diagnostic molecular genetics was dominated by low-scale targeted 
gene and/or mutation analysis (18). In a 2008 paper, ten Bosch and Grody wrote that 
‘eventually, the perceived clinical benefit of whole-genome sequencing will outweigh the 
cost of the procedure, allowing for these tests to be performed on a routine basis for 
diagnostic purposes’. In the meantime, small-scale NGS platforms and target enrichment 
allowed the implementation of the technology in the diagnostic setting. The main 
application in development was screening patients who have genetically heterogeneous 
conditions, such as non-syndromic hearing loss (19). In the short-term, other possible 
applications included pharmacogenetics, stratified treatment regimens via tumour analysis 
and metagenomics (9).  
1.2.5.1 Advantages and disadvantages of NGS in the diagnostic lab 
The use of NGS in diagnostics had, and continues to have, many advantages including the 
increased capacity and speed but decreased cost per base. This releases the potential for 
making use of all the information a patient’s genome has to provide. The development of 
more comprehensive screens for genetically heterogeneous conditions could, and indeed 
does, lead to assays with much greater analytical validity. Fundamentally, more people with 
a heterogeneous genetic disease will have a pathogenic mutation detected. However, there 
were also challenges and these challenges remain. Bioinformatic analysis and data storage 
present a problem but the main long-term stumbling block is that, along with the increased 
identification of pathogenic mutations, there will automatically be increased identification 
of variants of unknown significance (VUSs) (see section 1.4).  
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1.3 Genetic predisposition to cancer 
Cancer predisposition genes (CPGs) were defined in a 2014 review by Nazneen Rahman as 
‘those genes in which rare mutations confer high or moderate risks of cancer (greater than 
two-fold relative risks) and those for which at least 5% of individuals with the relevant 
mutations develop cancer’ (2). However the majority of CPGs far exceed these criteria for 
both risk and penetrance (2). In the same literature review, 114 CPGs were identified 
throughout the genome, using the above definition (2). 
1.3.1 Mutational mechanism 
CPGs can be subdivided based on the mechanism of action by which mutations within them 
are pathogenic, either by causing a gain-of-function or a loss-of-function. 
1.3.1.1 Gain of function mutations 
Gain of function mutations alter a gene product so that its protein has a novel or enhanced 
function compared to normal. These mutations occur in CPGs called proto-oncogenes when 
in their normal state and oncogenes once mutated. There are three basic mechanisms of 
activating a proto-oncogene to become an oncogene: 1) point mutation; 2) gene 
amplification; 3) chromosome rearrangement (20).  
A point mutation can cause activation of an oncogene when it resides within or near the 
gene and leads to increased activity or loss of regulation of the protein produced as a result 
of changes in the protein’s structure. An example of this is RET, a proto-oncogene that 
causes predisposition to multiple endocrine neoplasia type 2 (MEN2) / familial medullary 
thyroid cancer (FMTC) when specific amino acids are mutated (21). Mutations of these 
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particular amino acids results in constitutive activation of the RET protein, a receptor 
tyrosine kinase (21). This is the only mechanism of proto-oncogene activation which causes 
both inherited cancer due to mutations occurring in the germline and cancer as a result of 
somatic mutations. 
Gene amplification is a common mechanism for aberrant overexpression of a gene in a 
tumour. Amplified genes can be extra-chromosomal, forming structures called double 
minutes, or intra-chromosomal, forming homogeneously staining regions (22). An example 
is MYCN, which is commonly amplified in neuroblastomas (23). MYCN encodes a basic-helix–
loop–helix–zipper (bHLHZ) transcription factor that plays an important role in the regulation 
of gene expression associated with a range of cellular processes, including proliferation, 
growth, apoptosis, energy metabolism, and differentiation (23). Gene amplification occurs 
somatically. 
A chromosome rearrangement is an alteration in which a chromosome, or part of a 
chromosome, becomes attached to or interchanged with another chromosome or part of a 
chromosome. The best understood mechanism by which a translocation can activate a 
proto-oncogene is where a fusion gene is created that puts the control of the expression of 
the proto-oncogene under the control of another, often constitutively active, gene. The 
classic example of this is the Philadelphia chromosome, a translocation between the long 
arms of chromosomes 9 and 22, t(9:22)(q34;q11) (24). This translocation causes the fusion 
of the BCR gene with the ABL1 gene, which contains a tyrosine kinase domain, and leads to 
increased levels of tyrosine kinase activity within cells (24). The effects of this increased 
tyrosine kinase activity include a huge increase in myeloid cell numbers as the result of 
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increased proliferation or decreased apoptosis of a hematopoietic stem cell or progenitor 
cell and premature release of immature myeloid cells into the circulation (24). Alternatively, 
a chromosomal rearrangement can affect the expression of an oncogene by relocating it to 
a region of active chromatin. This occurs in Burkitt’s lymphoma, where the MYC gene is 
moved to an area of active gene expression, most commonly close to the IGH gene (25). 
1.3.1.2 Loss of function mutations 
In comparison, loss of function mutations occur in genes called tumour suppressor genes 
(TSGs). The mechanism of TSG pathogenesis was first postulated by Alfred Knudson, in an 
epidemiological study looking at unilateral and bilateral retinoblastoma patients, where he 
proposed that the two subsets were mechanistically linked (26). He suggested that, in the 
bilateral form, an inherited mutation provided the first ‘hit’ and the second ‘hit’ occurred 
somatically leading to both copies of the gene being inactivated (26). Whereas, in the 
sporadic unilateral form, both ‘hits’ occurred somatically (26). His theory, known as 
‘Knudson’s two hit hypothesis’, was demonstrated to be true once the RB1 gene was cloned 
in 1986 (27). Knudson’s two hit hypothesis explains why, while at a cellular level TSG 
mutations are recessive because they require inactivation of both copies of the gene for a 
phenotype to be observed, they have a dominant inheritance pattern, since anyone 
inheriting the mutation is at risk of disease (27). 
 
1.3.2 Identification and location of CPGs 
The majority of CPGs were discovered by genome-wide linkage analysis during the 1990s 
(2). The advent of next generation sequencing technology has led to additional CPGs being 
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identified via methodologies such as exome and genome sequencing (2), an example of 
which is the MAX gene (28). The remaining genes were identified by candidate strategies 
that, although occasionally successful, have been largely unfruitful (2). CPGs are located 
throughout the genome with little evidence of chromosomal clustering (see Figure 1.6). 
 
Figure 1.6 Chromosomal locations of cancer predisposition genes as of 2014 
Genes which lead to cancer via gain-of-function mutations are in red and those where 
cancer is caused by loss-of-function mutations in black. (Adapted from (2)). 
 
1.3.3 CPG inheritance patterns 
There is no set inheritance pattern for CPGs; of the 114 genes identified in Rahman’s review, 
65 showed an autosomal dominant inheritance pattern, 28 an autosomal recessive 
19 
 
inheritance pattern, 4 a X-linked inheritance pattern and 1 a Y-linked inheritance pattern (2). 
An additional 16 genes show both autosomal dominant and recessive inheritance, with a 
cancer phenotype noted in the case of both monoallelic and biallelic mutations (2). For eight 
of these genes the recessive disease is more severe than the dominant disease (2). For 
example, in BRCA2, monoallelic mutations cause increased risk of breast and ovarian cancer 
in adulthood, whereas biallelic mutations cause Fanconi anaemia (29). The identified CPGs 
were mainly tumour suppressor genes that require inactivation of both alleles for 
pathogenesis. However, haploinsufficiency and dominant-negative mechanisms also occur. 
Eleven of the identified CPGs were proto-oncogenes (2). 
 
1.3.4 CPG functions 
CPGs have a vast range of functions, many are expressed in all cells and perform essential 
functions in activities such as cell cycle regulation and DNA repair (2). However, mutations in 
genes involved in these very general functions can lead to highly specific cancer phenotypes 
(2). The reasons behind this have been puzzling scientists for decades (2). For example, the 
SDHB gene encodes a subunit of the succinate dehydrogenase complex which participates in 
both the citric acid cycle and the electron transport chain yet, despite the apparently 
universal role of the gene, the vast majority of patients with a germline loss of function 
mutation in this gene only get tumours of the paraganglia (30). In other cases, the normal 
function of genes relates closely to the cancer phenotype caused by the disruption of that 
function. For example, loss of function mutations in ABCB11 can lead to hepatocellular 
carcinoma. The gene is expressed in the hepatocyte canalicular membrane, where its 
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normal function is to export primary bile acids against high concentration gradients (31); 
loss of the normally functioning gene causes hepatic overload and liver cirrhosis, which in 
turn leads to an increased hepatocellular carcinoma risk (2). 
At present, it is estimated that CPG mutations are responsible for about 3% of cancers (2). It 
has been postulated that this is an underestimate, as there are still CPGs yet to be identified 
and not all CPG have been fully characterised with regard to the tumours they may cause 
(2). Whilst some cancers are caused by pathogenic mutations in a single gene, as is the case 
with retinoblastoma and RB1 (32), other tumours, such as phaeochromocytoma, can be 
caused by mutations in many different genes and not all genes may have been identified yet 
(33). A mutation in a CPG is found in approximately a third of patients with a 
phaeochromocytoma (33), whereas in patient with bilateral retinoblastoma, an RB1 
mutation is identified 95% of cases and the remaining 5% are thought likely to remain 
undetected due to low-level mosaicism (34).  
 
1.3.5 CPG non-cancer phenotypes 
Of the 114 CPGs reviewed by Rahman, over 75% cause clinical features in addition to cancer 
(2). These features are often very important in the clinical diagnosis of cancer predisposing 
syndromes since they are more readily distinguishable than the cancer alone (2). However, 
it is believed that fewer than the recognised 75% of CPGs actually cause additional clinical 
features and that the current overrepresentation is due to ascertainment bias, as families 
with additional features are more readily identifiable (2). The additional clinical features 
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caused by CPGs are diverse and include various skin manifestations, neurological features, 
skeletal features, dysmorphism and developmental delay (2). 
 
1.3.6 CPG cancer risks 
Whilst pathogenic mutations in CPGs increase an individual’s risk of getting cancer, the 
exact nature of the risk is highly complex with different mutations conferring different risks 
for different cancers (2). Pathogenic mutations in the BRCA2 gene provide a good example 
of this. An individual with a loss of function mutation in BRCA2 has a substantially increased 
risk of breast and ovarian cancer over their lifetime, but a much smaller increased risk of 
prostate and pancreatic cancer (35). Additionally different loss of function mutations within 
BRCA2 confer different risks, despite the majority of mutations causing a truncated protein 
which should lead to nonsense mediated decay of the RNA. Those mutations in the central 
part of the gene give a much higher risk of ovarian cancer as compared to breast cancer, as 
opposed to mutations in the rest of the gene (36). The reasons for this are not understood. 
 
1.3.7 Diagnostic CPG testing 
There are many benefits to performing diagnostic testing on patients who have developed 
cancer and identifying their pathogenic mutation(s), if present: 
1. Psychological benefit - The majority of patients find it useful to know why their 
cancer occurred (2);  
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2. Treatment decisions - In terms of management, identifying a mutation in a CPG can 
help decide if surgery to remove the cancer should be conservative or radical (2). It 
can also inform the type of therapy which may be instigated; indeed some therapies 
can be targeted to the specific CPG that is mutated. For example, BRCA1 or BRCA2 
mutation carriers particularly benefit from the use of Poly(ADP-ribose) polymerase 
(PARP) inhibitor treatment, which takes advantage of the fact that BRCA1 or BRCA2 
dysfunction in combination with the inhibition of the PARP enzyme leads to 
chromosomal instability, cell cycle arrest and subsequent apoptosis, because BRCA1 
and 2 and PARP are normally involved in two distinct DNA repair mechanisms (37); 
3. Utility of screening and risk reduction - If a patient is shown to have a CPG mutation 
the risk of a new primary and/or secondary cancer are often much increased and 
therefore rigorous screening or risk reducing surgery should be considered, where 
appropriate. For example, women with a BRCA1 or BRCA2 mutation who have breast 
cancer and have a bilateral mastectomy are less likely to die of breast cancer than 
those who only have a unilateral mastectomy of the breast which contains the 
cancer at diagnosis (38); 
4. Prognosis – Identification of the responsible CPG provides more accurate survival 
data. For example, a study in the Netherlands found that patients who met the 
diagnostic criteria for hereditary diffuse gastric cancer, and in whom a CDH1 gene 
mutation was identified, had a shorter survival time than those patients for whom a 
CDH1 mutation was not identified (39); 
5. Management of associated phenotypes – Identification of a CPG mutation may help 
manage the CPG related phenotypes that may occur in addition to the cancer. For 
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example, some WT1 mutations give rise to renal dysfunction which needs early 
intervention and monitoring (2); 
6. Predictive testing – Following identification of a CPG mutation in an affected 
individual, predictive testing can then be offered to at-risk family members (as 
discussed in the following section). 
 
1.3.8 Predictive CPG mutation testing in family members 
In addition to helping the affected individual themselves, the identification of a mutation(s) 
in a CPG allows dissemination of the knowledge of the genetic risk within the family and 
genetic analysis of at-risk family members, as appropriate, to determine if they are also 
carrying the pathogenic mutation(s). 
1. Positive predictive test - The identification of currently unaffected relatives who 
have the pathogenic change(s) mean that surveillance and preventative/risk-
reducing measures can be implemented as early as possible. The precise measures 
vary with the cancer. For the majority of cancers, surveillance involves imaging the 
organ or tissue at risk. However, biomarkers can also be used (2). For example 
functional paragangliomas and phaeochromocytomas produce catecholamines and 
the level of these in the blood can be monitored (2). Prevention involves removal of 
the tissue that is at risk, for example the thyroid for RET mutation carriers (40);  
2. Negative predictive test - It is equally important to identify family members who do 
not have the mutation, since the absence of the mutation greatly reduces the 
individual’s risk of getting cancer. Notably, however, this reduction is not always 
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thought to be back to the level of the general population. For example, in breast 
cancer families, studies have shown that mutation negative family members may still 
have a slightly increased risk compared to that of the general population (41).  
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1.4 Variants of unknown significance (VUSs) 
The application of genetics within the clinical context depends upon the identification of 
clearly pathogenic mutations. When a pathogenic mutation is found it can be very useful for 
both the management of the patient and the prevention or early detection of cancer in their 
family members. However, genetic analysis frequently results in the identification of 
variants of unknown significance (VUSs). This has been a well-recognised problem, for the 
diagnostic laboratory since the introduction of mutation scanning and continues to be a 
problem, even in genes which have been extensively examined already. This issue is 
discussed more comprehensively in Chapter 5. 
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Chapter 2 General Methods 
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The general methods described below were used as specified unless described otherwise 
within individual chapters. In addition, it should be noted that procedures which ultimately 
led to reporting patient results included appropriate procedures to comply with Clinical 
Pathology Accreditation (CPA) laboratory standards. 
 
2.1 Nucleic Acid Extraction 
2.1.1 DNA extraction from blood 
DNA extraction was generously performed by colleagues at the West Midlands Regional 
Genetics Laboratory (WMRGL). DNA was extracted from lymphocytes using the Gentra 
Puregene Blood Kit (Qiagen) according to the manufacturer‘s instructions. Extracted DNA 
was then quantified using a Nanodrop ND-1000 Spectrophotometer (Thermo Scientific). 
Some DNAs extracted from blood were received from other Regional Genetics Laboratories, 
where alternative DNA extraction methods were used. 
 
2.1.2 RNA extraction from blood 
RNA extraction also was generously performed by colleagues at the West Midlands Regional 
Genetics Laboratory (WMRGL). Extraction of RNA from whole blood samples was performed 
using the RNeasy Mini Kit (Qiagen). The process involves two stages, in the first stage 
erythrocytes are lysed and the leucocytes pelleted, then the pelleted leucocytes are lysed 
with guanidium-isothiocyanate and homogenized. In the second stage ethanol is added to 
the lysate to semi-precipitate the nucleic acids present and provide ideal binding conditions. 
28 
 
The lysate is then loaded onto the RNeasy silica membrane, to which RNA binds, and 
contaminants are efficiently washed through, finally the RNA is eluted in water. The kit was 
used as per the manufacturer’s instructions. 
 
2.1.3 DNA extraction from formalin fixed paraffin embedded (FFPE) tumour 
tissue 
DNA extraction from FFPE tumour tissue was again generously performed by colleagues the 
West Midlands Regional Genetics Laboratory (WMRGL). Material was received either as 
scrolls or mounted on slides, with or without a matched haematoxylin and eosin (H&E) 
stained slide with the tumour marked out.  
If mounted slides were received, slides were heated in an oven at 63 oC for 20 minutes. Each 
slide was washed in xylene (Sigma), then 100% ethanol (Sigma) and then ddH2O. The FFPE 
tissue was then removed to a 2 ml tube containing 150 µl ATL (Qiagen) and 30 µl proteinase 
K (Qiagen). If a marked H&E slide was available this was used to enable macro-dissection of 
the tumour tissue. 
If scrolls were received, they were placed in a 2 ml tube. 1 ml of xylene (Sigma) was added, 
the tube vortexed and centrifuged at 13, 000 rpm for 2 minutes, and the liquid removed 
from the pellet. Then 1 ml of 100% ethanol (Sigma) was added, the tube vortexed and 
centrifuged at 13, 000 rpm for 5 minutes, and the liquid removed from the pellet. The 
pellets were then left to air dry. 150 µl ATL (Qiagen) and 30 µl proteinase K (Qiagen) was 
added to each pellet and the sample left at 56 oC until it was fully digested. 
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After this point the rest of the extraction protocol was performed using the QIAcube 
(Qiagen), according to the manufacturer’s instructions using the DNA FFPE tissue protocol. 
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2.2 cDNA synthesis 
The cDNA was prepared from total RNA using the High Capacity cDNA Reverse Transcription 
kit (Applied Biosystems). The kit uses the Moloney murine leukaemia virus (MMLV) reverse 
transcriptase enzyme (branded as MultiScribe™) and random hexamer primers. The kit was 
used as per the manufacturer’s instructions. In brief, a master mix of the required reagents 
was made up, as per Table 2.1, for the required number of samples and water controls. The 
master mix was divided into 0.5 µl tubes (17 µl/tube) and 17 µl of RNA added. The tubes 
were then placed on a Tetrad PTC-225 Thermo Cycler (MJ Research) and underwent the 
thermal cycling profile given in Table 2.2. Finally the amount of cDNA was measured with a 
NanoDrop spectrophotometer (Thermo Scientific) and diluted to a working concentration of 
200 ng/µl with nuclease free water. 
Table 2.1 High Capacity cDNA Reverse Transcription kit master mix reagents and volumes 
Component Volume per reaction (µl) 
10x RT Buffer (Applied Biosystems) 3.4 
25x dNTP Mix (100 mM; Applied Biosystems) 1.36 
10x RT Random Primers (Applied Biosystems) 3.4 
MultiScribe™ Reverse Transcriptase (Applied Biosystems) 1.7 
RNase Inhibitor (Applied Biosystems) 1.7 
Nuclease free water (Applied Biosystems) 5.44 
TOTAL 17 
 
Table 2.2 Thermal cycling conditions for High Capacity cDNA Reverse Transcription kit 
Step Temperature Time 
1 25 oC 10 minutes 
2 37 oC 120 minutes 
3 85 oC 5 seconds 
4 4oC ∞ 
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2.3 Polymerase Chain Reaction (PCR) 
PCR was used to amplify targeted regions of DNA. Primers were designed using Primer3 (42) 
and tagged with a common sequence called M13 in order to allow efficient Sanger 
sequencing. The M13 forward sequence is TGTAAAACGACGGCCAGT and the reverse 
sequence is CAGGAAACAGCTATGACC. The PCR reaction was made up, as described in Table 
2.3. A negative control was run with all PCRs to exclude DNA contamination, in which ddH20 
replaced the DNA. The same ddH20 was used for any dilutions required during the 
procedure. The thermal cycling conditions were as shown in Table 2.4. A touchdown profile 
was used to allow multiple reactions with primer pairs of different annealing temperature to 
be run on the same thermal cycler. Thermal cycling was performed on a Tetrad PTC-225 
Thermo Cycler (MJ Research). 
Table 2.3 Generic PCR reaction master mix and volumes 
Component Volume per reaction (µl) 
Megamix-W (Microzone) 22 
Forward primer (20 nM; Sigma) 1 
Reverse primer (20 nM; Sigma) 1 
DNA (20 ng/µl) 1 
TOTAL 25 
 
Table 2.4 Thermal cycling conditions for generic PCR using a touch down profile 
Step Temperature Time Cycles 
1 (Initial denaturation) 95 oC 5 minutes 1 
2 (Denaturation) 95 oC 1 minute 10 
3 (Primer annealing) 65 oC (-1 oC each cycle) 1 minute 
4 (Extension) 72 oC 1 minute 
5 (Denaturation) 95 oC 1 minute 20 
6 (Primer annealing) 55 oC 1 minute 
7 (Extension) 72 oC 1 minute 
8 (Final extension) 72 oC 10 minutes 1 
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2.4 Agarose gel electrophoresis 
Amplified PCR products were resolved on a 1.5% (w/v) agarose gel. The gel was made by 
dissolving 3 g of agarose (Sigma) in 200 ml of 1 x TBE buffer (89 mM Tris, 89 mM Boric Acid; 
2 mM EDTA; pH8.3; Severn Biotechnology) by heating in a microwave at 400 W until fully 
dissolved. Once cooled 10 ng/ml ethidium bromide was added. Gels were cast in a 20 cm x 
30 cm tray, 4 combs added and left to set. Gel electrophoresis was carried out in a 
horizontal tank containing 1 x TBE buffer. 5ul of PCR product was mixed with 5ul of 2x 
loading buffer (10 mg Orange G (Sigma), 1.5 ml Glycerol (Sigma) with ddH2O added to a final 
volume of 25 ml) and run on the gel at 100 V for approximately 30 minutes. This allowed 
successfully amplified DNA products to be distinguished from those which had failed or 
where no specific amplification had occurred. 
 
2.5 Sanger sequencing 
The Sanger sequencing process was either performed manually by the author or by staff at 
the WMRGL using a robotically automated protocol. The methods used when the process 
was performed manually are described below. 
2.5.1 PCR clean-up for Sanger sequencing 
Successfully amplified PCR products underwent a PCR clean-up protocol during which a 
reaction was made up as per Table 2.5 and the enzymes activated and deactivated as per 
Table 2.6.  
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Table 2.5 PCR clean-up reaction master mix and volumes 
Component Volume per reaction (µl) 
Antarctic Phosphatase Buffer (10 x; New England 
Biolabs) 
1 
Antarctic Phosphatase (New England Biolabs) 1 
Exonuclease I (New England Biolabs) 0.25 
PCR product 6 
ddH2O 1.75 
TOTAL 10 
 
Table 2.6 Thermal profile for PCR clean-up reaction 
Step Temperature Time 
1  37 oC 30 minutes 
2  80 oC 20 minutes 
 
2.5.2 Sequencing 
Cleaned PCR reactions were Sanger sequenced. Each PCR product was sequenced in both 
the forward and reverse directions. The reaction master mix is shown in Table 2.7 and the 
thermal profile required in Table 2.8. 
Table 2.7 Sequencing reaction master mix and volumes 
Component Volume per reaction (µl) 
BigDye® buffer (5 x; Applied Biosystems) 2 
Big Dye® v3.1 (Applied Biosystems) 0.5 
M13 forward or reverse primer (20 µM; Sigma) 1 
PCR product 4 
ddH2O 2.5 
TOTAL 10 
 
Table 2.8 Thermal profile for sequencing reaction 
Step Temperature Time Cycles 
1 (Initial denaturation) 95 oC 5 minutes 1 
2 (Denaturation) 96 oC 30 seconds 30 
3 (Primer annealing) 50 oC 30 seconds 
4 (Extension) 60 oC 4 minutes 
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2.5.3 Sequencing clean-up  
An ethanol precipitation method was used to remove impurities from the reaction. The DNA 
was precipitated by addition of 1 μl of 250 mM EDTA (Sigma) and 35 μl of 100% ethanol 
(Sigma). Samples were centrifuged at 2500 rpm for 30 minutes at 4 oC to pellet the 
precipitated DNA, then ethanol removed by tapping samples upside down; the residual 
ethanol was removed by centrifuging plates upside down on filter paper at 400 rpm for 1 
minute. The DNA pellet was washed with 200 μl of 70% (v/v) ethanol and centrifuged at 
2500 rpm for 20 minutes at 4 oC to repellet the DNA. The ethanol was removed as previously 
and the pellet left to dry for 1 hour at room temperature. The DNA was mixed with 10 μl of 
HiDi™ formamide (Applied Biosystems), then denatured at 95 oC for 5 minutes, and then 
cooled on ice for 2 minutes. 
 
2.5.4 Sequence data collection 
Samples were then loaded onto an ABI 3730 capillary sequencer (Applied Biosystems). 
 
2.5.5 Sequence data analysis 
Data was analysed using Mutation Surveyor (SoftGenetics), against an appropriate gene 
specific reference file (GenBank file) downloaded from NCBI. Mutation Surveyor aids 
sequence analysis by comparing of the inputted electropherogram with the reference file 
and identifying discrepancies. 
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Chapter 3 Development of novel next 
generation sequencing (NGS) strategies for 
improved genetic diagnosis of inherited 
cancer predisposition diseases 
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Some of the work in this chapter has been reported in literature in the paper shown in 
section 9.1.  
3.1 Introduction 
As described in the introductory chapter, knowledge of cancer genetics has greatly 
advanced in the last 50 years. Many genes have been identified which cause predisposition 
to the development of a variety of tumours (2). Two examples of tumours that can be 
attributed to a genetic predisposition are phaeochromocytoma/paraganglioma and renal 
cell carcinoma (RCC; also known as kidney cancer). These tumour types are described 
below. 
 
3.1.1 Phaeochromocytoma (PHEO) / Paraganglioma (PGL) / Head and neck 
paraganglioma (HNPGL) 
A paraganglion is a group of cells derived from the neural crest. During differentiation 
paraganglia either become sympathetic and secrete catecholamines or parasympathetic and 
non-secretory. The term catecholamine describes a variety of naturally occurring amines 
that function as neurotransmitters and hormones within the human body. They are 
enzymatically synthesized from the amino acid l-tyrosine in the following sequence: 
tyrosine; dopa; dopamine; noradrenaline (norepinephrine); adrenaline (epinephrine). The 
majority of sympathetic paraganglia are located in the adrenal medulla, on top of the 
kidneys (43). Some sympathetic paraganglia also occur in the prevertebral and paravertebral 
sympathetic chains of the trunk and in the connective tissue within or near pelvic organs 
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(43). Parasympathetic paraganglia are almost always located in the head and neck, and 
located close to major arteries and nerves (43). 
Paragangliomas are tumours of the paraganglia. Paragangliomas can originate in either 
parasympathetic or sympathetic paraganglia. The ‘IARC WHO Classification of Tumours’ 
defines a phaeochromocytoma (PHEO) as a functional (catecholamine secreting) 
paraganglioma derived from the adrenal medulla (44). However it should be noted that 
previously some authors used the term extra-adrenal phaeochromocytoma 
(pheochromocytoma) to describe a functional paraganglioma, henceforth referred to as 
PGL, arising outside the adrenal medulla (33). Sympathetic paraganglia-derived tumours 
(PHEO and PGL) almost always hypersecrete catecholamines, compared to only about 5% of 
parasympathetic PGLs (43). Those PGLs that do not secrete catecholamines are described as 
non-functional. Tumours derived from parasympathetic ganglia are referred to as head and 
neck paragangliomas (HNPGL) and, because they are overwhelmingly non-functional, their 
clinical presentation differs from that of PGL and PHEO.  
Patients with PGL and PHEO (i.e. functional tumours) may present with headache, 
palpitations, sweating, nausea, flushing, weight loss, tiredness, hypertension, pallor, anxiety 
and/or panic attacks, with these symptoms often occurring paroxysmally (45). The majority 
of these symptoms are the result of the catecholamine production, with the paroxysmal 
nature of the symptoms related to episodic secretion of catecholamines by the tumour (45). 
By contrast, patients with non-functional tumours present with symptoms simply relating to 
the physical mass of the tumour compressing adjacent tissues and nerves (43). 
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PHEO/PGL/HNPGL have an estimated incidence of 1/300, 000 (43). The peak prevalence 
occurs at 40 years of age, with no evident gender bias (43). The majority of these tumours 
are benign but approximately 10% of PHEOs and 15-35% of PGLs are malignant (46). The 
majority of PHEOs present singly and if the tumour is going to metastasise this will normally 
occur within the first two years; however, metastasis can occur up to 40 years after the 
initial diagnosis (46). Patients with malignant PHEOs have a very poor prognosis, but it is 
very difficult to predict the malignant potential of a tumour when it is diagnosed (46). One 
study found a germline mutation in the SDHB gene to be present in 71.9% of paediatric 
patients with malignant tumours; in these patients the initial tumour was normally a 
functional PGL (47).  
An inherited predisposition for PHEO/PGL/HNPGL can be caused by a pathogenic mutation 
in a number of different genes. At the commencement of this study, in 2012, a review of the 
genes associated with PHEO/PGL/HNPGL predisposition was performed (see section 
3.4.1.1). 
 
3.1.2 Renal cell carcinoma (RCC, also known as kidney cancer) 
RCC was diagnosed in almost 340, 000 new patients in 2012, making it the 9th most 
common cancer worldwide (48). It mainly occurs in patients in their 60s and 70s, with 
double the number of males affected compared to females (49). There is a variable 
incidence of RCC throughout the world and the highest incidence is in developed countries 
(48). Over recent years there has been a rise in the frequency of RCC, this is thought to be 
only partially accounted for by improved screening and therefore partly to be the result of 
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an actual increase in disease (49). A small proportion (3-4%) of RCC is caused by an inherited 
susceptibility to disease, often in the context of a syndrome with other features (50). In 
comparison to sporadic cases, inherited RCC has an earlier age of diagnosis and is frequently 
bilateral and/or multicentric (49). There are a number of classes of RCC, as described in 
section 3.1.2.1. At the commencement of this study, in 2012, a review of the genes 
associated with RCC predisposition was performed (see section 3.4.1.2).  
3.1.2.1 RCC classification 
The main histopathological classes of RCC are listed below. Figure 3.1 provides examples of 
the typical histological findings. 
3.1.2.1.1 Clear cell RCC (ccRCC) 
ccRCC accounts for the vast majority of RCC cases, around 75% of tumours being of this type 
(49). When examined histologically, these tumours have clusters of cells with a clear 
cytoplasm, which results from the lipids in the cytoplasm dissolving during processing, and 
they are surrounded by a dense endothelial network (48). 
3.1.2.1.2 Papillary RCC (pRCC) 
pRCC makes up 10% of RCC cases (51). Histologically, these tumours have a papillary 
architecture, with basophilic cytoplasm and foamy histiocytes (48). There are two types of 
papillary tumour, referred to as Type I and Type II. Type I are small cell tumours, where the 
papillae are covered by small cells with little cytoplasm (51). Type II are higher grade with 
eosinophilic cytoplasm (51). 
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3.1.2.1.3 Chromophobe RCC (chRCC) 
chRCC account for 5% of renal tumours and have the lowest risk of metastasis (51). 
Histologically, they have a large empty cytoplasm and perinuclear clearing (48). As 
compared to ccRCC the blood vessels are thick walled and eccentrically hyalinised (51). 
3.1.2.1.4 Rare tumours 
In addition, there are other, rare tumours that originate from the nephron and collecting 
duct. These are highly distinct from RCCs (48). 
3.1.2.1.5 Oncocytoma (OC) 
Oncocytomas have low malignant potential but are histologically similar to chromophobe 
RCC, which can complicate their diagnosis (48). 
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Figure 3.1 Examples of the typical histological findings in RCC: a) ccRCC; b) pRCC; c) chRCC; 
d) OC.  
(Adapted from (51)). 
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3.1.3 Diagnostic genetic testing for PHEO/PGL/HNPGL and RCC 
predisposition  
The importance of achieving a genetic diagnosis of an inherited cancer predisposition 
disease for both the proband and their extended family is discussed in the introductory 
chapter.  
In 2012, when this study was conceived the vast majority of centres were offering testing of 
individual genes based on clinical request, with the lymphocyte DNA from an affected 
patient potentially undergoing multiple rounds of single gene analysis until the mutation 
was found or the cost became prohibitive. Clinicians used phenotype information combined 
with the prevalence of mutations within a gene to inform their strategy. 
To take inherited PHEO/PGL/HNPGL as an example, it was proposed by a number of papers 
that all patients should be offered genetic testing despite only about a third of patients with 
a detectable mutation also having a positive family history (52;53). However, as the number 
of known causative genes increased, most centres adopted a targeted testing strategy to 
reduce costs (33;54;55). For example, it was recommended that testing for mutations in 
RET, SDHB, SDHD and VHL, was restricted to patients with one or more of the following: 
family history of PHEO/PGL/HNPGL, age <45 years, multiple tumours, extra-adrenal location 
and previous HNPGL (54). Algorithms were published for the order in which to test these 
genes to provide the lowest cost route to genetic diagnosis (see Figure 3.2) (54). Though 
such targeted testing strategies have a high mutation detection rate (% of tests that detect a 
mutation), a significant fraction of mutation positive individuals remain undetected (56).  
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Figure 3.2 Genetic testing algorithm for apparently non-syndromic PHEO/PGL/HNPGL 
cases 
(Adapted from (54)). 
The priority for genes to be analysed for patients with RCC was more easily determined as 
the tumour subtype combined with other phenotype information made gene selection a 
more straightforward process. However there were still individuals for whom the most likely 
causative gene was not the one containing the pathogenic mutation. 
As discussed in Chapter One, the advent of massively parallel next generation sequencing 
(NGS) technologies has provided opportunities to radically alter strategies for diagnostic 
genetic testing. Compared to conventional Sanger sequencing, NGS provides increased 
capacity and speed at a significantly reduced cost (57). The use of molecular identifiers 
(“barcodes”) allows multiplexing of samples, increasing throughput and efficiency (58;59). 
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Therefore the hypothesis explored in this chapter was that NGS could facilitate a transition 
from targeted, sequential analysis of individual PHEO/PGL/HNPGL or RCC genes in selected 
high risk individuals to a strategy of simultaneously testing multiple predisposition genes in 
all at-risk individuals. The technology available to test this hypothesis was the Fluidigm 
Access Array (AA) and the Roche GS Junior. 
 
3.2 Aims 
The aims of the research reported in this chapter of the thesis were to: 
1. Perform a literature review to identify the genes known to cause inherited 
PHEO/PGL/HNPGL and RCC; 
2. Design and optimise the strategy selected to analyse the identified genes; 
3. Validate the novel PHEO/PGL/HNPGL gene panel testing strategy; 
4. Validate the novel RCC gene panel testing strategy; 
5. Use the novel NGS assays for prospective patient testing. 
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3.3 Materials and methods 
3.3.1 Literature review 
A review of the literature was performed in January 2012 to identify all genes known to 
cause a) PHEO/PGL/HNPGL and b) RCC. A combination of the word ‘gene’ plus 1) 
‘paraganglioma’, 2) ‘phaeochromocytoma’, 3) ‘pheochromocytoma’, 4) ‘renal cell cancer’, 5) 
‘renal cell carcinoma’ and 6) ‘kidney cancer’ were entered in the NCBI PubMed database 
search engine. All returns were examined for novel genes reported to be causing inherited 
disease and each gene reviewed. In addition two recent review articles were examined:      
a) Jafri M, Maher ER (2012) The genetics of phaeochromocytoma: using clinical features to 
guide genetic testing. Eur. J. Endocrinol. 166(2):151-8 (33);                                                            
b) Verine J, Pluvinage A, Bousquet G, Lehmann-Che J, de Bazelaire C, Soufir N, Mongiat-
Artus P. (2010) Hereditary renal cancer syndromes: an update of a systematic review. Eur. 
Urol. 58(5):701-10 (60). 
 
3.3.2 Subjects 
This study was formed of three main phases: 1) optimisation; 2) validation and 3) 
prospective analysis.  
In the first and second phases, DNA samples which contained variants previously identified 
by Sanger sequencing were studied. For the PHEO/PGL/HNPGL panel, 85 DNA samples 
containing known variant calls were run. Of the 182 variants which were analysed, 84 were 
unique. They comprised 59 single base substitutions, 14 deletions, 6 duplications, 3 
insertions and 2 indels. For the RCC panel, 42 DNA samples containing known variant calls 
46 
 
were run. There were 106 variants analysed of which 45 were unique. The unique variants 
comprised 31 substitutions, 9 deletions, 4 duplications and 1 insertion.  
In the third phase, 239 DNA samples were analysed prospectively. For the 
PHEO/PGL/HNPGL panel, 120 DNA samples for patients referred with PHEO/PGL/HNPGL 
were prospectively tested. Of these patients, 42 (35%) had previously had 1 or more genes 
on the panel tested by Sanger sequencing and either no variants identified or a variant of 
uncertain significance (VUS). The remainder had not undergone any previous genetic 
analysis. For the RCC panel, 119 DNA samples from patients with RCC were tested 
prospectively. Of these patients, 19% had had one or more genes analysed previously by 
Sanger sequencing and analysis of the additional genes on the panel was requested. These 
patients were referred from genetic centres around the United Kingdom. 
 
3.3.3 Assay design 
The technology to be used during this phase of the research was determined by what was 
locally available. For amplicon-based target enrichment, the 48.48 Access Array (AA) system 
(Fluidigm Corporation) was used. The available NGS sequencer was the GS Junior (Roche 
454 Life Sciences), which is a 454 pyrosequencing-based technology (61). 
3.3.3.1 PHEO/PGL/HNPGL panel 
The assay included 9 genes identified to be associated with inherited predisposition to 
PHEO/PGL/HNPGL following the literature review (section 3.4.1):  
 MAX (NM_002382.3),  
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 RET (NM_020975.4),  
 SDHA (NM_004168.2),  
 SDHAF2 (NM_017841.2),  
 SDHB (NM_003000.2),  
 SDHC (NM_003001.3),  
 SDHD (NM_003002.2),  
 TMEM127 (NM_017849.3) and  
 VHL (NM_000551.3).  
Primer pairs were designed using Primer3 (62) to amplify the full coding sequence of all 
genes, except for the RET gene for which only exons 10, 11 and 13-16 were included. 
Amplicons were designed following Fluidigm AA recommendations, amplicon sizes were 
within a 150 bp range (310-460 bp), melting temperatures were within a 2 oC range (59-
61 oC) and primers had no more than 3 of the same base in a run, whenever possible. To 
avoid amplification of SDHA pseudogenes, primers were designed so that the 3’ 
nucleotide of at least one but preferably both primers was specific to SDHA. The primer 
sequences are provided in Appendix Table 7.1. 
3.3.3.2 RCC panel 
The assay included 5 genes identified to be associated with inherited predisposition to RCC 
following the literature review (section 3.4.1):  
 FLCN (NM_144997.5),  
 FH (NM_000143.3),  
 MET (NM_000245.2),  
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 SDHB (NM_003000.2) and  
 VHL (NM_000551.3).  
Primer pairs were designed using Primer3 (62), again as per the Fluidigm specifications. 
Amplicon sizes ranged from 338-451 bp, had a melting temperature of 59-61 oC and 
primers had no more than 3 of the same base in a run, whenever possible. The primer 
sequences are provided in Appendix Table 7.1. 
 
3.3.4 Target enrichment and multiplexed next generation sequencing (NGS) 
Genomic DNA was amplified using the 48.48 AA system, which facilitates the simultaneous 
amplification of at least 48 targets for up to 48 patient DNA samples. Patient specific 
barcodes and the 454 sequencing adaptors were added during a second round of PCR. All 
processes were performed according to the manufacturer’s protocol ‘Multiplex Amplicon 
Tagging for 454 Titanium Sequencing on the 48.48 Access Array IFC’. The patient samples 
were then pooled in equal volumes prior to NGS on the GS Junior. Emulsion PCR, bead 
enrichment and pyrosequencing were carried out as per the manufacturer’s instructions. 
For the PHEO/PGL/HNPGL panel, the Lib-A kit with 0.5:1 molecule to bead ratio was used 
following optimisation and for the RCC panel the Lib-A kit with 1:1 molecule to bead ratio 
was used following optimisation. 
All optimisation and validation runs and some diagnostic runs were performed by the 
author. Some diagnostic runs were performed by Anna Yeung and Lindsey Vialard on behalf 
of the WMRGL. 
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3.3.5 NGS data analysis 
Data analysis was performed using NextGENe v2.16 sequence analysis software 
(SoftGenetics, State College, PA, USA) and a semi-automated in-house bioinformatics 
pipeline. Poor quality reads were removed, samples were demultiplexed and reads mapped 
against gene-specific GenBank reference files. Variants were then filtered step-wise, so 
variants were only considered when: 
 Within the coding sequence ± 5 base pairs; 
 In >15% of >15 total reads for the base being interrogated. Regions below 30-fold 
coverage were analysed by Sanger sequencing. The lower filtering parameter allow 
identification of likely variants; 
 Not a known benign polymorphism; 
 A defined threshold was exceeded (for insertion and deletion variants only): 
o Analysis of indels was performed using NextGENe variant comparison tool 
(VCT) and the in house pipeline, as a result of the issues surrounding 
homopolymer tract calls with the 454 chemistry. An indel variant was only 
included when it was not within 2 standard deviations of the mean 
percentage call for that variant for all patients in that run.  
 
3.3.6 Sanger sequencing 
PCR of exons requiring further analysis was followed by bidirectional Sanger sequencing 
using the ABI BigDye® v3.1 Terminator Cycle Kit (Applied Biosystems) and then analysed 
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using an ABI Prism 3730 (Applied Biosystems) and the Mutation Surveyor (SoftGenetics) 
program. See Chapter 2 for additional details. 
 
3.3.7 Multiplex ligation-dependent probe amplification 
The MLPA probemixes SALSA P256 FLCN, SALSA P226 SDH and SALSA P016 VHL (MRC 
Holland) were used for dosage analysis, as per the manufacturer’s instructions, and the data 
analysed using GeneMarker v1.70 (SoftGenetics) program. 
 
3.3.8 Variant assessment 
Variant pathogenicity assessment was performed as per best practice guidelines (63). The 
majority of the assessment used Alamut as an interface (Interactive Biosoftware) and 
involved a) interrogation of locus specific databases, the Human Gene Mutation Database 
and in house databases, b) literature review, c) search of dbSNP, NHLBI Exome Sequencing 
Project Exome Variant Server and 1000 genomes project databases, d) species conservation 
and e) in silico prediction for the impact of missense and splicing variants, as appropriate.  
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3.4 Results 
3.4.1 Literature review  
3.4.1.1 Genes known to cause an inherited predisposition to 
PHEO/PGL/HNPGL (January 2012) 
In January 2012, there were 12 genes known to be associated with PHEO/PGL/HNPGL. This 
section provides basic details of these genes in terms of PHEO/PGL/HNPGL susceptibility. 
3.4.1.1.1 The EGLN1 gene 
Germline mutations in EGLN1 have been associated with congenital erthyrocytosis (64). In 
2008, a single case of a patient with erthyrocytosis and a recurrent abdominal PGL was 
reported (65). Upon sequencing EGLN1 the patient was found to have a sequence variant; 
c.1121A>G (p.His374Arg), which was postulated to be causative as it showed loss of 
heterozygosity (LOH) in tumour studies, and functional assays showed it to affect EGLN1 and 
stabilise HIF-α proteins (65). However, there have been no subsequent reports of mutations 
in EGLN1 being associated with PHEO/PGL/HNPGL. Astuti et. al. carried out sequencing of 
the three 2-oxoglutarate-dependent prolylhydroxylase enzymes, including EGLN1, in 82 
patients with inherited PHEO/PGL/HNPGL and did not find any mutations (64). This suggests 
that mutations in these genes are not a common cause of inherited PHEO/PGL/HNPGL. 
3.4.1.1.2 The KIF1B gene 
In 2008, Schlisio et. al. reported missense mutations in KIF1B in 2 patients with PHEO (66). 
However, since then no additional reports of mutations in this gene have been published. It 
is therefore unclear if this is a true PHEO susceptibility gene. Zhao et. al. reported a family 
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with a loss of function missense mutation in KIF1B causing Charcot-Marie-Tooth type 2A1 
(67). 
3.4.1.1.3 The MAX gene 
In 2011, Comino-Méndez et. al. identified 3 pathogenic mutations in MAX during exome 
sequencing of individuals with inherited PHEO (68). The same study then looked for 
mutations in MAX in 59 additional patients and identified another 5 mutations (68). Analysis 
of mutation positive tumours identified acquired isodisomy for the MAX gene (68). MAX is 
part of the MYC-MAX-MXD1 network of transcription factors (68). 
3.4.1.1.4 The NF1 gene 
The NF1 gene is a tumour suppressor gene (TSG). Its most well characterised function is as a 
GTPase that inactivates RAS which in turn inhibits the MAPK signalling cascade (69). 
Heterozygous mutations in the NF1 gene cause autosomal dominant neurofibromatosis type 
1 (NF1), which is a characterised by pigmentary abnormalities and the neoplastic growth of 
neural crest-derived cells (70). PHEOs are observed in 0.1-5.7% of patients with NF1, always 
in conjunction with other symptoms (70). Bauch et. al. could not establish a correlation 
between a specific NF1 genotype and PHEO, although they did note that patients with PHEO 
were more likely to have a mutation in the cysteine rich domain of the protein (70). 
3.4.1.1.5 The RET gene 
The RET gene is a proto-oncogene which acts as a receptor tyrosine kinase. Ligand binding 
induces dimerisation of the RET protein which leads to activation of multiple signal 
transduction cascades (71). The RET gene shows phenotypic heterogeneity, causing two 
clinically distinct diseases, multiple endocrine neoplasia type 2 (MEN2)/familial medullary 
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thyroid cancer (FMTC) and Hirschsprung disease. In Hirschsprung disease there is congenital 
absence of the enteric neurons in the gastrointestinal tract, whereas MEN2 comprises 
diseases of the endocrine system. MEN2/FMTC can be subdivided in to 3 types (see Table 
3.1). PHEO is observed in two of those types, and is often the presenting symptom. 
Hirschsprung disease is caused by inactivating mutations which are spread throughout the 
gene, whereas MEN2/FMTC is caused by activating mutations, which have only been 
observed in exons 10, 11, 13, 14 and 16 (listed in Table 3.1). Therefore, mutation screening 
can be limited to specific codons or exons for MEN2 (21). 
Table 3.1 Classes of MEN2 
(Adapted from (21)). 
Type of MEN2 Symptoms Associated mutations 
Familial 
medullary 
thyroid cancer 
(FMTC) 
medullary thyroid cancer only - 
onset in middle age 
R321G, G533C, R600Q, K603E, 
Y606C, C609R/G/S/Y, 
C611R/G/F/S/W/Y, C618R/G/F/S/Y, 
C620R/G/F/S/W/Y, C630R/F/S/Y, 
C634R/G/F/S/W/Y, E768D, N777S, 
V778I, Q781R, L790F, Y791F, 
V804L/M, I852M, S891A, R912P 
MEN2A PHEO; Parathyroid adenoma 
or hyperplasia; Medullary 
thyroid cancer - onset in early 
adulthood 
C609R/G/S/Y, C611R/G/F/S/W/Y, 
C618R/G/F/S/Y, C620R/G/F/S/W/Y, 
C630R/F/S/Y, C634R/G/F/S/W/Y, 
K666E, E768D, L790F, Y791F, 
V804L/M, S891A 
MEN2B PHEO; Parathyroid adenoma 
or hyperplasia; Medullary 
thyroid cancer - onset in early 
childhood; Mucosal neuromas 
of the lips and tongue; 
Distinctive facies with enlarged 
lips; ganglioneuromatosis of 
the gastrointestinal tract; 
Asthenic "Marfanoid" body 
habitus. 
A883F, M918T 
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3.4.1.1.6 The SDHA gene 
The SDHA gene encodes one of 4 subunits of succinate dehydrogenase (SDH), a 
mitochondrial enzyme that participates in both the citric acid cycle and the electron 
transport chain. Biallelic SDHA mutations have been shown to cause an early onset 
encephalopathy called Leigh syndrome but the gene was not thought to have a role in 
PHEO/PGL/HNPGL formation (72). Burnichon et. al. identified a likely pathogenic missense 
mutation in a patient with a PGL in 2010 (72). Subsequently, the same group published a 
study in which they identified an additional 5 patients with a germline mutation in SDHA 
(73). SDHA analysis is complicated by its four known pseudogenes, generated by complete 
or partial gene duplications (74). 
3.4.1.1.7 The SDHB gene 
SDHB is the second of the four subunits of SDH. In 2001, it was shown that heterozygous 
loss of function mutations in SDHB could predispose an individual to PHEO/PGL/HNPGL (30). 
SDHB mutation carriers are at higher risk of developing abdominal PHEO/PGL than HNPGL 
(75). In addition SDHB mutation carriers have a higher risk of malignant disease (75). 
3.4.1.1.8 The SDHC gene 
SDHC encodes the third subunit of SDH. Mutations in SDHC were first shown to cause 
inherited PGL in 2000 (76). Mutations in SDHC are comparatively rare, compared to SDHB 
and SDHD. A 2004 study found that they only predispose to HNPGL and not PHEO/PGL (77). 
However there has since been a report of a patient with an SDHC mutation who has PGL 
(78). 
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3.4.1.1.9 The SDHD gene 
SDHD is the fourth of the SDH subunits but was the first of the SDH subunit genes to be 
associated with PHEO/PGL/HNPGL (79). Mutations in SDHD are more likely to predispose to 
non-functional HNPGL than functional PHEO/PGL (75). Inheritance of disease differs from 
the conventional autosomal dominant manner expected for mutations in cancer 
predisposition genes. Although more than one case of maternal transmission with disease in 
offspring is referenced in the literature (80), it is rare for maternal transmission of a 
pathogenic SDHD mutation to cause disease in offspring (80). Therefore the SDHD gene 
generally follows a mode of inheritance consistent with genomic imprinting (80), however, it 
sits in a chromosomal region that has been shown to have biallelic expression in several 
tissues (80).  
3.4.1.1.10 The SDHAF2 gene 
The SDHAF2 gene encodes SDH complex assembly factor 2, a co-factor of flavin adenine 
dinucleotide (FAD) insertion into the SDH complex (81). SDHAF2 has a role in flavination of 
SDHA, which is essential for a fully functional SDH complex (81). To date, three families have 
been identified with mutations and, like SDHD, SDHAF2 appears to show parent of origin 
specific expression with disease only being expressed when the mutation is inherited from 
the father (81-83). Both SDHD and SDHAF2 are located on the short arm of chromosome 11. 
3.4.1.1.11 The TMEM127 gene 
TMEM127 is a transmembrane protein which is part of the mTORC1 signalling complex, a 
critical control junction for protein synthesis and cell survival (84). A large multicentre study 
found that germline mutations of TMEM127 were responsible for disease in around 2% of 
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the patients examined, but were associated only with PHEOs and not PGL or HNPGLs (84). 
However, subsequent investigation has found likely pathogenic TMEM127 mutations in one 
patient with a HNPGL and one patient with a retroperitoneal PGL (85). 
3.4.1.1.12 The VHL gene 
The VHL gene is a TSG. Mutations in the VHL gene cause von Hippel-Lindau (VHL) disease. 
VHL disease can be categorised on the basis of the tumour types observed (see Table 3.2). 
PHEO is the distinguishing factor between Type 1 and Type 2 disease, with PHEO being the 
only manifestation in Type 2C. PGL is observed infrequently (60). For additional information 
on VHL refer to Chapter 4, where a detailed commentary is provided. 
Table 3.2 The types of VHL 
HAB = retinal and CNS haemangioblastomas, RCC = renal cell carcinoma, PHEO = 
pheochromocytoma (Adapted from (86)). 
VHL disease type Tumour types observed 
HAB RCC PHEO 
Type 1 + + - 
Type 2A + - + 
Type 2B + + + 
Type 2C - - + 
 
3.4.1.1.13 Conclusion 
The assay was intended to identify patients with either apparently sporadic 
PHEO/PGL/HNPGL or familial PHEO/PGL/HNPGL, and therefore any genes which only cause 
PHEO/PGL/HNPGL as part of a clear syndrome or where PHEO/PGL/HNPGL is never the 
presenting symptom were not included. The NF1 gene was ruled out of the assay as PHEO 
are only seen in a small percentage of cases of NF1 and the clinical features of NF1 are 
invariably already in place by the time PHEO presents (mean age 40 years) (53).  
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The remaining genes were prioritised according to potential for mutation identification. 
Table 3.3 lists the genes that have been shown to cause inherited and/or syndromic PHEO 
and/or PGL and/or HNPGL and gives the reported frequency of mutations identified in each 
gene in patients with an apparently sporadic PHEO/PGL/HNPGL. EGLN1 and KIF1B did not 
have frequency data available and the initial report was several years old with no 
subsequent publications, suggesting that the identification of pathogenic mutations had not 
been replicated in other centres. Therefore these genes were not included.  
Table 3.3 Frequency of mutations identified in apparently sporadic PHEO/PGL 
This table does not included familial mutation frequency. 
Gene Exons Frequency of mutations identified in apparently sporadic 
PHEO/PGL/HNPGL (Reference) 
EGLN1 5 No data 
KIF1B 47 No data 
MAX 5 1.2% (28)  
RET 5* 0.4%-5.0% (87)  
SDHA 15 3% (73) 
SDHAF2 4 0% (81)  
SDHB 8 1.5%-10.0% (87)  
SDHC 6 0% (77)  
SDHD 4 0.8%-10.0% (87)  
TMEM127 4 2% (84)  
VHL 3 3.5%-11.1% (87)  
* 5/20 exons have been shown to harbour mutations associated with MEN2 
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3.4.1.2 Genes known to cause an inherited predisposition to RCC (January 
2012) 
The sections below briefly describe the genes known to cause inherited predisposition to 
renal cell carcinoma, as of January 2012. 
3.4.1.2.1 The VHL gene 
VHL is the most common hereditary renal cancer syndrome (60). RCC is found in Type 1 and 
Type 2B VHL disease and in 24–45% of VHL patients (60). Almost all the tumours are ccRCCs 
(88). For additional information on VHL refer to Chapter 4, where a detailed commentary is 
provided. 
3.4.1.2.2 The MET gene 
The MET gene is a proto-oncogene situated on chromosome 7q31.3. It encodes the cell 
surface receptor for Hepatocyte Growth Factor (HGF). Predisposition to hereditary papillary 
renal carcinoma (HPRC) is caused by activating mutations in the tyrosine kinase domain of 
MET (89). 
3.4.1.2.3 The FH gene 
The FH gene encodes the fumarate hydratase protein, an enzyme that catalyses the 
conversion of fumarate to malate in the Krebs cycle (90). Mutations in this gene cause 
hereditary leiomyomatosis and renal cell cancer (HLRCC) (90). RCC is found in approximately 
20% of HLRCC families (60). pRCC or collecting duct tumours are typically observed and tend 
to be aggressive and thus require immediate removal upon detection (49). 
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3.4.1.2.4 The FLCN gene 
FLCN is a TSG involved in the regulation of adenosine monophosphate (AMP)-activated 
protein kinase (AMPK) and mTOR signalling pathways (91). Mutations in the FLCN gene 
cause Birt-Hogg-Dubé (BHD) syndrome, which is characterised by the development of 
benign skin tumours, fibrofolliculomas, on the face and upper torso, along with increased 
susceptibility to spontaneous pneumothorax and RCC (92). Renal tumours occur in 25–35% 
of BHD patients (60). BHD-related renal tumours can have different histologic subtypes, 
chRCCs and hybrid oncocytic tumours (mixed pattern of chRCCs and OCs) are most 
frequently observed but other types, including clear cell, are also seen (60). 
3.4.1.2.5 The TSC1 and TSC2 genes 
Tuberous sclerosis (TS) is caused by an inactivating mutation in TSC1 or TSC2 (93;94). TSC1 
encodes the protein hamartin and TSC2 encodes tuberin. Hamartin and tuberin interact to 
produce a heterodimer and together function as part of the mTOR pathway. TS is a 
multisystem disorder characterised by the formation of hamartomas in multiple organ 
systems, such as the heart, brain, skin, lungs and kidneys. Renal lesions occur in 50–80% of 
TS patients (60). However the majority of these lesions are angiomyolipomas with RCC only 
reported in 1–4% (60). This is similar to the general population rate of RCC but in TS patients 
the RCC occurs at a younger age (60). The RCCs observed are predominately ccRCCs, but 
other RCC types have also been recorded (chRCCs, pRCCs, and OCs). RCC is not seen alone in 
TS (60). 
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3.4.1.2.6 The CDC73 gene 
CDC73 is a TSG which encodes a protein called parafibromin. One of parafibromin’s roles is 
to act as part of the PAF multi-protein complex which associates with the large subunit of 
RNA polymerase II and a histone methyltransferase complex (95). Mutations in CDC73 cause 
hereditary hyperparathyroidism-jaw tumour (HPT-JT) syndrome which is characterised by a 
predisposition to develop primary hyperparathyroidism and multiple ossifying jaw fibroma 
(96). A variety of renal manifestations have been described. They occur in around 15% of 
patients and include RCCs (60). RCC is not the predominant or presenting feature. 
3.4.1.2.7 The SDHB gene 
Mutations in SDHB are typically implicated in PHEO/PGL/HNPGL predisposition (see section 
3.4.1.1.7); however, renal tumours, including ccRCCs, chRCCs and OCs have also been 
identified in up to 5% of patients and can be the presenting feature (75). 
3.4.1.2.8 Conclusions 
Of the eight genes discussed above, only five have been shown to give rise to RCC as the 
presenting feature of disease. The TSC1/TSC2 and CDC73 genes were not included in NGS 
panel design because the RCC should always be recognised in the context of the wider 
clinical picture. Therefore VHL, FH, FLCN, MET and SDHB were chosen to be included in the 
assay. 
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3.4.2 Assay design and optimisation 
3.4.2.1 The PHEO/PGL/HNPGL panel  
Assay design and optimisation was performed initially for the PHEO/PGL/HNPGL panel. A 
total of 55 primer pairs for the Access Array (AA) were designed for the selected genes and 
trialled using scaled up volumes of the reactions. All primer pairs had to amplify DNA at 
common reaction conditions, as the PCR occurred within the AA on a single thermal cycler. 
This meant that primer redesign was the only option for poorly performing primer pairs. Six 
amplicons were redesigned to optimize amplification as a result of non-specific 
amplification or excessive primer dimer. The majority of primers were then successful but 
despite redesign, RET exon 14 did not produce an amplicon of sufficient quality and it was 
removed from the AA set-up to be analysed by Sanger sequencing.  
Early NGS runs tested assay design and sequencing depth per fragment, and optimised the 
number of patients per run to give >30-fold coverage for all amplicons. Four amplicons 
producing consistently low reads were removed from the assay to be analysed by Sanger 
sequencing. These amplicons had >66% GC content: MAX exon 1 (67%); SDHA exon 1 (75%); 
SDHAF2 exon 1 (68%) and TMEM127 exon 2 (72%). This left 49 amplicons for the AA. 
The AA was adjusted to allow the most uniform NGS coverage possible. Six amplicons with 
consistently high read numbers were diplexed within the microreactions on the 48.48 AA, 
with diplexed amplicons matched for size and melting temperature as closely as reasonably 
possible. Those with low read numbers were amplified in duplicate (n=2). It was established 
that higher sequencing depth was achieved when a 2 stage PCR was employed (stage 1 
target specific PCR, stage 2 indexing PCR) rather than the initially trialled single reaction 
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‘step-out’ PCR. The optimal number of patients sequenced per run in order to attain >30-
fold coverage for all amplicons was determined to be 20 and the optimal DNA molecule to 
sequencing bead ratio for the NGS was determined to be 0.5:1. 
During the optimization and validation phase a mean number of 82, 000 passed filter reads 
was achieved for the PHEO/PGL/HNPGL panel. 
3.4.2.2 The RCC panel 
Lessons from the design and optimisation of the PHEO/PGL/HNPGL panel were applied to 
the RCC panel. Amplicons with greater than 66% GC content were not included on the AA 
assay and the 2-stage PCR for target amplification and indexing was applied from the outset. 
FH exon 9 did not work as part of this system and it instead was analysed by Sanger 
sequencing. The reason for this was unclear, as it did work at a scaled up reaction volume, 
however it did not produce any mapped reads on the validation runs. The optimal number 
of patients sequenced per run in order to attain >30-fold coverage for all amplicons was 
determined to be 24, as a result of the smaller number of amplicons. Finally, the optimal 
DNA molecule to sequencing bead ratio for the NGS was determined to be 1:1. 
  
63 
 
3.4.2.3 PHEO/PGL/HNPGL panel validation 
3.4.2.3.1 PHEO/PGL/HNPGL panel sensitivity 
The NGS assay was validated using 85 patient DNAs containing 182 variants (84 unique 
variants) (Table 3.4). 171 variants met the required minimum coverage threshold set (>30x 
depth) and of these 170 were detected (76/77 unique variants), giving an overall sensitivity 
of 98.7% (95% CI: 92.95% to 99.78%). 
The single undetected variant (with >30-fold coverage) was a 6 bp duplication in SDHB 
intron 4, c.424-19_424-14dupTTCTTC. This is a polymorphic tract where the major allele 
contains 8 TTC repeats. The duplication allele was correctly identified in 7/49 (14.3%) reads. 
A number of sequencing/alignment errors had occurred leading to the incorrect calling. This 
polymorphism was sequenced on an additional 5 occasions and detected each time (mean = 
26% of reads).  
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Table 3.4 Unique variants used to validate the PHEO/PGL/HNPGL panel and MiSeq 
technology 
Gene Exon/ 
Intron 
Nucleotide change Protein change Variant type 
RET 9 c.1760-158C>G   Substitution 
RET 10 c.1853G>C p.Cys618Ser Substitution 
RET 11 c.1900T>C p.Cys634Arg Substitution 
RET 11 c.2071G>A p.Gly691Ser Substitution 
RET 13 c.2307T>G p.= Substitution 
RET 14 c.2410G>A p.Val804Met Substitution 
RET 14 c.2608-24G>A 
 
Substitution 
RET 15 c.2712C>G p.= Substitution 
RET 16 c.2801+54A>T   Substitution 
SDHB 1 c.17_42dup26 p.Ala15Hisfs*4 Insertion/ 
Deletion 
SDHB 1 c.18A>C p.= Substitution 
SDHB 1 c.72+1G>A   Substitution 
SDHB 1 c.72+1G>T   Substitution 
SDHB 1 c.79C>T p.Arg27* Substitution 
SDHB 2 c.136C>T p.Arg46* Substitution 
SDHB 2 c.137G>A p.Arg46Gln Substitution 
SDHB 2 c.166_170delCCTCA p.Pro56Tyrfs*5 Insertion/ 
Deletion 
SDHB 2 c.200+33G>A   Substitution 
SDHB 2 c.200+35G>A   Substitution 
SDHB 2 c.200+104G>A   Substitution 
SDHB 2 c.88delC p.Gln30Argfs*47 Insertion/ 
Deletion 
SDHB 2 c.201-36T>G   Substitution 
SDHB 3 c.282_283insCTTA p.Glu95Leufs*25 Insertion/ 
Deletion 
SDHB 3 c.286+169A>G   Substitution 
SDHB 3 c.286G>A p.Gly96Ser Substitution 
SDHB 3 c.287-1G>C   Substitution 
SDHB 4 c.297delC p.Ser100Leufs*4 Insertion/ 
Deletion 
SDHB 4 c.311delAinsGG p.Asn104Argfs*15 Insertion/ 
Deletion 
SDHB 4 c.338G>A p.Cys113Tyr Substitution 
SDHB 4 c.379dupA p.Ile127Asnfs*28 Insertion/ 
Deletion 
SDHB 4 c.424-19_424-14dup6   Insertion/ 
Deletion 
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Gene Exon/ 
Intron 
Nucleotide change Protein change Variant type 
SDHB 5 c.502dupC p.Gln168Profs*11 Insertion/ 
Deletion 
SDHB 6 c.470T>A p.Val157Asp Substitution 
SDHB 6 c.553G>T p.Glu185* Substitution 
SDHB 6 c.587G>A p.Cys196Tyr Substitution 
SDHB 6 c.591delC p.Ser198Alafs*22 Insertion/ 
Deletion 
SDHB 7 c.685_686ins13 p.Glu229Alafs*31 Insertion/ 
Deletion 
SDHB 7 c.689G>A p.Arg230His Substitution 
SDHB 7 c.745_748dupTGCA p.Thr250Metfs*7 Insertion/ 
Deletion 
SDHB 8 c.801G>T p.Lys267Asn Substitution 
SDHC 1 c.20+11_20+12dupTG   Insertion/ 
Deletion 
SDHC 2 c.21-189A>G   Substitution 
SDHC 2 c.21-211C>T   Substitution 
SDHC 2 c.21-96C>T   Substitution 
SDHC 3 c.148C>T p.Arg50Cys Substitution 
SDHC 4 c.214C>T p.Arg72Cys Substitution 
SDHC 4 c.241+74C>T   Substitution 
SDHC 4 c.242-193A>G   Substitution 
SDHC 4 c.242-174T>C   Substitution 
SDHC 4 c.242-154A>G   Substitution 
SDHC 4 c.242-136G>T   Substitution 
SDHC 5 c.397C>T p.Arg133* Substitution 
SDHD 1 c.14G>A p.Trp5* Substitution 
SDHD 1 c.47_51+1del7   Insertion/ 
Deletion 
SDHD 1 c.52+136G>T   Substitution 
SDHD 2 c.144_145dupCA p.Ile49Thrfs*38 Insertion/ 
Deletion 
SDHD 2 c.57delG p.Leu20Cysfs*66 Insertion/ 
Deletion 
SDHD 2 c.94_95delTC p.Ala33Ilefs*35 Insertion/ 
Deletion 
SDHD 2 c.170-29A>G   Substitution 
SDHD 3 c.204C>T p.= Substitution 
SDHD 3 c.205G>T p.Glu69* Substitution 
SDHD 3 c.242C>T p.Pro81Leu Substitution 
SDHD 3 c.274G>T p.Asn92Tyr Substitution 
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Gene Exon/ 
Intron 
Nucleotide change Protein change Variant type 
SDHD 3 c.276_278delCTA p.Tyr93del Insertion/ 
Deletion 
SDHD 3 c.296delT p.Leu99Profs*36 Insertion/ 
Deletion 
SDHD 3 c.315-32T>C   Substitution 
SDHD 4 c.342T>A p.Tyr114* Substitution 
VHL 1 c.214delT p.Ser72Profs*87 Insertion/ 
Deletion 
VHL 1 c.239G>T p.Ser80Ile Substitution 
VHL 1 c.326_340+16del31insA   Insertion/ 
Deletion 
VHL 1 c.337delC   Insertion/ 
Deletion 
VHL 1 c.340+5G>C   Substitution 
VHL 2 c.293A>C p.Tyr98Ser Substitution 
VHL 2 c.358A>T p.Arg120* Substitution 
VHL 2 c.376G>A p.Asp126Asn Substitution 
VHL 2 c.381delG, p.Leu128Phefs*31 Insertion/ 
Deletion 
VHL 2 c.463+108T>G   Substitution 
VHL 2 c.463+174delT   Insertion/ 
Deletion 
VHL 3 c.479_480delAG p.Glu160Alafs*13 Insertion/ 
Deletion 
VHL 3 c.482G>C p.Arg161Pro Substitution 
VHL 3 c.499C>T p.Arg167Trp Substitution 
VHL 3 c.548C>T p.Ser183Leu Substitution 
VHL 3 c.562C>G p.Leu188Val Substitution 
VHL 3 c.598C>T p.Arg200Trp Substitution 
 
3.4.2.3.2 PHEO/PGL/HNPGL panel specificity 
False variant calls resulting from errors in determining the number of bases within 
homopolymer tracts is a recognized problem with the 454 sequencing chemistry (97). Inter-
run variability was observed for homopolymer errors, with the recurrent errors observed 
within a run, varying between runs. During the validation period, numerous false positive 
calls were identified for every DNA sample. In one sequencing run there were 164 unique 
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variants and each DNA sample had an average of 65 variants called, an average of 46 of 
which were likely homopolymer related artefacts. To limit the Sanger sequencing 
confirmations required and to increase specificity, two filtering steps were introduced: 1. 
the region of interest was limited to the coding sequence ±5 bp (with the exception of 5’ 
and 3’ untranslated regions). This reduced the number of unique variants identified to 27 
and only 4 were likely artefacts associated with homopolymer tracts. These 4 variant calls 
comprised 36% of all variants observed. 2. The in-house bioinformatics pipeline was set to 
filter out homopolymer related deletions/duplications that were within two standard 
deviations of the mean for that variant for the patients on that run. It also filtered benign 
polymorphisms leaving an average of 0.5 variants per DNA sample which required Sanger 
confirmation and pathogenicity analysis. Performing this filtering on the validation runs did 
not cause any known pathogenic mutations to be missed. 
3.4.2.3.3 PHEO/PGL/HNPGL variant frequency 
Variant frequency is calculated by dividing the number of mutant reads by the total number 
of reads. Figure 3.3 provides details of the variant frequency observed for the 171 variants 
input into the system. The average variant frequency was close to that expected for all 
variant types. The heterozygous substitution variants were seen in an average of 49.6% of 
reads (range: 16.2-94.0%) and the heterozygous insertion/deletion variants in an average of 
44.10% (range: 14.3-73.0%). The homozygous substitutions were seen at an average of 
99.4% (range: 89.3-100.0%). Outliers comprised the 6 base pair duplication discussed above 
and a heterozygous substitution observed at 94.0%, which upon investigation was 
considered likely to be the result of the sample being degraded. Also, 5/26 homozygous 
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substitutions were not identified in 100% of reads. This was caused by low level sequencing 
errors. 
 
Figure 3.3 Variant frequency observed for the variants input into the PHEO/PGL/HNPGL 
panel during validation that met the >x30 coverage threshold (n=171) 
 
3.4.2.4 RCC panel validation 
3.4.2.4.1 RCC panel sensitivity 
For the RCC panel validation, 42 DNA samples were run, comprising 106 variants. 3 of which 
did not meet the coverage threshold of ≥30 reads. Of the variants examined, 50 were 
unique (see Table 3.5) and 49 had reads which met the required coverage threshold. All 
variants were detected, providing a sensitivity of 100% (95% CI: 92.68% to 100.00%).  
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Table 3.5 Unique variants used to validate the RCC panel 
Gene Exon/ 
Intron 
Nucleotide change Protein change Variant type 
FH 2 c.268-28T>A   Substitution 
FH 2 c.268-24A>T   Substitution 
FH 2 c.268-22A>T   Substitution 
FH 5 c.698G>A p.Arg233His Substitution 
FH 6 c.904+47G>A   Substitution 
FH 7 c.1108+98C>A   Substitution 
FH 7 c.1108+109G>A   Substitution 
FH 7 c.927G>A p.= Substitution 
FH 9 c.1347delG p.Met449Ilefs*5 Insertion/ 
Deletion 
FH 9 c.1391-1G>T   Substitution 
FLCN 2 c.347dupA p.Leu117Alafs*16 Insertion/ 
Deletion 
FLCN 3 c.469_471delTTC p.Phe157del Insertion/ 
Deletion 
FLCN 3 c.583G>T p.Gly195* Substitution 
FLCN 4 c.240delC p.Asp80Glufs*50 Insertion/ 
Deletion 
FLCN 5 c.340dupC p.His114Profs*19 Insertion/ 
Deletion 
FLCN 5 c.396+59T>C   Substitution 
FLCN 5 c.397-14C>T   Substitution 
FLCN 6 c.494delG p.Gly165Alafs*12 Insertion/ 
Deletion 
FLCN 6 c.890_893delAAAG p.Glu297Alafs*25 Insertion/ 
Deletion 
FLCN 8 c.871+226G>A   Substitution 
FLCN 8 c.871+36G>A   Substitution 
FLCN 9 c.1062+6C>T   Substitution 
FLCN 9 c.1062+47G>A   Substitution 
FLCN 10 c.1076delC p.Pro359Leufs*1
6 
Insertion/ 
Deletion 
FLCN 10 c.1176+1G>C   Substitution 
FLCN 10 c.1176+39G>A   Substitution 
FLCN 10 c.1177-5_1177-3delCTC   Insertion/ 
Deletion 
FLCN 11 c.1285dupC p.His429Profs*27 Insertion/ 
Deletion 
FLCN 12 c.1301-59C>T   Substitution 
FLCN 12 c.1301-38G>A   Substitution 
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Gene Exon/ 
Intron 
Nucleotide change Protein change Variant type 
FLCN 12 c.1318_1334dup17 p.Leu449Glnfs*2
5 
Insertion/ 
Deletion 
FLCN 12 c.1367_1398del32 p.Asp456Glyfs*19 Insertion/ 
Deletion 
MET 17 c.3577-75T>C   Substitution 
SDHB 1 c.72+1G>T   Substitution 
SDHB 2 c.200+104A>G   Substitution 
SDHB 2 c.200+33G>A   Substitution 
SDHB 2 c.79C>T p.Arg27* Substitution 
SDHB 3 c.268C>T p.Arg90* Substitution 
SDHB 3 c.286+169A>G   Substitution 
SDHB 4 c.380T>G p.Ile127Ser Substitution 
SDHB 4 c.423+1G>A   Substitution 
SDHB 6 c.590C>G p.Pro197Arg Substitution 
SDHB 6 c.600G>T p.Trp200Cys Substitution 
VHL 1 c.240T>G p.Ser80Arg Substitution 
VHL 2 c.350G>T p.Trp117Leu Substitution 
VHL 2 c.457delC pLeu153Cysfs*6 Insertion/ 
Deletion 
VHL 2 c.463+108T>G   Substitution 
VHL 3 c.491A>G p.Glu164Arg Substitution 
VHL 3 c.525C>A p.Tyr175* Substitution 
VHL 3 c.568_567dupGA p.Asp190Glufs*1
3 
Insertion/ 
Deletion 
 
3.4.2.4.2 RCC panel specificity 
The same filtering system designed for the PHEO/PGL/HNPGL panel was used to limit false 
variant calls resulting from errors in determining the number of bases within homopolymer 
tracts. Within the specified region of interest, the genes analysed on this panel do not have 
many homopolymeric stretches. In the validation phase, this meant over 80% fewer 
deletion/insertion calls required additional analysis and of those flagged as requiring 
additional investigation 81% were true variants. No true variants were missed.  
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3.4.2.4.3 RCC panel variant frequency 
Figure 3.4 provides details of the variant frequency observed for the 103 variants detected 
by NextGENe. Again, the average variant frequency was close to that expected for all variant 
types. The heterozygous substitution variants were seen in an average of 46.8% of reads 
(range: 24.4-67.9%) and the heterozygous insertion/deletion variants in an average of 45.8% 
(range: 22.9-66.3%). The homozygous substitutions were seen at an average of 99.7% 
(range: 95.6-100.0%). Again for this panel, homozygous substitutions were not always 
identified in 100% of reads (n=5/27).  
 
Figure 3.4 Variant frequency observed for the variants input into the RCC panel during 
validation that met the >30x coverage threshold (n=130) 
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3.4.3 Workflow establishment 
After optimisation and validation of each panel a full workflow was determined. This was 
common for both panels. 
 
Figure 3.5 Panel workflow, common to both the PHEO/PGL/HNPGL and RCC panels 
 
For the PHEO/PGL/HNPGL panel the non-NGS exons were MAX exon 1, SDHA exon 1, 
SDHAF2 exon 1 and TMEM127 exon 2. The MLPA probemixes used were P226 SDH, which 
includes SDHA, SDHC and SDHD and P016 VHL which includes the VHL gene and flanking 
region. 
For the RCC panel, FH exon 1 and FH exon 9 were non-NGS exons. The MLPA probemixes 
used were P256 FLCN, which includes the FLCN gene, P226 SDH, which includes SDHB, SDHC 
and SDHD and P016 VHL which includes the VHL gene and flanking region. 
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3.4.4 Prospective patient analysis 
3.4.4.1 Prospective patient analysis PHEO/PGL 
The second phase involved prospective analysis of 120 patient samples using the 
PHEO/PGL/HNPGL workflow. The mean number of passed filter reads was ~108, 000 per 
run, higher than the average of the validation runs (~82, 000) and increasing amplicon 
coverage. This was likely to be the result of a Roche software upgrade during that period, in 
combination with increased user experience. The complete genetic workflow (Figure 3.5) 
identified 44 variants (excluding benign polymorphisms of no clinical significance), of which 
36 were unique. 12 were classed as pathogenic, 3 as likely pathogenic and 21 as a variant of 
unknown significance (VUS) (5 patients had multiple variants). The variants have been 
summarized in Table 3.6. An example of a pathogenic nonsense mutation detected by NGS 
and confirmed by Sanger sequencing is shown in Figure 3.6. 
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Figure 3.6 An example of a pathogenic mutation in the MAX gene, c.[223C>T]; [=] 
p.(Arg75*), identified by NGS and confirmed by Sanger sequencing 
a) NGS read pile up of ten example reads visualised by NextGENe; b) Sanger sequencing 
forward electropherogram visualised by Mutation Surveyor. 
 
As might be expected, the detection rate for novel pathogenic variants was inversely related 
to the extent of previous molecular genetic analysis. One or more genes had been 
sequenced previously in 35% of patients, of whom six patients had a VUS identified (all 
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confirmed by the NGS panel). Ten additional variants in seven patients (three of whom had 
a previously diagnosed VUS) were identified. All 10 additional variants were identified in 
genes that had not previously been analyzed and three were considered likely to be 
pathogenic.  
No previous genetic analysis had been performed in 65% of patients and a total of 28 
variants were identified in 27 individuals. Of these, 46% were considered to be pathogenic 
mutations (10 in SDHB, SDHD and VHL and 3 in genes that were not previously part of the 
routine diagnostic service). In addition, 3 likely pathogenic changes and 12 VUSs were 
identified (two of which were identified in one patient). In summary, a variant of interest 
was identified in 34.6% of new referrals and a definite pathogenic mutation in 16.6% (see 
Table 3.6). 
3.4.4.2 Prospective patient analysis RCC 
For the RCC panel 119 patients were analysed prospectively. The complete RCC genetic 
workflow identified 12 unique variants (2 were seen twice), 5 were pathogenic and 7 were 
VUSs, with 2 VUSs seen in 1 patient (see Table 3.7). This equates to a variant detection rate 
of 11/119 (9.2%) and a genetic diagnosis confirmed in 5/119 patients (4.2%). 
As with the PHEO/PGL/HNPGL panel the detection rate was affected by the amount of 
previous analysis performed, one or more genes has been analysed previously in 23/119 
(19.3%) of patients, of whom 1 had previously had a VUS identified (detected by NGS). No 
additional variants were identified in any of the previously analysed patients.  
A variant of interest was identified in 14/119 (11.8%) patients and a pathogenic mutation 
identified in 5/119 (4.2%).  
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Table 3.6 Variants identified during prospective PHEO/PGL/HNPGL panel analysis.  
HNPGL = head and neck paraganglioma, PGL = paraganglioma (abdominal), PHEO = phaeochromocytoma (adrenal), VUS = variant of uncertain 
significance.  
Gene Exon/ 
Intron 
Variant type Variant (coding DNA) Variant (protein) Times 
observed 
Variant class Tumour type 
MAX 4 Nonsense c.[223C>T];[=] p.(Arg75*) 1 Pathogenic PHEO 
MAX 5 Missense c.[425C>T];[=] p.(Ser142Leu) 1 VUS PHEO 
SDHA 2 Nonsense c.[91C>T];[=] p.(Arg31*) 2 Likely 
pathogenic 
1. HNPGL 
2. PGL 
SDHA 2 Missense c.[136A>G];[=] p.(Lys46Glu) 1 VUS PGL 
SDHA 5 Synonymous c.[549C>T];[=] p.(=) 1 VUS HNPGL 
SDHA 7 Synonymous c.[822C>T];[=] p.(=) 1 VUS HNPGL 
SDHA 8 Missense c.[923C>T];[=] p.(Thr308Met) 1 VUS PGL 
SDHA 8 Synonymous c.[1002G>A];[=] p.(=) 1 VUS HNPGL 
SDHA 10 Missense c.[1273G>A];[=] p.(Val425Met) 1 VUS PHEO/PGL 
SDHA 10 Frameshift c.[1338delA];[=] p.(His447Metfs*23) 1 VUS HNPGL 
SDHA 12 Synonymous c.[1623G>A];[=] p.(=) 1 VUS HNPGL 
SDHA 13 Missense c.[1753C>T];[=] p.(Arg585Trp) 1 Likely 
pathogenic 
HNPGL 
SDHA 13 Synonymous c.[1776T>C];[=] p.(=) 1 VUS PGL 
SDHAF2 3 Missense c.[319C>T];[=] p.(Arg107Cys) 1 VUS PGL 
SDHB 1 Splicing c.[72+1G>T];[=]   1 Pathogenic PHEO 
SDHB 1 Deletion c.[-?_200+?del];[=] p.0? 1 Pathogenic PGL 
SDHB 2 Deletion c.[73-?_200+?del];[=]  1 Pathogenic PGL 
SDHB 2 Missense c.[118A>G];[=] p.(Lys40Glu) 1 Pathogenic PGL 
SDHB 4 Splicing c.[423+1G>A];[=]   1 Pathogenic PHEO 
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Gene Exon/ 
Intron 
Variant type Variant (coding DNA) Variant (protein) Times 
observed 
Variant class Tumour type 
SDHB 5 Missense c.[487T>C];[=] p.(Ser163Pro) 5 VUS 1. PHEO 
2. PHEO 
3. PHEO 
4. PHEO 
5. HNPGL 
SDHB 6 Missense c.[587G>A];[=] p.(Cys196Tyr) 1 Pathogenic HNPGL 
SDHB 7 Missense c.[725G>A];[=] p.(Arg242His) 1 Pathogenic HNPGL 
SDHB 8 Frameshift c.[770dupT];[=] p.(Asn258Glufs*17) 1 Likely 
pathogenic 
PHEO 
SDHB 2-7 Deletion c.[73-?_765+?del];[=]  1 Pathogenic PGL 
SDHC 1 5'UTR c.[-118_-117delAG];[=]   1 VUS HNPGL 
SDHC 2 Splicing c.[77+2dupT];[=]   1 Pathogenic HNPGL 
SDHC 3 Missense c.[148C>T];[=] p.(Arg50Cys) 1 VUS HNPGL 
SDHC 4 Missense c.[214C>T];[=] p.(Arg72Cys) 1 VUS HNPGL 
SDHC 5 Missense c.[380A>G];[=] p.(His127Arg) 1 VUS HNPGL 
SDHD 1 Missense c.[34G>A];[=] p.(Gly12Ser) 3 VUS 1. HNPGL 
2. PHEO 
3. HNPGL 
SDHD 3 Missense c.[242C>T];[=] p.(Pro81Leu) 2 Pathogenic 1. HNPGL 
2. HNPGL 
SDHD 3 Synonymous c.[312C>T];[=] p.(=) 1 VUS PGL 
TMEM127 3 Missense c.[268G>A];[=] p.(Val90Met) 1 VUS PGL 
TMEM127 3 Frameshift c.[512delTinsGCC];[=] p.(Val171Glyfs*137) 1 Pathogenic HNPGL 
TMEM127 4 Synonymous c.[411T>A];[=] p.(=) 1 VUS HNPGL 
TMEM127 4 Synonymous c.[534C>T];[=] p.(=) 1 VUS PHEO 
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Table 3.7 Variants identified during prospective RCC panel analysis.  
VUS = variant of uncertain significance.  
Gene Exon/Intron Variant type Variant (coding DNA) Variant (protein) 
Times 
observed 
Variant class 
FLCN 7 Missense c.[715C>T];[=] p.(Arg239Cys) 2 VUS  
FLCN 11 Frameshift c.[1285dupC];[=] p.(His429Profs*27) 1 Pathogenic 
FLCN 12 Missense c.[1333G>A];[=] p.(Ala445Thr) 1 VUS 
FLCN 12 Frameshift c.[1333_1337dupGCACG];[=] p.(Ser447Hisfs*23) 1 Pathogenic 
FLCN 3'UTR 3'UTR c.[*4G>A];[=]   1 VUS 
MET 17 Missense c.[3356G>C];[=] p.(Gly1119Ala) 1 VUS 
SDHB 1 Missense c.[32G>A];[=] p.(Arg11His) 1 VUS 
SDHB 5 Missense c.[487T>C];[=] p.(Ser163Pro) 2 VUS 
SDHB 7 Missense c.[724C>T];[=] p.(Arg242Cys) 1 Pathogenic 
VHL 1 Missense c.[233A>G];[=] p.(Asn78Ser) 1 Pathogenic 
VHL 3 Missense c.[629G>A];[=] p.(Arg210Gln) 1 VUS 
VHL 3 Splice-site c.[464-2A>G];[=]   1 Pathogenic 
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3.5  Discussion 
The hypothesis for this chapter was that NGS could facilitate a transition from targeted, 
sequential, analysis of individual PHEO/PGL/HNPGL or RCC genes in selected high risk 
individuals to a strategy of simultaneously testing multiple predisposition genes in all at-risk 
individuals. To determine if this strategy was likely to be a feasible innovation for clinical 
practice it was necessary to establish a) whether NGS could be used as a reliable alternative 
to Sanger sequencing to interrogate all relevant parts of the genes of interest and b) the 
sensitivity and specificity by validation of the NGS test.  
The AA was found to be an effective system to produce an amplicon library for the GS Junior 
and has the advantage that additional amplicons could be included as further genes 
applicable to either the PHEO/PGL/HNPGL or RCC phenotype are identified. However the 
validation processes identified some exons unsuitable for analysis in this workflow. In 
particular those with a GC-content greater than 66% tended to produce poor results and 
this should be considered when designing assays using this system. Also, as in the case of FH 
exon 9, very occasionally amplicons will not work in the assay for no determinable reason. 
As these were novel assays, validation for diagnostic use was essential. For the 
PHEO/PGL/HNPGL panel, analytical sensitivity was experimentally determined to be 98.7%. 
Only 1/77 unique variants was not detected during phase one. However, this undetected 
variant was identified on five other occasions (although in a lower average percentage of 
reads than might be expected for a heterozygous change). This was likely to be the result of 
sequence context, as the technology appeared to have difficulty sequencing this region. The 
variant in question was a benign polymorphism and the failure to detect it was not of 
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clinical significance but it is important to consider that in other circumstances a pathogenic 
mutation on an underrepresented allele may be overlooked. Also, it is important to note 
that non-homopolymer repeat tracts, such as a TTC repeat, can also lead to sequencing 
errors when using Roche NGS technology. For the RCC genes the analytical sensitivity was 
experimentally determined to be 100%. 
There is no consensus regarding the minimum coverage and variant filtering threshold (VFT) 
required to reliably detect a heterozygous variant. Though de Leeneer et. al. theoretically 
calculated that a 15% VFT with 30-fold coverage would allow detection of 99.995% of 
heterozygous variants, this assumes that neither allele is preferentially amplified or 
sequenced (98). If this is not the case, then higher coverage would be required. Several 
groups have used a similar enrichment strategy and sequencing chemistry, and set locally 
derived limits to detect heterozygous mutations. For example Hollants et al. (99) proposed 
that a VFT of 20% and a minimum coverage of 25-fold was sufficient to detect heterozygotes 
in familial hypercholesterolemia genes, whereas for BRCA1 and BRCA2 screening Michils et. 
al. suggested that 10% VFT and 27-fold coverage was required to detect all heterozygous 
changes (100). Our findings suggest a 15% VFT with 30-fold coverage is required to optimize 
variant detection whilst attenuating the concomitant increase in false positive results, for 
this combination of methodologies.  
It is well established that homopolymer tract sequencing errors are problematic when using 
the Roche 454 chemistry (101). To reduce the number of variants requiring Sanger 
sequencing confirmation, the regions analysed were reduced to comprise the coding 
sequence +5 bp of flanking intronic sequence for all genes. Additionally, a variant 
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comparison strategy was implemented to simultaneously interrogate all variants in all 
patient DNAs on a single NGS run. Any deletion/duplication called was compared to the data 
from the same base for all samples sequenced on that run. Only variants for which the 
percentage deletion or duplication call was greater than 2 standard deviations from the 
mean were confirmed by Sanger sequencing. When these filters were applied to the 
validation data, all known mutations were detected and the number of false positive calls 
was dramatically reduced. Not all NGS chemistries have inherent issues with homopolymer 
tract sequencing and other platforms such as the Illumina MiSeq would offer some 
advantages in this respect. However this was not an available option for this project at the 
time.  
For the PHEO/PGL/HNPGL panel, the largest deletion identified during the validation phase 
was 7 bp in SDHD exon 1 and the largest duplication 13 bp in SDHB exon 7. For the RCC 
panel the largest deletion and duplication observed in the validation phase were both in 
FLCN exon 12 and were 32 bp and 17 bp in size, respectively. The ability to identify whole 
exon deletions and duplications was not thoroughly examined given that the enrichments 
were PCR based and therefore highly unlikely to produce reliable data. Additionally a dosage 
analysis tool was not available in the commercial software used for analysis. Brief attempts 
to use normalised average exon read numbers to detect whole exon copy number changes 
reinforced that theory (data not included). 
As reported previously for similar assays (100;102;103), the variant frequency was variable 
for both heterozygous and homozygous changes. For homozygous changes, the lack of 100% 
variant calls can be explained by low level sequencing errors. However for heterozygous 
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changes, the large variability may reflect random sampling of the PCR product. This is 
exemplified by a heterozygous substitution for which the same DNA was run on three 
occasions and gave variant frequencies of 32.91, 53.03%, 94.03%. Investigation of the DNA 
suggested that the variation may have been exacerbated by mild DNA degradation. For a 
direct amplicon-based sequencing strategy, duplicate reads cannot be identified and 
removed (as would occur when performing a method using fragmentation), which may lead 
to bias for one allele, and hence the requirement for a lower VFT. An alternative target 
enrichment methodology could be trialed to determine whether a capture and 
fragmentation approach would lead to less allelic bias. 
After establishing a diagnostic testing workflow for both PHEO/PGL/HNPGL and RCC, a 
prospective analysis of samples referred for diagnostic testing was undertaken, with use of 
the panels upon clinician request. It is interesting to note the difference in the pathogenic 
mutation identification rate for the PHEO/PGL/HNPGL panel vs the RCC panel (16.6% vs 
4.2%). The low RCC rate is likely to be the result of referral bias. It appeared that those 
patients with a likely diagnosis of a specific condition were often not referred for panel 
testing but rather for the specific gene of interest, meaning that those samples referred for 
the panel test were more likely to be from patients where the clinician was less certain of 
the likelihood that it was an inherited RCC or where the case was complex. Two interesting 
cases are described briefly in section 3.6. In contrast PHEO/PGL/HNPGL are more rarely 
identified as part of a clinically clear syndrome and there are more candidate genes for each 
tumour subtype (PHEO, PGL and HNPGL). Therefore the PHEO/PGL/HNPGL panel was used 
for the vast majority of referred cases. 
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There were two major advantages for the NGS workflows. The first was that each group of 
genes was analysed simultaneously whereas conventional sequential molecular genetic 
testing strategies analyse one gene and then proceed to testing another (if no mutation is 
detected). Thus, the workflows decreased the time taken to find a pathogenic mutation or 
determine that no pathogenic mutation could be identified in the analysed genes. In 
practice, this would enable predictive testing to be made available to at risk family members 
in a timelier manner. National guidelines suggest that testing for an unknown mutation in a 
large gene should be performed within 40 working days and that an NGS panel test should 
be performed within 80 working days. The second major advantage was the reduced cost 
per gene analysed, which was most diminished for the PHEO/PGL/HNPGL panel. The 
diagnostic screening workflow was locally priced by the NHS diagnostic laboratory at £500 
per sample (for NHS diagnostic referrals) to test 9 PPGL/HNPGL genes (MAX, RET, SDHA, 
SDHB, SDHC, SDHD, SDHAF2, TMEM127 and VHL), or ~£56 per gene. Compared to the local 
charge for testing VHL, RET, SDHB and SDHD by conventional sequential (Sanger) sequencing 
technology of ~£1800 (104). This equates to a 70% cost reduction for users with a 125% 
increase in the number of genes examined. The RCC panel was locally priced at £550 per 
sample for analysis of 5 genes or ~£110 per gene, compared to testing of any of the RCC 
genes alone which were charged at between £400 and £800 depending on the number of 
exons in the gene. This meant that there was minimal cost difference for the analysis of an 
additional 4 genes. 
An inevitable consequence of testing more genes is the identification of additional VUSs. For 
the PHEO/PGL/HNPGL panel, it was found that 61% of variants detected were VUSs and for 
the RCC panel, 64% of variants detected were classed as VUSs. In a diagnostic laboratory, 
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accurate variant classification is essential as it impacts directly on patient care and family 
management. In the short term, the identification of a VUS can cause uncertainty for the 
patient and additional workload for the laboratory staff and clinicians. For the 
PHEO/PGL/HNPGL panel, 51.9% of the VUSs (but only 15.4% of pathogenic mutations) were 
in MAX, SDHA, SDHAF2 or TMEM127, genes not analyzed previously by the diagnostic 
laboratory. These genes were all relatively newly identified and thus there was a paucity of 
references to them in the literature. It is anticipated that as research and diagnostic testing 
of these genes expands, more VUSs will be assigned to pathogenic or benign classes. 
Classification will be further aided by the large population studies which are now being 
performed, such as the NHLBI GO Exome Sequencing Project. Nevertheless, it is anticipated 
that some VUSs will remain difficult to classify and will require in depth clinical, in silico and 
in vitro investigation. Testing multiple genes in parallel can aid VUS classification such that if 
VUS is identified with a known pathogenic mutation in the same or another gene then, 
unless there is digenic inheritance, the likelihood of the VUS being pathogenic is reduced 
(though genetic information should always be interpreted in the context of clinical and 
pathological findings, including immunohistochemical studies).  
In theory this assay could be applied to the analysis of fresh frozen tumour samples but this 
would require the analysis of fewer samples so that coverage could be increased to detect 
clonal variants. Additionally, another set of primers could be designed with shorter amplicon 
lengths in order to analyse FFPE material. 
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3.6 Case Studies 
3.6.1 RCC case 1 
The patient had an oncocytoma diagnosed at 40 years. They also had two skin tags and two 
lesions on their trunk. The clinician queried a diagnosis of BHD. The panel identified a 
pathogenic missense mutation in SDHB, c.724C>T p.(Arg242Cys). A different pathogenic 
mutation in SDHB has previously been reported in association with oncocytoma (105).  
 
3.6.2 RCC case 2  
The female patient is one of eight siblings and has no family history of disease. She had 
bilateral renal cancer diagnosed at 36 years of age. One renal tumour was papillary type and 
the other was clear cell type. The clinician queried HLRCC. The panel identified a FLCN 
frameshift mutation, c.1333_1337dupGCACG p.( Ser447Hisfs*23). Retrospective analysis of 
the patient identified no other symptoms consistent with a BHD phenotype. For example 
there were no skin abnormalities consistent with fibrofolliculomas. This finding allowed this 
patient to be counselled regarding her risk of the other clinical features of BHD and her large 
family to have predictive genetic analysis. 
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3.7 Conclusion 
In summary, for this study two novel diagnostic assays were developed and validated. Both 
panels allowed increased detection of germline mutations in patients with 
PHEO/PGL/HNPGL and RCC at a lower cost per gene and reduced processing time compared 
to conventional sequential (Sanger-based) molecular genetic analysis. For the 
PHEO/PGL/HNPGL panel, in a cohort of 120 prospectively analyzed patients, 10 pathogenic 
germline mutations were identified in the genes analysed in the previous “standard” 
mutation analysis strategy (SDHB, SDHD, RET and VHL) and a further 3 mutations by 
analysing the less frequently interrogated PHEO/PGL/HNPGL genes, a 30% increase in 
diagnostic yield compared to the previous strategy. For the RCC panel, the case studies 
show examples of expedited molecular genetic diagnosis of pathogenic mutations in genes 
that may not have been otherwise requested by the referring clinician. Longer term it is 
predicted that better classification of potential VUSs will further enhance the utility of 
assays similar to this and enable the advantages of precise molecular diagnosis to be offered 
to larger cohorts of patients. 
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Chapter 4 Development of an enhanced next 
generation sequencing (NGS) strategy for 
improved genetic diagnosis of von Hippel-
Lindau (VHL) disease
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4.1 Introduction 
4.1.1 von Hippel-Lindau (VHL) disease and its name 
von Hippel-Lindau (VHL) disease is an autosomal dominant inherited condition which causes 
multiple benign and malignant tumours including clear cell renal carcinoma (ccRCCs), retinal 
and central nervous system (CNS) haemangioblastomas (HABs), phaeochromocytomas 
(PHEOs), pancreatic neuroendocrine tumours (106) and some additional rarer tumours. It is 
thought to affect approximately 1 in 36, 000 individuals (107). VHL was named after Eugen 
von Hippel, who described a family with retinal angiomas in 1904 (108), and Arvid Lindau, 
who described the cerebellar and spinal HABs in 1927 (109), but the term did not become 
commonly used until the 1970s (106). Prior to the advent of molecular diagnostics a clinical 
diagnosis of VHL was given when a patient had two relevant tumours without a family 
history of disease or one tumour with a family history (110). 
 
4.1.2 VHL gene identification and tumour suppressor activity 
In 1993, positional cloning identified the VHL gene at 3p25-26 (111). It is a tumour 
suppressor gene. VHL disease-related tumour development results from the combination of 
an inherited mutation on one allele of VHL and inactivation or loss of the second allele, 
conforming to Knudson’s two hit hypothesis (26). This was initially demonstrated when loss 
of heterozygosity (LOH) analysis found that inactivation of both VHL alleles was required for 
tumour formation to occur, both for VHL-related tumours and sporadic ccRCC (112-114). 
Biallelic loss of VHL protein (pVHL) is found in the majority of sporadic ccRCC (115;116). In 
addition, it was shown that when pVHL was reintroduced into VHL-null ccRCC cells it 
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supressed their ability to form tumours in nude mice (117) and restored their capacity to 
exit the cell cycle and become quiescent upon serum withdrawal, which suggests a role for 
pVHL in regulation of cell cycle exit in the kidney (118). 
 
4.1.3 VHL phenotypic heterogeneity 
4.1.3.1 VHL disease 
VHL disease exhibits phenotypic heterogeneity (119;120) and is classified into various types 
dependent on the clinical features observed in the patient. Type 1 and Type 2 are 
differentiated by the absence or presence of PHEO respectively (119). Type 2 is then further 
subdivided, depending on the presence or absence of RCC and other tumours, as described 
in Table 4.1 (121). Whilst the division can aid genotype-phenotype analysis, families have 
been shown to move between the types (106) and this classification is not used widely for 
clinical management.  
Table 4.1 Genotype-phenotype correlations in VHL disease 
(Adapted from (106)). 
 
VHL disease subtype Clinical manifestations Type of VHL gene mutations observed 
1 ccRCC, HAB Deletions (not including upstream 
BRK1), nonsense, frameshift, missense 
1B HAB Deletion including BRK1 
2A HAB, PHEO Missense 
2B ccRCC, HAB, PHEO Missense 
2C PHEO Missense 
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4.1.3.2 Chuvash polycythaemia (CSP) 
Mutations in the VHL gene are also known to cause Chuvash polycythaemia (CSP), the first 
inherited disorder of oxygen sensing to be reported (122). The CSP phenotype consists of 
varicose veins, vertebral haemangiomas, elevated serum VEGF concentration and increased 
risk of stroke (123). Erythropoietin is high compared to haemoglobin in the majority of 
patients (123). In contrast to VHL disease, which is autosomal dominant and caused by a 
large variety of heterozygous germline mutations, CSP is autosomal recessive and caused by 
specific VHL germline missense mutations when present homozygously or compound 
heterozygously (122;124-127). The c.598C>T p.(Arg200Trp) mutation (also known as 
R200W) is the most common CSP mutation and is endemic to the Chuvash Autonomous 
Republic of the Russian Federation, hence the disease name (128). In the literature there 
are cases of patients with CSP and an apparently single heterozygous VHL mutation (128). 
The vast majority of patients with CSP do not develop tumours, but there have been two 
reports of patients with isolated HAB (106) and one compound heterozygous patient who 
presented with polycythaemia aged 7 and PHEO in his 30s (129). A knock-in R200W 
transgenic mouse shows polycythaemia without tumour formation (130) and it is believed 
that heterozygous carriers of c.598C>T p.(Arg200Trp) do not have an increased risk of 
cancer (131;132). Additionally, polycythaemia is rarely observed in individuals with VHL 
disease and then only as a component of paraneoplastic syndrome in those with a tumour 
(133;134).  
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4.1.4 VHL mRNA isoforms 
The VHL gene is composed of three exons. There are two mRNA isoforms: 1) NM_000551, 
which is the longer and includes all 3 exons and 2) NM_198156, which lacks exon 2, an in-
frame coding exon (135-137). Given that deletion of exon 2 is a pathogenic mutation which 
leads to VHL Type 1, the isoform lacking exon 2 cannot be sufficient for pVHL function 
(138;139). 
4.1.5 The VHL protein (pVHL) and its function 
There are two isoforms of pVHL resulting from the longer mRNA transcript. The larger 
consists of 213 amino acids and encodes a 30kDa protein named pVHL30 (140). The smaller 
isoform consists of 160 amino acids and encodes a 19kDa protein named pVHL19 (141;142). 
pVHL19 is the result of an internal methionine at amino acid position 54; when it is used the 
protein does not include an acidic pentamer repeat domain. It has been shown that pVHL30 
co-localises principally with cytoplasmic microtubules, whereas pVHL19 localises largely in 
the nucleus (143). The smaller isoform is thought to be predominant in multiple tissues 
(106). Early functional studies suggested the two isoforms have equivalent effects in assays 
(141) and both isoforms possess tumour suppressor activity in vivo (142). There is strong 
evolutionary conservation over the majority of pVHL19, however the first 53 amino acids of 
pVHL30 do not exhibit such strong conservation and there is an extreme paucity of 
pathogenic familial mutations reported in that region compared to the rest of the gene 
(144). 
pVHL comprises two structural domains, the alpha and beta domains. The alpha domain is 
mainly α-helices and acts as a binding site. The beta domain comprises β-sheets, is 
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approximately 100 residues in size and is involved in substrate recognition (145). pVHL 
forms a ternary complex with the elongin C and elongin B proteins (146-149), named the 
VCB complex, which is critical for pVHL’s function. Figure 4.1 depicts the structure (149). The 
VCB complex nucleates another complex containing CUL2 and RBX1 to create the VCB-CR 
complex (150-152). The formation of the VCB complex stabilises its component proteins 
(153) and makes it resistant to proteasomal degradation. However if pVHL contains a 
mutation which disrupts elongin binding, it becomes unstable and rapidly degraded by the 
proteasome (146-148;150). 
 
Figure 4.1 The VCB complex 
The VCB complex has two interfaces, the first between VHL (pink) and elongin C (blue) and 
the second between elongin C and elongin B (green). (Adapted from (106)). 
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4.1.5.1 Hypoxia-inducible factor (HIF)-dependant VHL functions 
pVHL is known to have a variety of functions but the best understood is its role in oxygen 
sensing, as shown in Figure 4.2. In VHL disease, this pathway is thought to contribute to 
tumourigenesis because under normoxic conditions pVHL is necessary to switch off HIF 
action. Without any functional pVHL, inappropriate activation of HIF downstream target 
genes occurs despite normal oxygen levels. Many of the pathogenic VHL mutations are 
predicted, or have been demonstrated, to impair interaction between pVHL and HIF (154-
158). 
 
Figure 4.2 Schematic depicting pVHL function in normoxia and hypoxia 
In the presence of oxygen (normoxia), HIFα proteins bind exclusively to the beta domain of 
pVHL (154;155). The binding of HIFα by pVHL is dependent upon its hydroxylation by prolyl 
hydroxylases 1-3 (PHD1-3) at two conserved proline residues (Pro564 and Pro402 for 
HIF1α), also known as the oxygen-dependant degradation domain (123). PHD1-3 only 
function under normoxic conditions as they require oxygen as a co-substrate (155;159-162). 
The prolyl-hydroxylation of HIFα allows it to be recognised and ubiquitinated by the VCB-CR 
complex and thus recognised and degraded by the cellular proteasome. In contrast, under 
hypoxic physiological conditions, or when functional pVHL is lost, HIFα is not degraded and 
therefore accumulates and forms heterodimers with HIFβ, which translocates to the nucleus 
binds to hypoxia response elements(163). It is thought that there are more than 800 HIF 
target genes (164;165); many of which promote acute or chronic hypoxia adaption(166). In 
addition, HIFs are thought to bind and transactivate genes, encoding microRNAs (167) and 
chromatin modifying enzymes (164;168-170), and thus indirectly regulate genes (Adapted 
from (106)). 
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Three isoforms of HIFα have been identified, HIF1α, HIF2α and HIF3α. Knowledge of HIF3α is 
limited, but more extensive work has been done on HIF1α and HIF2α. HIF1α is ubiquitously 
expressed whereas HIF2α is mainly expressed in endothelial, lung, renal and hepatic cells 
(171). In hypoxic conditions, both HIF1α and HIF2α activate transcription of target genes by 
binding to the same hypoxia-response element, following dimerization with HIF1β (172). 
They have been shown to promote transcription of different genes with HIF1α promoting 
genes involved in the glycolytic pathway and HIF2α promoting growth and angiogenesis 
genes (173-175) . It is thought that HIF2α is the key driver of renal cancer progression 
(reviewed in (172)).  
4.1.5.2 HIF independent functions 
pVHL also has HIF-independent functions and it is these functions that are likely to explain 
the VHL type 2C phenotype, in which only PHEOs are observed and the mutations have been 
shown to maintain their ability to downregulate HIF (121). The molecular mechanism central 
to the pathogenesis of VHL-associated CSP is unclear, but two theories have been 
presented. The first suggests that these variants only mildly affect oxygen sensing by only 
affecting a subset of HIF activated genes and that a greater level of dysfunction is required 
for tumour formation, whereas the second suggests that a separate pathway is affected for 
each of the two phenotypes (106). 
4.1.5.2.1 Microtubule stabilisation and maintenance of the primary cilium 
Primary cilia act as chemical and mechanical sensors on the surface of cells (176). Those 
present on renal epithelial cells have a variety of roles including responding to changes in 
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urine flow, maintaining the nephrons and aiding in development. pVHL binds and stabilises 
microtubules that are important in cilia maintenance (177). 
4.1.5.2.2 Regulation of the extracellular matrix assembly 
pVHL has been shown to be essential for the assembly of the extracellular fibronectin matrix 
(178). pVHL-negative RCC cells show hugely defective extracellular fibronectin matrix 
assembly, which is restored by reintroduction of wild type pVHL (178). 
4.1.5.2.3 Regulation of apoptosis 
pVHL has been shown to modulate a number of apoptosis regulators (179). For example it 
activates NFκB by promoting phosphorylation agonist CARD9 (180) and inactivating p53 via 
inhibiting MDM2-mediated ubiquitination and nuclear export (181). 
4.1.5.2.4 Control of cell senescence 
VHL inactivation results in cell senescence via activation of pRB and down regulation of p400 
(a SWI/SNF chromatin remodeling protein) (182). 
4.1.5.2.5 Transcriptional regulation 
An example of HIF-independent VHL transcriptional regulation is that pVHL targets RNA 
polymerase II for ubiquitination, using the same binding site as HIF (183). 
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4.1.6 VHL mutation spectrum 
Germline VHL mutations have been reported in more than 900 families with VHL disease 
(144;184) which has allowed genotype-phenotype correlations to be made. The first 53 
amino acids of pVHL30 display poor evolutionary conservation and are not present in pVHL19. 
Only a handful of potentially pathogenic mutations have been reported in this domain 
(144;184). The majority of patients with truncating mutations or exon deletions have Type 1 
VHL disease (Table 4.1) (144). A subset of Type 1 patients have a pathogenic full or partial 
VHL deletion where the deletion encompasses BRK1, an adjacent gene. These individuals 
develop retinal and CNS HABs but have a low-risk of ccRCC. This phenotype has been 
referred to as Type 1B (139;185-187). The lack of ccRCC is thought to result from the 
combination of BRK1 and VHL inactivation causing renal cells to be defective in proliferation, 
polarisation and motility, and therefore inefficient in tumour formation (188). The majority 
of Type 1 deletions are mediated by Alu repeats which occur with comparatively high 
frequency in the VHL genomic region (139).Type 2 VHL disease is mainly caused by germline 
missense mutations (84%) (144). The majority of kindreds have RCC, HBB and PHEO and are 
considered to be Type 2B. Protein conformation analysis has suggested that surface amino 
acid substitutions yield a higher risk of PHEO than those closer to the protein core (189). 
In vitro modelling of VHL mutations has provided evidence that the risk of developing HAB 
or ccRCC is associated with the ability of mutant pVHL to impair HIF activity (121;157;158). 
Major defects in HIF regulation are associated with Type 1 and Type 2B VHL mutations, 
whereas Type 2A mutations appear to be less defective. Some Type 2C VHL disease 
mutations can still downregulate HIF1α (121;157) , which means VHL-related PHEOs are 
likely to be caused by a HIF-independent mechanism. It has been suggested that compete 
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loss of pVHL function is lethal/disadvantageous for PHEO precursor cells (106). These 
correlations are complicated by the high likelihood that genetic modifiers also influence VHL 
disease expression (190-192). 
 
4.1.7 Testing VHL to date 
Diagnostic molecular genetic testing currently comprises sequence analysis of the three VHL 
exons and a small amount of adjacent intronic material, either alone or as part of a panel of 
genes (193), and dosage analysis of the three exons using MLPA. This methodology is 
thought to identify the vast majority of VHL mutations (>95%). However, there are affected 
individuals in whom a pathogenic mutation has not been identified, and there are a several 
possible reasons why mutations in VHL could be missed by the routine screening strategy. 
Firstly, a number of regions of the VHL gene are not routinely analysed, including the 
promotor/5’ untranslated region (UTR), the ‘deep’ introns, the 3’UTR and other potential 
regulatory elements. Pathogenic mutations, which are associated with other conditions, 
have been identified in these regions of other genes (194), and it therefore seems possible 
that this could be the case for VHL too. 
Secondly, it is also conceivable that germline promotor hypermethlylation of VHL occurs, as 
it does in MLH1 for Lynch syndrome, since this can be one of the ‘hits’ in sporadic ccRCC 
cases (195).  
Thirdly, whilst dosage analysis will affect deletions and duplications of the gene, it cannot 
detect structural rearrangements which may disrupt the gene. 
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Fourthly, mosaic level mutations have previously been identified in VHL probands (196;197). 
The majority of diagnostic laboratories either use a conventional PCR and Sanger 
sequencing approach, which is not designed to identify mosaic mutations although they 
may be observed to varying levels in different laboratories, or NGS workflows designed to 
confidently identify heterozygous mutations (193).  
Finally, the pathogenic mutation may be in another gene. A recent example of this is the 
identification of SUFU as a gene causing Gorlin syndrome, which was thought to be 
monogenic with mutations in PTCH1 alone (198).  
 
4.2 Aims  
Not all patients with a clinical diagnosis of VHL disease have had their pathogenic VHL gene 
mutation identified. The identification of a mutation is of importance as it allows 
appropriate management of individuals within a family. The aim of the research reported in 
this chapter of the thesis was to design an NGS assay in order to comprehensively search for 
the ‘missing’ sequence mutations in VHL by screening the entire gene region at high depth 
of coverage in order to be able to identify variants in regions not commonly analysed and/or 
at mosaic level. 
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4.3 Materials and methods 
4.3.1 DNA Samples 
The study was comprised of a development phase, a blind validation phase and a diagnostic 
phase. Phase I encompassed validating the system using a set of 75 DNAs with known 
Sanger sequencing and multiplex ligation dependent probe amplification (MLPA) results 
where a likely pathogenic variant had been identified (Table 4.2).  
Table 4.2 Types of Class IV and Class V variants used to validate the assay 
Variants classed as IV (likely pathogenic) or V (pathogenic)  based on the ‘Classification 
System for Sequence Variants Identified by Genetic Testing’ proposed by Plon et. al.(199). 
 
Variant type Class V Class IV TOTAL 
Large deletions 29 0 29 
Indels 15 0 15 
Nonsense 3 0 3 
Missense 15 11 26 
Inframe 0 1 1 
Intronic 0 1 1 
TOTAL 62 13 75 
 
Phase II comprised confirming the capacity of the system to identify mosaicism. This was 
achieved by creating admixtures of a common DNA with 4 DNAs at 5 different ratios (50%, 
25%. 12.50% 6.25% and 3.13%) in addition to processing those 4 DNAs alone. The variants in 
each of the DNAs are described in Table 4.3 
Table 4.3 Variants included in the mosaicism experiment 
Sample Variant 
DNA 1 c.[212_213delCC];[=] p.(Pro71Leufs*60) 
DNA 2 c.[238dupA];[=] p.(Ser80Lysfs*52) 
DNA 3 c.[407T>C];[=] p.(Phe136Ser) 
DNA 4 c.[500G>A];[=] p.(Arg167Gln) 
DNA 5 c.[525C>A];[=] p.(Tyr175Ter) 
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Phase III was designed to search for causative mutations in those DNAs where standard VHL 
analysis had not identified a likely pathogenic mutation. Fifty DNAs were analysed, 41 DNAs 
where previous Sanger sequencing had identified no variants (excluding known Class I 
polymorphisms) and an additional 9 DNAs where the only variant identified has been given 
a Class II - Likely Benign or Class III - Variant of Uncertain Significance status. 
4.3.2 Next Generation Sequencing (NGS) assay 
NGS analysis was performed on a 15, 956 bp genomic region (ch3: 10, 179, 440-10, 195, 396 
hg19) containing the VHL gene and its flanking sequences. Peripheral leukocyte DNA was 
amplified in 3 overlapping fragments of 6, 158 bp, 6, 487 bp and 4, 690 bp respectively. The 
genomic region was selected to include the entire VHL gene region and flanking DNA. These 
fragments were amplified using the SequalPrep Long PCR kit (Life Technologies). Amplicons 
were electrophoresed on a 1% W/V TBE gel for quality control. Then the amplicons for each 
DNA were pooled in equimolar concentrations, indexed and prepared for sequencing using 
the Nextera XT kit (Illumina), in accordance with the manufacturer’s instructions.  
Sequencing was performed using the Illumina MiSeq (Illumina), using 2 x 151 bp reads, again 
in accordance with the manufacturer’s instructions. Twenty four DNAs were analyzed per 
MiSeq run. 
Six NGS runs were performed by the author alone and four with assistance from Shaun 
Green or Vera Cercqueira on behalf of the WMRGL. 
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4.3.3 NGS data analysis 
Data analysis was performed using NextGENe v2.3 sequence analysis software 
(SoftGenetics) and a semi-automated in-house bioinformatics pipeline. After removal of 
poor quality reads (median score threshold <20, maximum number of uncalled bases <2, 
called base number of each read <100 and/or <3 bases with score of <16), samples were 
demultiplexed and reads mapped against gene-specific GenBank reference files. Reads were 
aligned with a matching requirement of >=12 bases with >=85% coverage, with ‘detect large 
indels’ and ‘rigorous alignment’ selected. Data was analysed by 2 methods. 1) The entire 
~16kb region was examined for variants in >5% of >30 total reads. 2) The coding region was 
analysed for variants in > 1% of >30 total reads. 
Multiple variants were identified for each DNA. Variants were removed if considered to be a 
Class I – Benign variant or an artefact. A Class I – Benign variant was defined as a variant 
present in dbSNP132 and the 1000 genomes project with a minimum allele frequency of 
greater than 1% in 1 or more of the core populations (African (AFR), American (AMR), Asian 
(ASN) and European (EUR)). An artefact was defined as any intronic variant that occurred in 
a homopolymer tract and was present in at least 50% of the samples on the run, or any 
variant that was called in at least 1 sample but observed in all samples within a run at a 
broadly similar level. Reads containing likely artefacts were examined and lack of 
consistency with a known variant was also considered. The Class I variants and artefacts 
excluded from further analysis are listed in Appendix Table 7.2 and Table 7.3, respectively.  
 
102 
 
4.3.4 Variant assessment 
Following variant identification and confirmation, determination of variant pathogenicity 
was performed according to previously published best practice guidelines (200). Much of 
this analysis was performed using Alamut as an interface (Interactive Biosoftware). This 
involved a) interrogation of locus specific databases, Human Gene Mutation Database and 
in house databases, b) literature review, c) search of NHLBI Exome Sequencing Project 
Exome Variant Server and 1000 genomes project databases, d) species conservation and e) 
in silico prediction for the impact of missense and splicing variants, as appropriate. The data 
was summarized and an informed assessment was made of likely pathogenicity. 
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4.4 Results 
4.4.1 Phase I 
The first phase encompassed blind validation of the system using a set of 75 DNAs with 
known Sanger sequencing and multiplex ligation dependent probe amplification (MLPA) 
results where a likely pathogenic variant had been identified. Table 4.4 provides a list of the 
24 small scale Class VI and V mutations which had previously been identified by Sanger 
sequencing in 46 patient DNAs. All the sequence changes were identified by the pipeline. 
Table 4.5 lists all the whole exon deletions that had previously been identified by MLPA. A 
number of the exon 1 deletions were visible upon gel electrophoresis of the long PCR 
product. In addition the deleted region showed a drop in coverage when compared visually 
to the standard coverage profile (Figure 4.3). The remaining deletions were not visible upon 
gel electrophoresis or upon NGS. Called sequence variants were examined for zygosity, 
where the examined region was divided into the three amplicons and regions of overlap 
ignored. Lack of any heterozygous calls was considered indicative of potential hemizygosity 
for that amplicon.  
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Table 4.4 Small scale VHL sequence mutations used for Phase I blind validation of the 
system 
 
DNA Variant Protein description Variant 
Type 
Class Number 
of 
patients 
c.[163dupG];[=] p.(Glu55Glyfs*77) Indel V 6 
c.[194delC];[=] p.(Ser65Trpfs*2) Indel V 2 
c.[227_229delTCT];[=] p.(Phe76del) Inframe IV 1 
c.[233A>G];[=] p.(Asn78Ser) Missense V 5 
c.[239G>A];[=] p.(Ser80Asn) Missense IV 1 
c.[240T>G];[=] p.(Ser80Arg) Missense IV 1 
c.[250G>A];[=] p.(Val84Met) Missense IV 3 
c.[250G>T];[=] p.(Val84Leu) Missense IV 1 
c.[257C>T];[=] p.(Pro86Leu) Missense V 1 
c.[262T>G];[=] p.(Trp88Gly) Missense IV 3 
c.[292_295delTACC];[=] p.(Tyr98Glnfs*60) Indel V 1 
c.[326_340+16del31insA];[=] p.(Ile109Lysfs*18) Indel V 1 
c.[332G>A];[=] p.(Ser111Asn) Missense IV 2 
c.[337C>T];[=] p.(Arg113Ter) Nonsense V 1 
c.[361delG];[=] p.(Asp121Metfs*38) Indel V 1 
c.[369delG];[=] p.(Thr124Hisfs*35) Indel V 1 
c.[463+3A>T];[=]  Intronic IV 1 
c.[479_480delAG];[=] p.(Glu160Alafs*13) Indel V 1 
c.[481C>T];[=] p.(Arg113Ter) Nonsense V 2 
c.[486C>G];[=] p.(Cys162Trp) Missense V 1 
c.[499C>T];[=] p.(Arg167Trp) Missense V 7 
c.[500G>A];[=] p.(Arg167Gln) Missense V 1 
c.[509delT];[=] p.(Val170Alafs*32) Indel V 1 
c.[606dupA];[=] p.(Gln203Thrfs*53) Indel V 1 
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Table 4.5 Results for large deletion mutation included in blind validation 
Details of whole exon deletions used for Phase I blind validation of the system, showing if 
the deletion was visualised upon gel electrophoresis and/or if there were any heterozygous 
variants (Class I-V) observed in each of the three long PCR amplicons. 
 
DNA Variant Class Gel visualised? Only homozygous variants observed? 
Amplicon 
1 
Amplicon 
2 
Amplicon 
3 
Exon 1 deletion V Yes Y Y Y 
Exon 1 deletion V Yes N N N 
Exon 1 deletion V Yes Y Y Y 
Exon 1 deletion V Yes Y Y Y 
Exon 1 deletion V Yes Y Y Y 
Exon 1 deletion V Yes Y Y Y 
Exon 1 deletion V Yes N N N 
Exon 1 deletion V Yes Y Y Y 
Exon 1-2 deletion V No Y Y N 
Exon 1-2 deletion V No Y Y N 
Exon 1-2 deletion V No Y Y Y 
Exon 1-2 deletion V No Y Y Y 
Exon 1-2 deletion V No Y Y Y 
Exon 1-3 deletion V No Y Y Y 
Exon 1-3 deletion V No Y Y Y 
Exon 1-3 deletion V No Y Y Y 
Exon 1-3 deletion V No Y Y Y 
Exon 1-3 deletion V No Y Y Y 
Exon 1-3 deletion V No Y Y Y 
Exon 1-3 deletion V No Y Y Y 
Exon 1-3 deletion V No Y Y Y 
Exon 1-3 deletion V No Y Y Y 
Exon 1-3 deletion V No Y Y Y 
Exon 1-3 deletion V No Y Y Y 
Exon 1-3 deletion V No Y Y Y 
Exon 1-3 deletion V No Y Y Y 
Exon 3 deletion V No N Y Y 
Exon 3 deletion V No N N Y 
Exon 3 deletion V No N N Y 
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a) 
 
b) 
 
c) 
 
Figure 4.3 Coverage graphs a) Standard coverage profile; b) Example deletion profile, 
estimated size of deletion ~1, 600 bp; c) second deletion profile, estimated size of deletion 
~2, 800 bp. 
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4.4.2 Phase II  
The capacity of the system to identify mosaicism was validated by spiking four DNAs 
containing a known heterozygous variant (DNA 1-4) with a common DNA, also containing a 
known heterozygous variant (DNA 5) at 6 different admixtures (Table 4.6). 
Table 4.6 DNA admixtures for mosaic validation panel 
Low admixture samples High admixture sample 
DNA 1-4 
(% of sample) 
Frequency variant 
allele expected (%) 
DNA 5 
(% of sample) 
Frequency variant 
allele expected (%) 
100.00% 50.00% 0.00% 0.00% 
50.00% 25.00% 50.00% 25.00% 
25.00% 12.50% 75.00% 37.50% 
12.50% 6.25% 87.50% 43.75% 
6.25% 3.13% 93.75% 46.88% 
3.13% 1.56% 96.87% 48.44% 
 
The percentage of reads in which each variant was called at each admixture and the depth 
of coverage were recorded. All variants at all admixtures were identified (Table 4.7). All 
variants above 5% were called by the 5% pipeline, with no additional coding variants called. 
Variants at 1.5% and 3.13% were called using the 1% pipeline. In this pipeline additional 
coding variants were called at a very low level; however these erroneous variants were 
present in all DNAs and therefore excluded from analysis as an artefact. The assay was 
designed to maintain a very high coverage depth in order to increase the probability of 
identifying variants at a low level. Variants expected to be observed at 1.56% were all 
identified at an average of 2.0% (Range: 1.50-2.05%) with an average read depth of 2809 
(Range: 798-5992). 
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Table 4.7 Results of mosaicism identification experiment for: a) low level admixture samples and b) high level admixture samples. 
a) 
Frequency 
variant 
allele 
expected 
(%) 
Mix 1 (DNA1 and 5) 
c.212_213delCC 
Mix 2 (DNA2 and 5) 
c.238dupA 
Mix 3 (DNA3 and 5) 
c.407T>C 
Mix 4 (DNA4 and 5) 
c.500G>A 
Average 
Variant % 
Coverage 
Depth 
Variant % 
Coverage 
Depth 
Variant % 
Coverage 
Depth 
Variant % 
Coverage 
Depth 
50.00% 46.88% 480 43.86% 4099 44.73% 7299 46.40% 11682 45.78% 
25.00% 21.42% 985 27.53% 2815 24.79% 5213 24.00% 8390 24.50% 
12.50% 10.70% 2598 13.17% 4291 14.07% 6190 12.35% 13789 12.70% 
6.25% 4.61% 347 6.27% 3415 7.55% 6307 7.30% 8955 6.53% 
3.13% 2.47% 1297 4.38% 3150 4.00% 8043 3.10% 15960 3.50% 
1.56% 1.50% 798 2.05% 3169 1.80% 5992 1.90% 1277 2.00% 
          b) 
         Frequency 
variant 
allele 
expected 
(%) 
Mix 1 (DNA1 and 5) 
c.525C>A 
Mix 2 (DNA2 and 5) 
c.525C>A 
Mix 3 (DNA3 and 5) 
c.525C>A 
Mix 4 (DNA4 and 5) 
c.525C>A 
Average 
Variant % 
Coverage 
Depth 
Variant % 
Coverage 
Depth 
Variant % 
Coverage 
Depth 
Variant % 
Coverage 
Depth 
0.00% 0.00% 1817 0.00% 15255 0.00% 11136 0.00% 11942 0.00% 
25.00% 18.65% 3228 18.24% 9587 19.50% 8788 19.62% 8222 19.21% 
37.50% 30.18% 7943 29.81% 13548 29.44% 9864 29.29% 13279 29.94% 
43.75% 37.19% 847 36.52% 11087 36.58% 10936 35.12% 8564 36.86% 
46.88% 41.24% 3615 39.15% 9587 40.41% 13028 39.37% 14924 40.53% 
48.44% 43.54% 2269 42.22% 9244 42.03% 9495 42.56% 1189 43.36% 
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4.4.3 Phase III 
The third phase involved prospective analysis of an additional 50 DNAs, in which either no 
reported variant or a variant in Class II or Class III had been identified previously (Table 4.8). 
In this phase all 9 of the Class II/III variants that had been previously identified by Sanger 
sequencing analysis were confirmed. For five of those DNAs no additional sequence variants 
were identified, but in four DNAs an additional one or two heterozygous non-coding 
variants were observed. These variants were classified as II or III and therefore were not 
confirmed to be pathogenic. Phase III patients were not interrogated for sequence variant 
zygosity as all had previously been analysed for dosage by MLPA in a diagnostic laboratory 
setting. 
Table 4.8 Class II and III variants, previously identified and confirmed by this assay 
Variant call Protein call Variant Class 
c.[183C>G];[=] p.(Pro61Pro) II 
c.[242C>T];[=] p.(Pro81Leu) III 
c.[338G>A];[=] p.(Arg113Gln) III 
c.[341-21_341-17delAACCT];[=] 
 
III 
c.[361G>C];[=] p.(Asp121His) III 
c.[463+8C>T];[=] 
 
III 
c.[464-10G>A];[=] 
 
III 
c.[554A>G];[=] p.(Tyr185Cys) III 
c.[639T>C];[=] p.(Asp213Asp) III 
 
Forty one patient DNA samples were examined where no previous variant or mutation had 
been identified by Sanger sequencing of the exons or MLPA dosage analysis. In 26 DNA 
samples no sequence variants were identified. In 12 DNAs Class II or III variants were 
observed, specifically 8 contained a Class III sequence variant and 4 DNAs had 1 or 2 Class II 
sequence variants (Table 4.10). Finally, 3 DNAs contained a mosaic level Class IV or V 
mutation (Table 4.11).  
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Whilst exon level dosage examination was considered outside the remit of the test, variant 
calls were examined to look for samples showing heterozygous calls that were recurrently 
outside the normal range. One sample gave multiple calls throughout the analysed region at 
an approximately 60:40 ratio rather than an approximately 50:50 ratio. This finding could 
indicate a mosaic full gene dosage change. As with all included samples, it had previously 
been analysed by MLPA in a diagnostic setting and a normal result recorded. The sample 
also had one Class III variant, c.[340+203G>A];[=]. 
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Table 4.9 Additional variants identified in samples with previously identified Class II or III variants 
Variant call Protein call Additional variant identified Class Brief reason for classification 
c.[338G>A];[=] p.(Arg113Gln) c.[464-1212A>G];[=] II Observed with 1 x Class V variant in another sample 
c.[341-21_341-
17delAACCT];[=] 
 c.[*3482dupA];[=] II Observed with 1 x Class V variant in another sample, 
no splicing alterations predicted 
c.[464-10G>A];[=]  c.[-3197_-3195delCTC];[=] III Not observed with Class IV or V variant, no additional 
information 
c.[639T>C];[=] p.(=) c.[*2511A>G];[=] III Not observed with Class IV or V variant, Ensembl VEF 
predicts it is in a regulatory element. 
c.[*3021T>C];[=] III Not observed with Class IV or V variant, no additional 
information 
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Table 4.10 Variants identified in samples which did not have a variant identified previously 
Variants identified Additional variant Reason 
1 x Class III non-coding 
variant 
c.[-3933C>T];[=] Not observed with Class IV or V variant, no additional information 
1 x Class III non-coding 
variant 
c.[-3933C>T];[=] Not observed with Class IV or V variant, no additional information 
1 x Class III non-coding 
variant 
c.[-963G>A];[=] Not observed with Class IV or V variant, no additional information 
1 x Class II non-coding 
variant 
c.[340+376C>A];[=] Observed with 3 x Class V variant in other samples 
1 x Class III non-coding 
variant 
c.[340+203G>A];[=] Not observed with Class IV or V variant, no additional information 
2 x Class II non-coding 
variants 
c.[340+280T>G];[=] Observed with 1 x Class V variant in another sample 
c.[464-1434C>T];[=] Observed with 1 x Class V variant in another sample 
1 x Class III non-coding 
variant 
c.[341-123G>T];[=] Not observed with Class IV or V variant, no additional information 
1 x Class III non-coding 
variant 
c.[464-1530C>T];[=] Not observed with Class IV or V variant, no additional information 
1 x Class II non-coding 
variant 
c.[464-1434C>T];[=] Observed with 1 x Class V variant in another sample 
1 x Class II non-coding 
variant 
c.[*820A>G];[=] Not observed at high enough frequency in stated population groups but in 2% of 
GBR alleles (1000 genomes) 
1 x Class III non-coding 
variant 
c.[*3082C>T];[=] Not observed with Class IV or V variant, no additional information 
1 x Class III non-coding 
variant 
c.[*3170G>A];[=] Not observed with Class IV or V variant, no additional information 
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Table 4.11 Details of mosaic mutations identified and level at which identified 
Variant call Protein call Class Replicate 1 Replicate 2 
Reads 
containing 
variant 
base (%) 
Depth Reads 
containing 
variant 
base (%) 
Depth 
c.[394C=/394C>T] p.(Gln132Ter) V 6.75 10723 6.74 1915 
c.[277G=/277G>C] p.(Gly93Arg) IV 5.78 4635 6.78 1623 
c.[499C=/499C>T] p.(Arg167Trp) V 1.45 6563 0.92 3696 
 
A number of clinical subgroups were represented in those patients where no likely 
pathogenic mutation had been found previously (n=50) (Table 4.12). Of those diagnosed 
clinically with VHL, three of the 17 patients were found to have likely pathogenic mutations 
at mosaic level in their lymphocyte DNA (see section 4.6 for case studies). In addition, three 
had a previously identified Class III variant, specifically one patient had a missense variant 
and two had an intronic variant where splicing analysis may be of benefit, and in five 
patients a novel Class III variant was identified (Table 4.13). No variant was identified for the 
remaining 7 patients.  
Table 4.12 Reported phenotype of negative VHL gene screen patients 
Reported phenotype Number of individuals 
Clinically diagnosed VHL 17 
Single tumour type 22 
 HAB only  17 
 Retinal angioma only  2 
 ccRCC only  2 
 PHEO only  1 
Unknown 11 
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Table 4.13 Class III variants in clinically diagnosed VHL patients 
Variant Number of times 
identified in cohort 
(n=17) 
Identified in previous 
analysis 
c.[-3933C>T];[=] 2 No 
c.[-963G>A];[=] 1 No 
c.[341-21_341-17delAACCT];[=] 1 Yes 
c.[361G>C];[=] p.(Asp121His) 1 Yes 
c.[463+8C>T];[=] 1 Yes 
c.[*820A>G];[=] 1 No 
c.[*3082C>T];[=] 1 No 
 
Of those patients with a single tumour type (n=22), which alone is not diagnostic of VHL, 14 
had no variant identified, 5 had a Class III variant identified worthy of further analysis and 2 
had a Class II variant identified. 
Table 4.14 Class II variants in patients referred for analysis with a single tumour type 
Variant Number of times 
identified in 
cohort (n=22) 
Identified in previous 
analysis 
Tumour type 
c.[242C>T];[=] p.(Pro81Leu) 1 Yes PHEO 
c.[338G>A];[=] p.(Arg113Gln) 1 Yes HAB 
c.[340+203G>A];[=] 1 No HAB 
c.[341-123G>T];[=] 1 No HAB 
c.[464-1530C>T];[=] 1 No HAB 
 
For the remaining 12 patients the clinical details could not be accessed.  
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4.5 Discussion 
Current routine practice for the identification of VHL mutations involves MLPA dosage 
analysis for large deletions and duplications and sequence analysis, using either Sanger 
sequencing or next generation sequencing, to examine the coding regions and a limited 
amount of the flanking intronic sequence (193). Recent publications looking at small 
numbers of patients have demonstrated the potential for using NGS to look for mosaic level 
mutations (196;197). A strategy was designed to interrogate VHL for both heterozygous and 
mosaic mutations in the entire VHL gene region to a 5% variant level. Additionally, the 
coding region was examined for variants down to a 1% level. 
Phase I encompassed a blind validation using 75 DNAs. All 24 of the heterozygous small 
scale (<40 base pairs) sequence variants were identified correctly, providing a sensitivity of 
100% (95% CI: 85.62-100.00%). 
Whole exon deletions and duplications were outside the expected detection capability of 
the assay. However during Phase I those deletions which fell inside an amplicon were 
identified upon gel electrophoresis and NGS allowed further visualisation of the deletion. 
Eight DNAs with exon 1 deletions were identified by this strategy. While additional exon 
level deletions could not be visualised, they could be predicted due to the absence of 
heterozygous calls within the amplicon, indicating potential hemizygosity. 
Phase II confirmed the capacity of the system to identify low level mutations by analysing 
admixtures of two heterozygous variants to create a range of ‘mosaic level’ variants of 
different types. All the variants were identified down to the lowest admixture (1.5%), using 
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the two pipelines. This demonstrated the capability of the assay to identify very low level 
variants. 
The third phase of the study involved the analysis of 50 new DNAs, where a likely 
pathogenic mutation had not been identified by conventional VHL gene analysis. In three 
patient samples a mosaic mutation was identified within the coding region of the gene. All 
of the mosaic variants were identified in patients with clinically diagnosed VHL and the 
identified variant was considered to be the likely cause of their disease (see section 4.6). It is 
likely that mosaic whole exon or gene copy number changes are also responsible for some 
of these cases, and a potential example of this was identified in this dataset, but reliably 
detecting and confirming these variants remains difficult.  
Of the remaining 47 patients, 26 had no variants of interest identified and 21 had at least 1 
previously or newly identified variant, which were spread throughout the gene region 
analysed. Unfortunately none of these variants could be classed as likely to be pathogenic. 
Of most interest are the 5 variants identified in patients with clinically diagnosed VHL 
disease, in whom a mutation should be identified. It is noteworthy that one of the variants, 
c.-3933C>T, was identified in two unrelated patients, but in less than 1% the 1000 genomes 
populations. Additional work has been performed, and is reported in Chapter 5, to attempt 
to ascertain the pathogenicity of these variants. 
There were 6 patients who were clinically described as having VHL disease but in whom no 
mutation or variants was identified. There are several possible reasons for this, firstly that 
there is another rare, as yet undiscovered, gene which causes this phenotype or secondly, 
and perhaps more likely, that this test is not identifying all the mutations in the VHL gene. 
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For example, neither a mosaic large copy number imbalance nor a mutation which acts at 
very long range would be detected by this analysis. 
 
4.6 Case reports – mosaic mutations 
4.6.1 Case I - c.[394C=/394C>T] p.(Gln132Ter) at approximately 7% 
Case I was a 43 year old man with a clinical diagnosis of VHL. He had bilateral ccRCC, 
cerebellar HAB and a suspected spinal HAB. Standard diagnostic VHL sequencing analysis 
and deletion and duplication analysis did not identify a pathogenic mutation. This 
methodology identified a mosaic nonsense mutation at approximately 7%, 
c.[394C=/394C>T] p.(Gln132Ter) in exon 2 of VHL. This mutation would cause the protein to 
be truncated early and would be likely to be subject to nonsense mediated decay (NMD). It 
has been reported previously in the literature in patients with Type 1 and Type 2B VHL 
disease (144) and can be considered as Class V – Pathogenic. 
4.6.2 Case II - c.[277G=/277G>C] p.(Gly93Arg) at approximately 6% 
Case II is a 37 year old male with a clinical diagnosis of VHL. He had PHEO, four cerebellar 
HAB and bilateral ccRCC. Standard diagnostic VHL sequencing analysis, and deletion and 
duplication analysis, did not identify a pathogenic mutation. This methodology identified a 
mosaic missense mutation at approximately 6%, c.[277G=/277G>C] p.(Gly93Arg). This 
mutation has been reported in the literature in a patient with Type 1 VHL disease (144). It is 
a highly conserved amino acid and additional sequence changes that cause missense 
mutations at the same amino acid have been reported in the literature. The variant has not 
had any functional work performed and is considered to be Class IV – Likely pathogenic. 
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4.6.3 Case III – c.[499C=/499C>T] p.(Arg167Trp) at approximately 1% 
Case III is a deceased male with a clinical diagnosis of VHL. He had two cerebellar HABs, a 
PHEO and renal tumour. He had no family history and his two children were unaffected at 
over 40 years of age. The assay identified a missense mutation at approximately 1%, 
c.[499C=/499C>T] p.(Arg167Trp). This mutation is at the limits of the assay’s detection. This 
mutation has been reported in the literature on multiple occasions in patients with all 
subtypes of VHL disease (144). This variant is considered to be Class V – Pathogenic. 
 
4.7 Conclusion 
In summary, for this study a novel diagnostic assay was developed and validated. It was 
effective in identifying mosaic level variants, with identification of a clinically actionable 
mutation in 18% of those patients with clinically diagnosed VHL disease without a VHL 
mutation identified by previous analysis methods. It also identified a number of Class III 
variants which warrant further analysis.
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Chapter 5 Variant classification 
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5.1 Introduction 
5.1.1 Identification of variants of unknown significance (VUSs) 
The identification of variants of unknown significance (VUSs) has been a well-recognised 
problem for the diagnostic genetics laboratory since the introduction of mutation scanning 
and continues to be a problem in genes which have already been extensively examined.  
Mutations in the BRCA1 and BRCA2 genes are a well-known cause of inherited breast and/or 
ovarian cancer, and provide a good example of the problems diagnostic genetic laboratories 
encounter. The identification of a pathogenic mutation in BRCA1 or BRCA2 in an affected 
individual allows presymptomatic screening throughout a family with prophylactic surgery, 
heightened screening and targeted drug therapy available for those carrying the mutation, 
whilst those who don’t carry the mutation can return to the less costly screening offered to 
the general population. Both of these genes have a huge variety of pathogenic mutations, 
many of which occur in only one or two families worldwide.  
Even though BRCA1 or BRCA2 are probably the most commonly sequenced genes in the 
genome, when a genetic variant is identified it may still be almost impossible to determine if 
the change is pathogenic (18). Even in a laboratory that has sequenced in excess of 150, 000 
individuals for BRCA1 and 2, every week 1% to 2% of patients have a variant identified that 
has never been found previously, many of which will be VUSs (18). Given that there is no 
reason to believe that the BRCA1 and BRCA2 genes are any more mutable or unstable than 
any other gene in the genome (18), these data suggest that the problem of classifying 
variants will increase proportionally with the number of genes analysed.  
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5.1.2 Variant classification 
The diagnostic genetic community has adopted a five class system to categorise genetic 
variants based on their risk of pathogenicity (see Table 5.1), originally proposed by Plon et. 
al. (199). This classification system only pertains to variants that if classified as pathogenic 
would have reasonable penetrance; it does not include variants, such as those identified in 
genome wide association studies, that only confer slight alterations to risk of disease (199). 
Ideally a likelihood ratio would be calculated empirically from multiple lines of evidence, but 
it is recognised that this is often not possible and it is still very useful to assign each variant 
to one of the designated classes (199). 
Table 5.1 Classification system for sequence variants identified by genetic testing 
(Adapted from (199)). 
Class Description Probability of being 
Pathogenic 
Descriptors used in this thesis 
V Definitely Pathogenic >0.99 Pathogenic (V) 
IV Likely Pathogenic 0.95–0.99 Likely pathogenic (IV) 
III Uncertain 0.05–0.949 VUS (III) 
II Likely Not Pathogenic or of Little 
Clinical Significance 
0.001–0.049 Likely benign (II) 
I Not Pathogenic or of No Clinical 
Significance 
<0.001 Benign (I) 
 
5.1.3 Methods for classifying a variant 
The methods available for categorising the pathogenicity of a mutation can be divided into 
direct methods and indirect methods (201;202). These methods are discussed below, with 
specific focus on autosomal dominant cancer predisposition genes, although some of the 
general theories can be extrapolated to other genes and inheritance patterns. 
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Direct 1: Co-segregation with disease in pedigrees 5.1.3.1 
One of the least complicated forms of genetic evidence for pathogenicity is the co-
segregation of a variant with the cancer phenotype in a family (201). A pathogenic variant 
will segregate with affected individuals, whereas a benign variant will segregate randomly. 
Likelihood ratios can be established using a method similar to linkage analysis by examining 
the segregation of the variant rather than linked markers (201). Penetrance, the potential 
for phenocopies, non-paternity and the possibility of the variant being in linkage 
disequilibrium with the causative mutation must be taken into account (201). The main 
advantage of this approach is that it depends only on the availability of DNA samples from 
members of the family with a variant but, as with linkage analysis, its power depends on the 
number of informative meioses (201). The disadvantages are that often families with a 
variant are small and it can also be hard to obtain the required samples (201). 
Unfortunately, it is rarely possible to categorise variants as pathogenic on the basis of 
segregation alone (201). 
Direct 2: Comparison of allele frequency between cases and controls 5.1.3.2 
This simple method involves comparing the variant frequency in series of cases and controls. 
The main disadvantage is that most VUSs are very rare, so an extremely large sample size 
with extensive phenotypic information would be required to demonstrate that a variant is 
pathogenic (201). Additionally, the variant of interest may only occur in a certain 
geographical region or ethnic group making appropriate samples hard to obtain (201). This 
approach is more successfully used as a rapid way of determining neutral variants (201). If 
200 controls are genotyped and the variant of interest is shown to have a frequency of >1% 
it is highly unlikely to be a high-risk variant, in a rare autosomal dominant condition (201). 
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However it is very difficult to determine a true control population for a late-onset cancer 
predisposition disease. 
The task of identifying likely benign variants using control populations has been facilitated 
by a number of genetic variation datasets, which are available online. The first of these is 
the 1, 000 genomes project, which aimed ‘to characterize over 95% of variants that are in 
genomic regions accessible to current high-throughput sequencing technologies and that 
have allele frequency of 1% or higher in each of five major population groups’ (203;204). 
The major population groups included were African, Ad Mixed American, East Asian, 
European and South Asian, with the data released in a number of phases and a total of 2507 
human genomes analysed (205). Interestingly, the Phase I release data showed that almost 
all variants found at a frequency of 10% or greater were identified in all the populations 
studied, whereas 17% of variants found at a frequency of 0.5-5% were observed in only a 
single ancestry group (204). Given the diverse ancestry of the British population, reference 
populations reflecting multiple ancestral groups are an invaluable tool.  
The 1, 000 genomes project was followed by the Exome Sequencing Project (ESP). The ESP 
data have also been released in a number of phases. Currently, data are available from 6503 
individuals who are sub-divided into those of European American origin and those of African 
American origin (206). The cohort is made up of a number of well phenotyped populations, 
many of whom have heart, lung or blood disorders (206).  
Finally, the most recent variation database, the Exome Aggregation Consortium (ExAC), 
which incorporates 60,706 unrelated individuals from many different studies, was released 
in October 2014 (207). Again the data are subdivided by ancestral origin, this time into 
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seven populations, African, Ad-Mixed American, East Asian, South Asian, Non-Finnish 
European, Finnish European and Other. ExAC includes 1,851 of the 1, 000 genomes 
individuals, 3,936 of the ESP individuals and numerous individuals from other studies (207). 
When using the ExAC data for analysis of variants identified in cancer predisposition genes it 
is important to note that ExAC includes 7,601 samples from the Cancer Genome Atlas (207) 
and to consider the incidence of disease compared to the minor allele frequency for the 
variant.  
Together these three projects have created ready-made datasets which can be interrogated 
when analysing any identified variant. The large numbers of samples genotyped mean that 
individuals with any given cancer predisposition disease are likely to have been included but 
as long as this is considered when using the data, they provide an invaluable resource. 
Direct 3: Severity of personal and family cancer history 5.1.3.3 
One hypothesis is that the fact a variant associated with disease will tend to occur in 
families with a stronger history of disease can be used to aid pathogenicity assessment 
(201). This theory is based on the premise that an individual with a pathogenic mutation will 
tend to have a family history similar to that of individuals with other known pathogenic 
mutations, while a neutral variant will tend to have a weaker family history comparable to 
individuals without a causative germline mutation (201). The advantage of this approach is 
that it only requires genotyping of a single individual per family (201). However, it does 
require detailed data about all the families on whom mutation testing has been performed, 
to allow comparison (201). This information is often difficult to obtain and those families 
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which have been screened will have been chosen for their high-risk pedigrees, causing an 
ascertainment bias. 
Direct 4: Co-occurrence of a variant of interest with a pathogenic 5.1.3.4 
variant 
In dominant disease, the co-occurrence in trans of a variant with a known pathogenic 
mutation can be used to refute pathogenicity. Obviously this is dependent on gene and 
disease specific information, for example mutations on both alleles of a BRCA1 gene are 
thought to be embryonically lethal but mutations on both alleles of a BRCA2 gene produce a 
Fanconi anaemia phenotype rather than a breast cancer susceptibility one (201). Thus a 
variant in trans with a clearly pathogenic BRCA1 mutation implies that the variant is benign 
but in BRCA2 the patient should be examined for a Fanconi anaemia phenotype which, 
when ruled out, implies the variant is benign (201). This is a straightforward method of 
determining pathogenicity but relies on establishing phase. Phase is most easily determined 
by analysing the genotype of the parents; however the parents will not always be available 
to provide a sample. Moreover, this approach can only contribute towards ruling out 
pathogenicity. 
Direct 5: De novo appearance of the mutation with sporadic disease 5.1.3.5 
The concurrent de novo appearance of a variant in a known disease-associated gene with 
sporadic disease in a family is good evidence of pathogenicity (63). The labelling of a variant 
as de novo relies on absolute determination that the variant is not present in unaffected 
parents, and the possibility of the assay not detecting the variant in a parent and non-
paternity must both be considered. Additionally it is reported that every individual has an 
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average of 74 de novo single nucleotide variations and whilst these are generally more likely 
to be deleterious, as a result of the lack of evolutionary selection (208), it should considered 
that a neutral change could have occurred. 
Direct 6: Tumour pathology methods 5.1.3.6 
Tumour analysis is only possible and of use when examining tumour suppressor genes 
(TSGs). TSG pathogenicity relies on Knudson’s two hit hypothesis and therefore loss of 
function of the first allele in the germline and the second allele in the tumour (209). Loss of 
function can occur by mutation, loss of heterozygosity (caused by a deletion or mitotic 
recombination) or hyper-methylation of the promoter of the second allele of the gene (209). 
Various methods are available to examine the loss of function of a gene. One of the 
simplest, if applicable, is immunohistochemistry (IHC), used to detect loss of the associated 
protein. Loss of heterozygosity (LOH) can also be examined, by looking directly at tumour 
DNA to establish if the variant is found in the homozygous state, which would indicate 
deletion of the other allele. 
IHC is not always appropriate for variant analysis. For example, loss of function of the VHL is 
an early event in almost all ccRCC, independent of whether they have a germline mutation 
(210). Therefore IHC would not be a beneficial. However immunohistochemistry for SDHA 
and SDHB have been shown to be useful in identifying tumours which are likely to have 
pathogenic germline mutations in the succinate dehydrogenase genes (73;211). It has been 
shown that mutations in SDHB, SDHC and SDHD will cause loss of staining for SDHB (212) 
and mutations in SDHA will cause loss of staining in SDHA and SDHB (73). However, it should 
be noted that not all tumours that show loss of staining will have mutations identified. In 
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recent studies, between 6% and 16% of tumours without an identified mutation had loss of 
SDHB staining (211-213). 
Tumour analysis is confounded by the difficulty of obtaining samples with good quality DNA. 
Pathology laboratories routinely formalin fix and paraffin embed tumour samples because 
this is the best compromise between cost, practicality and the morphological fixation of the 
tissue (214). Unfortunately, formalin causes cross-linking between DNA stands and 
degradation leading to low molecular weight DNA (214). This makes the analysis of DNA 
extracted from FFPE tumour samples difficult to perform. 
Indirect 1: Assessment of a variant’s effect on splicing 5.1.3.7 
Evidence suggests that 15 – 50% of VUSs could influence splicing, including missense, 
synonymous and intronic variants (215). Intronic changes that sit within the invariant splice 
sites (AG/GU) almost always alter splicing and in doing so are generally pathogenic (209). 
The consensus splice site sequences are detailed in Figure 5.1. The prediction of the possible 
splicing-related effects of a VUS located within the variable bases within the consensus 
sequences can be difficult and the predictions for those VUSs at a deep intronic position or 
within an exon are highly complex. Furthermore, exonic VUSs can induce splicing defects 
instead of, or in addition to, producing functionally relevant protein changes (215). Splicing 
can be examined in silico but data should always be confirmed with an in vitro assay. 
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Figure 5.1 Splicing consensus sequences 
The three consensus sequences involved in splicing machinery recognition, the 5’ splice site 
(donor site) is 11 bp and comprises the last 3 bp of the exon and first 8 bp of the intron, the 
branch site is 11 bp and the 3’splice site (acceptor site) is 14 bp and comprises the last 12 bp 
of the intron and the first 2 bp of the exon. (Adapted from (216)). 
 
5.1.3.7.1 In silico assessment of splicing 
In silico splicing assessment can be used to predict pathogenicity. There are numerous 
programs available (217), all using two classes of algorithm: 1) those that predict splice 
donor and acceptor sites; 2) those that predict possible exonic or intronic splice enhancer 
(ESE/ISE) and exonic or intronic splice silencer (ESS/ISS) sites. 
The first class of program predicts if a variant disrupts or weakens a true splice site or 
creates a cryptic splice site in an intron or exon. These predictions tend to be more accurate 
than those concerning ESE/ISE/ESS/ISS sites, which can be unclear as to the level of effect 
any disruption may have. ESE/ISE/ESS/ISS predictors search for the many sequences that are 
potential binding sites of splicing factors, but will not determine which sites are actually 
used under physiological conditions for a particular gene (218).  
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There is little published data regarding the validation of splicing prediction programs for 
diagnostic use (219). In 2012, Houdayer et. al. conducted validation upon 327 BRCA1 and 
BRCA2 variants which had undergone both in silico and in vitro splicing analysis. They used 6 
programs, splice site prediction by neural network (NNSplice), splice site finder (SSF), 
MaxEntScan (MES), human splicing finder (HSF), ESE finder and relative enhancer and 
silencer classification by unanimous enrichment (RESCUE-ESE) (219). Their findings 
confirmed that mutation at the invariant splice sites (AG/GU) always affected splicing but 
that a local cryptic splice site should be considered which may lead to a splicing event other 
than exon skipping (219). They found that, for the variants examined in BRCA1 and BRCA2 
within the 5’ and 3’ splicing consensus sequences, a pathway that combined MES and SSF 
gave 96% sensitivity and 83% specificity (see Figure 5.1) (219). The pathway used is shown in 
Figure 5.2. Their study also confirmed the known poor specificity of ESE prediction and 
branch point prediction (219). 
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Figure 5.2 Houdayer’s recommended analysis pipeline for analysis of variants in the 5’ or 
3’ splice site consensus sequences 
Firstly the location of the variant nucleotide should be confirmed to be within the 11 bp the 
5’ splice site (donor site) or the 14 bp 3’splice site (acceptor site). A reliability threshold 
should be obtained by defining the mean score and SD for all 5’and 3’ splice sites for the 
given gene and setting the threshold at the mean-2SD (excluding those wild type sites that 
don’t meet this criterion from the pathway). The variant is then considered to require RNA 
study if the MES score decreases by at least 15% and the SSF score by at least 5%. (Adapted 
from (219)). 
5.1.3.7.2 In vitro assessment of splicing 
RT-PCR analysis of patient RNA is the most direct method for assessing splicing aberrations. 
However its use is hampered by the requirement to obtain RNA from the patient, because 
RNA is not routinely extracted from blood at the same time as DNA due to cost and, even 
when it is, the gene of interest may not be expressed in blood (218). Additionally, even if 
RNA from an expressing tissue can be extracted, analysis is complicated by normal splice 
isoforms and nonsense mediated decay (NMD) leading to degradation of abnormal products 
(218). Methods have been created to circumvent some of these problems, including the use 
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of minigenes (220) and extraction of RNA from lymphoblastoid cell lines treated with 
puromycin that have been cultured for each patient (221). Unfortunately, not all diagnostic 
laboratories have access to the cell culture facilities which are required for these two 
methodologies. 
5.1.3.7.3 Indirect 2: Assessment of missense variants 
Missense VUSs can be particularly problematic to assess given that they can affect splicing 
and/or the function of the protein. This section focuses on in silico and experimental 
methods of looking at altered protein function. 
5.1.3.7.3.1 In silico assessment of altered function 
It is very difficult to design an in silico method which is applicable to all missense (MS) 
variants and genes given that the mechanism by which a MS variant can be pathogenic is 
variable and genes have numerous functions. Very broadly, the available tools can be 
subdivided into three groups: 1) Sequence and evolutionary conservation-based methods; 
2) Protein sequence and structure-based methods; 3) Supervised learning methods (222). In 
addition there are some meta-analysis tools which incorporate several tools to make 
consensus prediction. 
Sequence and evolutionary conservation-based methods use the premise that a disease 
causing variant is more likely to occur at a position that has been conserved during 
evolution if it is essential to the function and/or structure of the protein (222). Evolutionary 
conservation can be assessed by aligning homologous genes from multiple species and 
looking to see what degree of divergence has occurred between them (222). In addition, the 
physiochemical difference between the wild type and variant amino acid can be calculated. 
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The quality of the sequence alignment and the number of species included can both directly 
impact the results produced from these programs (222). There are numerous tools available 
which use these methods and they include SIFT (223), Align-GVGD (224), Mutation assessor 
(225), PANTHER (226) and PROVEAN (227). 
Protein sequence and structure-based methods use information on the normal proteins 
structure and sequence to predict the consequence of an amino acid substitution (222). 
Tools which use this method often take into account how the variant amino acid it likely to 
change the structure of the protein and/or if it sits within a known domain e.g. a binding 
domain (222). There are a limited number of programs of this type available and the most 
commonly used is PolyPhen-2, which has two different algorithms HumDiv and HumVar 
(228). 
The final set of tools use supervised-learning methods. There are various supervised 
learning algorithms which include neural networks, support vector machines, random 
forests and naive Bayes classifiers (222). These programs may also use sequence and 
evolutionary conservation and/or protein sequence and structure but rather than using 
them directly they are trained with variants of known pathogenicity. Neural networks and 
support vector machines use two datasets, one comprising known disease mutations and 
one comprising known benign variants and the algorithm learns to discriminate between 
the two (222). Random forest methods work by combining the predictions of different 
methods associated with a pathogenic mutation and when an unknown variant is submitted 
it assesses the same methods to see if it matches a known pathogenic change and makes a 
prediction (222). However, all supervised-learning methods rely on the quality of the 
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datasets used to train them and the number and diversity of the variants included. There 
are numerous tools of this type including, I-Mutant (229), MutationTaster (230), MutPred 
(231), nsSNPAnalyzer (232), PON-2P (233), PhD-SNP (229), SNAP (234) and SNPs&GO (235).  
There are also tools which perform meta-analyses of a number of these programs. They 
include MetaSNP, which incorporates PhD-SNP, SIFT and SNAP (236), PredictSNP which 
incorporates MAPP, nsSNPAnalyzer, PANTHER, PhD-SNP, PolyPhen-1, PolyPhen-2, SIFT and 
SNAP (237), and CONDEL, which incorporates Log R Pfam E-value, MAPP, Mutation Assessor, 
Polyphen2 and SIFT (238). 
A number of studies have looked at the performance of a subset of these prediction tools, 
however comparatively few are independent. One of the largest studies was performed by 
Thusberg et. al. who evaluated the performance of nine prediction algorithms (MutPred, 
nsSNPAnalyzer, Panther, PhD-SNP, PolyPhen, PolyPhen2, SIFT, SNAP, and SNPs&GO) using 
more than 40, 000 variants which had previously been classified into pathogenic and neutral 
(239). Pathogenic missense variants were identified using the Phencode database, registries 
in IDbases and 18 locus specific databases (LSDBs) (239). Neutral variants were taken from 
the dbSNP database and had to have an allele frequency greater than 0.01 and a 
chromosome count of greater than 49 (239). The group performed statistical analysis on the 
findings and concluded that SNPs&GO and MutPred were the most reliable predictors in 
their dataset, because these methods had high accuracy, precision, specificity, sensitivity 
and negative predictive value (239). However, no single program was rated best by all 
statistical methods used, which indicates the complexity of attempting to predict the 
pathogenicity of variants computationally (239). Inevitably, the performance of a program 
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will vary depending on the gene analysed, with one being more applicable to a specific 
structure and/or function of the protein than another. While the predictions made by these 
programs can be used to suggest the likely pathogenicity of a variant, they should never be 
used alone to assign pathogenicity. 
5.1.3.7.3.2 In vitro assessment of altered function 
Functional assay development is notoriously difficult and, when used for the purpose of 
assigning or rejecting pathogenicity, the assay must be very well validated. Assays should be 
designed with the specific gene in mind and even then are very unlikely to encompass all 
the functions of a multifunctional protein, such as pVHL. Some of the confounding factors in 
functional analysis are summarised in Figure 5.3, which highlights the ease with which an 
assay can be misinterpreted. Proving that a variant has no functional effect is very difficult 
and ideally requires multiple lines of evidence, as a negative result only refers to the specific 
function analysed (240). 
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Figure 5.3 Interpretation of functional assays, the pitfalls and steps to avoid false results 
(Adapted from (240)).  
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5.2 Aims 
The aim of this stage of the study was to undertake further assessment of variants identified 
during the course of the gene screening, reported in chapters 3 and 4. Having provided a 
comprehensive list of the ways in which a variant can be assessed, this chapter now goes on 
to set out the findings from performing those analyses which it was possible to undertake 
within the laboratory setting and includes: 
1) Compilation of all variants identified; 
2) Interrogation of currently available variation databases for all Class II and III variants 
identified; 
3) In silico prediction of: 
a. splicing aberrations for all Class II and III variants identified; 
b. protein function for all Class II and III missense variants identified; 
4) In vitro analysis of predicted splicing aberrations, where possible; 
5) Tumour analysis for loss of protein function, where possible; 
6) In vitro functional assessment of protein stability for VHL variants; 
7) Compilation of all data obtained to allow reclassification of variants observed. 
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5.3 Materials and methods 
5.3.1 Compilation of all variants identified during the project 
All the variants identified during the course of gene screens were compiled in a table. 
5.3.2 Variation database interrogation – updated July 2015 
Three online variation databases were interrogated for the variants defined at Class II or III 
during the gene screening period of this research. 
 1000 genomes (super populations: African (AFR); Ad-Mixed American (AMR); East 
Asian (EAS); European (EUR) and South Asian (SAS)). The discrete populations within 
each super population were not examined individually due to their smaller sample 
size (204);  
 Exome sequencing project (ESP) (populations: European Americans (EA) and African 
Americans (AA)) (206) ; 
 Exome Aggregation Consortium (ExAC) (populations: African (AFR); Ad-Mixed 
American (AMR); East Asian (EAS); South Asian (SAS); Non-Finnish European (NFE); 
Finnish European (FIN) and Other (OTH)) – it should be noted that ExAC incorporates 
the data from 1000 genomes and ESP and should therefore not be considered an 
independent source. It also contains samples from the Cancer Genome Atlas. (207). 
Once the data were collated those variants that occurred in any population at ≥1% were 
examined for with the aim of downgrading their pathogenicity class, if appropriate. 
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5.3.3 In silico variant analysis 
In silico splicing analysis 5.3.3.1 
In silico splicing analysis was performed with five different algorithms, using Alamut as an 
interface. The algorithms incorporated were: 
 SpliceSiteFinder-like (SSF), which gives a score of 0-100 (241); 
 MaxEntScan (MES), which gives a score between 0-12 (242); 
 NNSplice (NNS), which gives a score between 0-1 (243); 
 GeneSplicer (GS), which gives a score between 0-15 (244); 
 Human Splicing Finder (HSF), which gives a score between 0-100 (245). 
The results were considered in two ways. Firstly, the pathway established by Houdayer et.al. 
was used to interrogate variants within the 5’ and 3’consensus sequences (see Figure 5.2) 
(219). 
Secondly all variants were interrogated with more permissive criteria. It was recorded that 
splicing may be affected if 1) any true donor or acceptor site was predicted to have a greater 
than 10% decrease in score by more than one program; 2) any cryptic donor or acceptor site 
was predicted to have a greater than 10% increase in score by more than one program.  
Those samples in which the variant was identified to potentially affect splicing were further 
examined. For variants that were predicted to abolish a true splice site, the local sequence 
predictions were examined for cryptic splice sites to allow anticipation of the alternative 
splicing that may occur. For the variants that were predicted to activate a cryptic splice site, 
the scores were compared to the average scores less two standard deviations for the actual 
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donors or acceptors for that gene, as appropriate, to allow prediction of the likelihood of 
the cryptic splice site’s use. Additionally, the splicing scores in the sequence local to the 
variant base were considered. 
In silico missense variant analysis  5.3.3.2 
Seventeen in silico missense mutation prediction tools, including three meta-servers were 
used to analyse the variants identified (see Table 5.2). Three programs are routinely used by 
the diagnostic genetics community in the UK as a result of their integration into Alamut, 
which is reference software for human variation interpretation used by many diagnostic 
laboratories. These three programs are AlignGVGD, SIFT and PolyPhen2.  
The programs were divided into four categories based on the method used for their 
prediction: 1) Sequence and evolutionary conservation; 2) Protein sequence and structure; 
3) Supervised learning; 4) Meta-analysis. The results of running the programs in each 
category were tabulated and the concordance (100%) between the predictions of the 
programs within each category was examined. If there were more than 3 programs in a 
category 75% concordance was also examined. If the same prediction was obtained for 
≥75% of programs in a category that result was taken as the prediction for that category. In 
addition to the concordance within a category of programs, the concordance between the 
categories of program was examined. 
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Table 5.2 In silico missense tools used for analysis of identified Class II and III variants 
Name Method type Uniform Resource Locator (URL) 
Align GVGD 
(224) 
Sequence and 
evolutionary 
conservation 
http://agvgd.iarc.fr/agvgd_input.php 
CONDEL (238) Meta-predictor http://bg.upf.edu/condel 
I-Mutant (229) Supervised-learning  http://gpcr2.biocomp.unibo.it/cgi/predictors/I-
Mutant3.0/I-Mutant3.0.cgi 
MetaSNP (236) Meta-predictor http://snps.biofold.org/meta-snp/ 
Mutation 
Assessor (231) 
Sequence and 
evolutionary 
conservation 
http://mutationassessor.org/ 
Mutation 
Taster (225) 
Supervised learning http://www.mutationtaster.org/ 
MutPred (230) Supervised learning http://mutpred.mutdb.org/ 
nsSNPAnalyzer 
(232) 
Supervised learning http://snpanalyzer.uthsc.edu/ 
PANTHER (226) Sequence and 
evolutionary 
conservation 
http://pantherdb.org/tools/csnpScoreForm.jsp? 
PhD-SNP (229) Supervised-learning http://snps.path.uab.edu/phd-snp/phd-snp.html 
Polyphen-2 
(228) 
Protein sequence 
and structure 
http://genetics.bwh.harvard.edu/pph2/ 
PON-P2 (233) Supervised-learning http://structure.bmc.lu.se/PON-P2/ 
PredictSNP 
(237) 
Meta-predictor http://loschmidt.chemi.muni.cz/predictsnp/ 
PROVEAN (227) Sequence and 
evolutionary 
conservation 
http://provean.jcvi.org/protein_batch_submit.php?species
=human 
SIFT (223) Sequence and 
evolutionary 
conservation 
http://sift.jcvi.org/ 
SNAP (234) Supervised-learning http://www.bio-sof.com/snap 
SNPs&GO (235) Supervised-learning http://snps-and-go.biocomp.unibo.it/snps-and-go/ 
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5.3.4 RNA analysis 
PCR of cDNA for analysis of VHL gene splicing 5.3.4.1 
PCR of cDNA was performed with primers designed using the Primer3 software (62). Primers 
then had a common forward or reverse M13 sequence added as appropriate to allow the 
use of a common forward or reverse sequencing primer.  
Table 5.3 VHL cDNA amplification primers 
Primer name Primer sequence (M13 tag underlined) 
VHL_cDNA_F_M13 TGTAAAACGACGGCCAGTGAGTACGGCCCTGAAGAAGA 
VHL_cDNA_R_M13 CAGGAAACAGCTATGACCTCAATCTCCCATCCGTTGAT 
VHL_full_cDNA_F_M13 TGTAAAACGACGGCCAGTATCCACAGCTACCGAGGTCAC 
VHL_Δ2_cDNA_F_M13 TGTAAAACGACGGCCAGTCTACCGAGTGTATACTCTGAAAGAGC 
VHL_FullΔ2_cDNA_R_M13 CAGGAAACAGCTATGACCCCGCTACGGATGTAGAATGG 
 
Table 5.4 VHL cDNA PCR master mix reagents and volumes 
Component Volume per reaction (µl) 
Megamix-W (Microzone) 22 
Forward primer (20nM; Sigma) 1 
Reverse primer (20nM; Sigma) 1 
cDNA (20ng/µl) 1 
TOTAL 25 
 
Table 5.5 Thermal cycling conditions for VHL cDNA PCR 
Step Temperature Time Cycles 
1 (Initial denaturation) 95 oC 5 minutes 1 
2 (Denaturation) 95 oC 1 minute 30 
3 (Primer annealing) 60 oC 1 minute 
4 (Extension) 72 oC 1 minute 
5 (Final extension) 72 oC 10 minutes 1 
 
VHL cDNA PCR agarose gel electrophoresis and imaging 5.3.4.2 
Amplified PCR products were resolved on a 2% (w/v) agarose gel. The gel was made by 
dissolving 4 g of agarose (Sigma) in 200 ml of 1 x TBE buffer (89 mM Tris, 89 mM Boric Acid; 
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2 mM EDTA; pH8.3; Severn Biotechnology) by heating in a microwave at 400 W, until the 
agarose had fully dissolved. Once cooled, 10 ng/ml ethidium bromide was added. Gels were 
cast in a 20 cm x 30 cm tray, a comb added and left to set. Gel electrophoresis was carried 
out in a horizontal tank containing 1 x TBE buffer. 5ul of PCR product was mixed with 5ul of 
2x loading buffer (10 mg Orange G (Sigma), 1.5 ml Glycerol (Sigma) with ddH2O added to a 
final volume of 25 ml) and run on the gel at 100 V for approximately 1 hour and 30 minutes. 
To approximately determine the size of amplified products, Hyperladder II (Bioline) was also 
loaded. Gels were viewed using ultraviolet transilluminator (254nm wavelength) and images 
captured using an Ingenius Syngene Bioimaging machine. 
Digital Droplet PCR using the Biorad QX200 5.3.4.3 
The PCR reaction components were mixed as per Table 5.7. Two mixes were made for each 
patient, one using the forward primer designed to amplify the full cDNA of VHL and one 
using the forward primer designed to amplify the isoform lacking exon 2 (Table 5.6). Each 
mix was added into a well of a droplet generator cartridge and loaded onto the QX100 
Droplet Generator (Bio-Rad), which compartmentalised each mix into approximately 20, 000 
oil droplets. The mixes were then amplified by thermal cycling, as per Table 5.8. Following 
amplification, the QX100 Droplet Reader (Bio-Rad) digitally enumerated the number of 
positive and negative droplets in each mix. The QuantaSoft program (Bio-Rad) was used to 
analyse the samples, using the total number of droplets, with and without probe signal, to 
calculate the number of amplicons as copies/μl. The average relative isoform abundance for 
each patient or control sample was calculated by dividing the average number of copies/μl 
of the VHL isoform lacking exon 2 by the average number of copies/μl of the full VHL mRNA 
transcript. 
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Table 5.6 VHL Droplet PCR Primer and Probe sequences 
Primer name Primer sequence 
VHL_full_cDNA_F_RQ TGTTGACGGACAGCCTATTT 
VHL_Δ2_cDNA_F_RQ CATCCACAGCTACCGAGTGT 
VHL_FullΔ2_cDNA_R_RQ GTAGAGCGACCTGACGATGT 
VHL TaqMan Hydrolysis Probe VIC-GCCTCCAGGTTGTCCGGAGC-MBG 
 
Table 5.7 VHL Droplet cDNA PCR master mix reagents and volumes 
Component Volume per reaction (µl) 
2 x Supermix (Biorad) 12.5 
VHL Forward primer (10 µM; Sigma) 2.25 
VHL Reverse primer (10 µM; Sigma) 2.25 
VHL probe (10 µM; Sigma) 0.75 
ddH2O 2.25 
cDNA (20 ng/µl) 5 
TOTAL 25 
 
Table 5.8 Thermal cycling conditions for VHL Droplet cDNA PCR 
Step Temperature Time Cycles 
1 (Initial denaturation) 95 oC 10 minutes 1 
2 (Denaturation) 94 oC 30 seconds 40 
3 (Primer 
annealing/Extension) 
65 oC 1 minute 
4 (Enzyme deactivation) 98 oC 10 minutes 1 
NB – Slow ramping speed between temperatures - 2 oC/minute 
5.3.5 FFPE Tumour analysis 
Tumour DNA PCR 5.3.5.1 
PCR of DNA extracted from FFPE tumour tissue was performed with primers designed using 
the Primer3 software (62). Care was taken to keep amplicons short as FFPE DNA can be 
degraded. Primers then had a common forward or reverse M13 sequence added as 
appropriate to allow the use of a common forward or reverse sequencing primer. PCR was 
144 
 
carried out using a hot-start PCR enzyme with a high cycle number thermal profile to give 
increased yield. 
Table 5.9 FFPE DNA amplification primers 
The M13 forward and reverse sequences are underlined to distinguish from the gene 
specific sequence. 
Primer name Primer sequence 
SDHB_ex3_M13_FFPE_F TGTAAAACGACGGCCAGTGGATAAGCTAATACATCCAGG 
SDHB_ex3_M13_FFPE_R CAGGAAACAGCTATGACCTTAGGTTGCACAGCAAGTTC 
SDHB_ex4_M13_FFPE_F TGTAAAACGACGGCCAGTCAGCAAGGAGGATCCAGAAG 
SDHB_ex4_M13_FFPE_R CAGGAAACAGCTATGACCACAAATCCTGCCCTGAAAAA 
SDHB_ex5_M13_FFPE_F TGTAAAACGACGGCCAGTTGATGATGGAATCTGATCCT 
SDHB_ex5_M13_FFPE_R CAGGAAACAGCTATGACCCAGATTGAAACAATAAATAGGGA 
SDHB_ex6_M13_FFPE_F TGTAAAACGACGGCCAGTCAGCTGAAGACATAGCAGAG 
SDHB_ex6_M13_FFPE_R CAGGAAACAGCTATGACCCAGCAATCTATTGTCCTCTTG 
SDHB_ex8_M13_FFPE_F TGTAAAACGACGGCCAGTTTTCCCTTTCAGTTTCAGTT 
SDHB_ex8_M13_FFPE_R CAGGAAACAGCTATGACCCTGTATTCATGGAAAACCAAG 
SDHC_ex3_M13_FFPE_F TGTAAAACGACGGCCAGTCGTTATGCAAAATATTAAACCA 
SDHC_ex3_M13_FFPE_R CAGGAAACAGCTATGACCCAACCTTCAGAACTTTCACC 
SDHC_ex5_M13_FFPE_F TGTAAAACGACGGCCAGTTGTAACTTATGAGCAGCTGTG 
SDHC_ex5_M13_FFPE_R CAGGAAACAGCTATGACCTTCACAGAGAAAATGTGCAA 
SDHD_ex1_M13_FFPE_F TGTAAAACGACGGCCAGTGTTGGTGGATGACCTTGA 
SDHD_ex1_M13_FFPE_R CAGGAAACAGCTATGACCGATGAGTCCTCACTTCCATC 
SDHD_ex2_M13_FFPE_F TGTAAAACGACGGCCAGTTGATGTTATGATTTTTTCTTTTTCT 
SDHD_ex2_M13_FFPE_R CAGGAAACAGCTATGACCCAATTCTTCAAAGTATGAAGTCA 
 
Table 5.10 PCR master mix reagents and volumes from DNA extracted from FFPE tumour 
Component Volume per reaction (µl) 
GeneAmp 10X PCR Gold Buffer (ThermoFisher) 2.5 
MgCl2 (25mM; ThermoFisher) 2.5 
dNTPs (2mM; ThermoFisher) 2.5 
Forward primer (20nM; Sigma) 1 
Reverse primer (20nM; Sigma) 1 
AmpliTaq Gold® polymerase (5U/µL; ThermoFisher) 0.15 
DNA (concentration as at extraction) 1 
ddH2O 10.35 
TOTAL 25 
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Table 5.11 Thermal cycling conditions for DNA extracted from FFPE tumour 
Step Temperature Time Cycles 
1 (Initial denaturation) 95 oC 15 minutes 1 
2 (Denaturation) 95 oC 1 minute 40 
3 (Primer annealing) 55 oC 1 minute 
4 (Extension) 72 oC 1 minute 
5 (Final extension) 72 oC 10 minutes 1 
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5.3.6 Bacterial Assays 
Vectors 5.3.6.1 
5.3.6.1.1 pcDNA3.1 
The open reading frame of VHL had previously been cloned into pcDNA3.1 by Prof E Maher’s 
group. The vector carries an ampicillin selection marker. 
5.3.6.1.2 pIRES2-AcGFP1 
The pIRES2-AcGFP1 vector (Clontech; see Figure 5.4) is bicistronic and allows the 
simultaneous expression of green fluorescent protein (AcGFP1) and a cloned protein of 
interest, which in turn allows determination of the level of the cloned protein relative to the 
amount of AcGFP. The vector contains an internal ribosome entry site (IRES2) of the 
encephalomyocarditis virus. When expressed in cells, the protein of interest is translated in 
a CAP-dependent manner and AcGFP1 is translated in an IRES dependent manner. AcGFP1 is 
a green fluorescence protein from Aequore coerulescens that can be detected by a specific 
monoclonal antibody. The vector carries a kanamycin selection marker. 
 
Figure 5.4 pIRES-AcGFP1 vector information and multiple cloning site sequence 
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Bacterial transformation 5.3.6.2 
A general transformation protocol was used for introducing vectors into competent E.coli 
cells, increasing vector quantities and isolating ligated vectors. 5 µl of vector was mixed with 
50 µl gold competent E. coli cells (Bioline) and incubated for 20 minutes on ice. The tube 
was then heat shocked for 45 seconds at 42 oC and returned to ice. 500 µl of SOC medium 
(Invitrogen) was added to the mix, which was incubated at 37 oC, shaking at 220RPM for 1 
hour. 150 µl of the incubated cells were then plated onto pre-made agar plates containing 
the required selective antibiotic. The plates were incubated at 37 oC for 16 hours to allow 
transformed cells to grow. 
Plasmid preparation 5.3.6.3 
Plasmid preparation was used to extract and purify plasmid DNA from bacterial cells. It 
comprised the initial growth of the bacterial culture, lysis of the bacteria and purification of 
plasmid DNA.  
For growth of bacterial cultures, a single colony was picked and transferred into 5 ml of LB 
broth containing the required selective antibiotic. The cultures were left to propagate 
overnight at 37 oC in a shaking incubator (220 rpm). 
Two commercial kits were used for bacterial lysis and plasmid DNA purification, depending 
on the plasmid yield required. A Miniprep kit (Qiagen) was used for yields of 20 – 30 µg of 
DNA and a Maxiprep kit (Qiagen) was used for yields of 500 – 850 µg. The kits were used as 
per the manufacturer’s instructions, which are described in brief below. 
148 
 
5.3.6.3.1 Miniprep Kit 
The bacterial cells were pelleted by centrifugation at 6, 000 x g for 15 minutes at 4 oC. The 
cell pellet was re-suspended in 250 µl of buffer P1, containing RNase A. The cells were lysed 
by addition of 250 µl of buffer P2. This reaction was neutralized by addition of 350 µl of 
buffer N3. Cells were then centrifuged for 10 minutes at 15,600 x g to pellet the cell debris. 
The supernatant which contained the plasmid was transferred to a QIAprep spin column and 
centrifuged at 15600 x g for 30-60 seconds. The flow though was discarded. The DNA bound 
to the column filter was washed firstly with 500 µl of buffer PB and centrifuged at 15,600 x g 
for 30-60 seconds and the flow though discarded, followed by repeat centrifugation at 
15,600 x g for 60 seconds and the flow though discarded. Secondly the column was washed 
with 750 µl of buffer PE at 15,600 x g for 30-60 s and then again for 60 s and the flow 
thorough discarded both times. The column was then transferred to sit on a clean tube and 
50 µl of nuclease-free water added. After 1 minute of incubation, the DNA was eluted by 
centrifugation at 15600 x g for 1 minute.  
5.3.6.3.2 Maxiprep Kit 
The bacterial cells were pelleted by centrifugation at 6000 x g for 15 minutes at 4 oC. The cell 
pellet was resuspended in 10 ml of buffer P1, containing RNase A. The cells were lysed by 
addition of 10 ml of buffer P2, 4-6 inversions of the tube and incubation at room 
temperature for 5 minutes. Precipitation of genomic DNA, cell debris and proteins was 
achieved by addition of 10 ml of buffer P3, 4-6 tube inversions and incubation on ice for 20 
minutes. The tube was centrifuged at 20, 000 x g for 30 minutes at 4 oC to pellet the 
precipitate. The supernatant was removed and centrifuged again at 20, 000 x g for 15 
minutes. The supernatant was removed again. A QIAGEN-tip 500 was equilibrated by 
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addition of 10 ml of buffer QBT and allowed to empty by gravity flow. The supernatant was 
added to the tip. The tip was then washed twice with 30 ml of QC buffer which washed the 
DNA bound to the resin in the tip. The DNA was eluted from the resin with 15ml of buffer 
QF. The DNA was precipitated by addition of 10.5ml of isopropanol, mixed and centrifuged 
at 15, 000 x g for 30 minutes at 4 oC. The pellet was washed twice with 5 ml 70% (v/v) 
ethanol and centrifuged at 15, 000 x g for 10 minutes. The pellet was left to dry for 10 
minutes at room temperature and then eluted in 200 µl of nuclease-free water. 
Plasmid Digestion 5.3.6.4 
Plasmid digestion was performed to enable moving an insert from one vector to another. 
HA-tagged VHL was transferred from pcDNA3.1 to pIRES2-AcGFP1. A digestion mix was 
prepared as per Table 5.12 and then incubated for 1-3 hours at 37 oC. 
Table 5.12 Digestion mix for VHL insert 
Reagent Volume (µl) 
Multicore Buffer (x10, Promega) 3 
BSA (Diluted 1/10, Promega) 3 
SacI (Promega) 1 
PstI (Promega) 2 
Water 16 
Plasmid DNA 5 
TOTAL 30 
 
Gel extraction 5.3.6.5 
Gel extraction was performed to establish that the insert had been removed from the vector 
and to purify the insert from the vector and digestion mix before ligation. Agarose gel 
electrophoresis was performed by loading the total ligation mix and running at 180V for 1 
hour. The insert was cut out of the gel under ultraviolet light and the DNA extracted using 
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the QIAquick Spin Kit (Qiagen), as per the manufacturer’s instructions. Briefly, the piece of 
gel was weighed and placed in a 1.5ml tube. Three volumes of QG buffer were added per 
one volume of gel (100 µl QG per 100 mg gel). The tube was incubated at 50 oC for 10 
minutes until the gel was completely dissolved. One gel volume of isopropanol was added 
and then the sample was added to a collection column and centrifuged at 15,600 x g for 1 
minute at room temperature and the flow though discarded. Next, 0.5 ml of OG buffer was 
added to the column to remove any remaining agarose and the column centrifuged again 
and the flow through discarded. The DNA was washed by addition of 0.75 ml of PE buffer 
and repeat centrifugation; the flow through discarded. Finally the DNA was eluted by 
addition of 30 µl of nuclease free water to the centre of the column, incubation for 1 minute 
and centrifugation at 15600 x g for 1 minute, followed by collection of the flow though 
containing the plasmid insert DNA. 
Ligation 5.3.6.6 
Ligation of the insert into a new vector was achieved by digesting the new vector in the 
same way as the insert and ligating in the insert. A ligation mix was prepared as per Table 
5.13. This was then incubated at 4 oC for 16 hours. The ligated vector and insert were then 
ready for transformation into competent cells. 
Table 5.13 Ligation mix for introducing an insert into a new vector 
Reagent Volume (µl) 
Buffer (x10, Promega)) 2 
T4 ligase (Promega) 1 
Water 5 
Digested vector DNA 2 
Digested insert DNA 10 
TOTAL 25 
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Site-directed mutagenesis (SDM) 5.3.6.7 
SDM was achieved using the QuikChange II Site-Directed Mutagenesis Kit (Agilent). The 
method was performed as per the manufacturer’s instructions. Briefly, PCR was carried out 
using a proofreading PCR enzyme with a specific thermal profile designed for the size of the 
plasmid being mutated (see Table 5.14.and Table 5.15). Once the PCR was completed, 0.5 µl 
of DpnI was added to each reaction, mixed and incubated at 37 oC for 1 hour, to allow 
digestion of the parental methylated DNA. 
Table 5.14 Site directed mutagenesis PCR master mix reagents and volumes 
Component Volume per reaction (µl) 
Reaction buffer (10 x; Agilent) 2.5 
dNTP mix 0.5 
Forward primer (10µM; Sigma) 0.6 
Reverse primer (10µM; Sigma) 0.6 
PfuUltra HF DNA Polymerase (Agilent) 0.5 
dsDNA template (25ng) 1.7 
ddH2O 18.6 
TOTAL 25 
 
Table 5.15 Thermal cycling conditions for site directed mutagenesis of VHL in pcDNA3.1 
Step Temperature Time Cycles 
1 (Initial denaturation 95 oC 30 seconds 1 
2 (Denaturation) 95 oC 30 seconds 30 
3 (Primer annealing) 55 oC 1 minute 
4 (Extension) 68 oC 6 minutes 
5 (Final extension) 68 oC 5 minutes 1 
 
Primer design for SDM 5.3.6.8 
For each mutation, primers were designed where both primers contained the desired 
mutation at the centre of the primer flanked by 10-15 bases on each side with a minimum 
40% GC-content. Each primer annealed to the same sequence on opposite strands of the 
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plasmid. Each primer was between 25 and 45 bases in length with a melting temperature 
greater than 78 oC. For mismatch mutations the Tm was calculated as below: 
Tm = 81.5 + 0.41(%GC) – 675/N - % mismatch 
Where N is the primer length (bases).  
Transformation following SDM 5.3.6.9 
0.5 µl of a DpnI digested product of SDM was added to 25 µl of thawed ultra-competent 
cells and incubated on ice for 30 minutes. Tubes were heat shocked at 42 oC for 30 seconds, 
then incubated on ice for 2 minutes. 250 µl of pre-warmed SOC medium (Invitrogen) was 
added to each tube, and the tubes were incubated at 37 oC for one hour whilst rotating at 
220 rpm. For each tube, 100 µl of cells and 150 µl of cells respectively were spread onto two 
separate kanamycin plates which were incubated at 37 oC for 16 hours. 
5.3.7 Tissue culture techniques 
All cell culture was performed in a Class II externally vented hood using sterile equipment 
and reagents. All reagents were stored at 4 oC and warmed to 37 oC in a water bath prior to 
use, unless otherwise stated. All work was performed using the human embryonic kidney 
cell line 293 (HEK293). 
Maintenance of growing cell lines 5.3.7.1 
Cells were grown in 75 cm2 flasks stored in humidified incubators in a 95% air and 5% 
carbon dioxide environment at 37 oC. The growing cells were maintained in Dulbecco’s 
modified eagle medium (DMEM; Sigma) supplemented with 10% foetal bovine serum (FBS), 
200mM L-glutamine (GIBCO), penicillin/streptomycin (penicillin 10.000units/ml, 
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streptomycin 10.000µg/ml; GIBCO) and non-essential amino acids (GIBCO). Passage of 
adherent cells was achieved by removing all the medium and washing the cells with PBS. 
Then 1 ml of trypsin (Sigma) was added and the flask incubated at 37 oC for 5 minutes, also 
called trypsinisation. The cells were then checked under a light microscope to confirm they 
had detached. 9 ml of medium was added to give a final volume of 10 ml in the flask. A 1/10 
dilution was performed by removing 9mls of medium containing suspended cells and adding 
9 ml of fresh medium. Finally the flask was returned to the incubator. 
Cryopreservation of cells 5.3.7.2 
Cells were trypsinised (as described in 5.3.7.1 ), 9 ml of medium added to resuspend the 
cells and then the medium removed to a 15 ml tube and centrifuged at 1250 rpm for 3 
minutes. The medium was removed and 1ml of freezing medium (900μl FBS; 100μl Dimethyl 
sulfoxide (DMSO; Sigma)) added to the cell pellet. The cells were resuspended in the 
freezing medium and transferred to a cryovial. The cryovial was placed in a freezing 
container (Nalgene), which was in turn put in a -80 oC freezer. This allows a -1 °C/minute 
cooling rate. Once frozen the cryovial was transferred to a liquid nitrogen storage tank.  
Resurrecting cells from liquid nitrogen 5.3.7.3 
Cells in a cryovial were thawed at 37 oC. The thawed cells were added to a 75 cm2 flask and 
10 ml of supplemented DMEM was added dropwise. The flask was then placed in the 
incubator to grow. The medium was changed, as required, to promote growth. 
Assessing cell concentration 5.3.7.4 
A haemocytometer was used to estimate the number of cells in a given quantity of medium. 
It was first cleaned with 70% ethanol and a cover slip was placed on top. 25 µl of trypsinised 
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cells in DMEM were added beneath the cover slip. The number of cells in four 1 mm2 grid 
sections was counted using a light microscope and then the average number calculated. 
Given that 1 mm2 of the grid contains 100 nl of cells, the number of cells in 1 ml was 
calculated by multiplying the average of the counts by 10000 (104). 
Transient transfection 5.3.7.5 
Prior to transfection, cells were transferred into 6-well tissue culture plates. First the cells 
were trypsinised and counted. Then, 4x105 cells were added to each well with 2ml of 
medium. The cells were grown in the incubator until they reached 90% confluency, changing 
the medium if required. Transfection was performed by preparing a transfection solution 
containing 100 μl of Optimem (Invitrogen), 2 µg of the plasmid DNA of interest and 7 μl of 
Fugene (Roche), which was vortexed and incubated for 15 minutes at room temperature. 
Individual mixes were created for each plasmid transfection to be performed. Each solution 
was then added dropwise to a well in the 6-well plate. The cells were then incubated until 
confluent and the cells lysed to extract the protein (see 5.3.7.6 ). 
Preparation of cell lysates from adherent cells 5.3.7.6 
Tissue culture medium was removed and the adherent cells washed with 2 ml of cold PBS. 
Cells were lysed using 50 μl of RIPA buffer (25mM Tris-HCl pH 7.6, 150mM NaCl, 1% NP-40, 
1% sodium deoxycholate, 0.1% SDS (Thermo scientific)). Following incubation on ice for 5 
minutes, cells were detached from the well using a sterile plastic scraper and removed to a 
1.5 ml plastic tube. Harvested cells were incubated on ice for 10 minutes and then 
centrifuged at 13, 000 rpm for 20 minutes at 4 oC. The supernatant was transferred to a 
fresh tube and stored at -80 oC for downstream applications. 
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5.3.8 Protein Analysis 
Protein quantification 5.3.8.1 
The amount of protein obtained from each cell lysate was quantified using the DC protein 
assay (Biorad). 5 μl of each sample was added to separate wells of a microtitre plate, in 
duplicate. 25 μl of reagent A’ was added to each well, followed by 200 μl of reagent B. The 
plate was gently agitated to mix the samples, and then left for 15 minutes. The 750 nm 
absorbencies were read using a Victor X3 Multilabel plate reader (PerkinElmer) and the 
protein concentration for each lysate was determined by comparison with a standard 
calibration curve prepared from known quantities of bovine serum albumin (0-2 mg/ml). 
Sodium dodecyl sulphate-polyacrylamide gel electrophoresis (SDS-5.3.8.2 
PAGE) 
Gel casting plates were cleaned with 70% ethanol before use and assembled in a stand. A 
mix for two 12% (w/v) resolving SDS-PAGE gels was prepared as per Table 5.16. 250 µl of 
10% ammonium persulphate (APS, Sigma) and 5 µl tetramethyl ethylene diamine (TEMED, 
Sigma) was added to instigate polymerisation and the gel was immediately poured between 
the casting plates in the stand to 4/5 capacity. Water was added to fill the plates to ensure a 
straight edge. Once the gel polymerised the water was removed and the stacking gel 
prepared as per Table 5.17 and then 180 µl of APS and 10 µl of TEMED added. The gel was 
then poured to fill the casting plates, a comb inserted and the gel left to polymerise. 
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Table 5.16 Mix for 12% resolving gel 
Reagent Volume (ml) 
Water 6.6 
1.5 M TRIS-HCl pH 8.8 (Sigma) 5.0 
30% Acrylamide/Bisacrylamide 
(37.5:1) 
8.0 
10% SDS 0.2 
 
Table 5.17 Mix for stacking gel 
Reagent Volume (ml) 
Water 6.8 
0.5 M TRIS-HCl pH 6.8 (Sigma) 3.0 
30% Acrylamide/Bisacrylamide 
(37.5:1) 
2.0 
10% SDS 0.12 
 
Once the gels were set, they were placed into an electrophoresis tank part filled with 1x SDS 
running buffer (25mM Tris, 192mM Glycine, 0.1% (w/v) SDS pH8.3). 
10ul of samples that had been normalised to 1.5 µg/µl were diluted in an equal volume of 
Laemmli sample buffer (25% v/v glycerol, 62.5mM Tris pH 6.8, 5% β-mercaptoethanol, 2% 
w/v SDS and 0.01% w/v bromophenol blue), boiled for 5 minutes and loaded onto the gel. 
Pre-stained molecular weight markers were also loaded. The samples were electrophoresed 
until the bromophenol blue reached the end of the gel, which typically took 2 hours at 100V. 
Immunoblotting 5.3.8.3 
Four pieces of filter paper and two sponges were soaked in 1 x transfer buffer (25mM Tris, 
192mM glycine and 20% methanol). A sheet of Hybond membrane (GE Healthcare) was cut 
to size and activated by soaking in methanol. The gel was cut to remove the stacking section 
and the stack for electroblotting was assembled as in Figure 5.5. 
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Sponge 
Filter paper 
 Filter paper 
Activated Hybond membrane 
Gel 
Filter paper 
Filter paper 
Sponge 
Figure 5.5 Stack for electroblotting 
 
The stack was rolled to get rid of any air bubbles which disrupt efficient transfer. The 
cassette was then placed in a transfer tank containing an ice block. The cassette was 
orientated with the gel closest to the anode and run at 100 V for 2 hours. 
Once transfer was complete, the membrane was blocked in 15 ml of milk (5% w/v dried milk 
(Marvel) in distilled water) for 1 hour at RT whist being agitated. The membrane was then 
transferred to a 25 ml polypropanyl tube containing the primary antibody (see 5.3.8.4 ) and 
a milk solution (5% w/v dried milk, 0.6% w/v bovine serum albumin (BSA) in distilled water). 
It was then incubated for 16 hours at 4 oC whilst on a roller. The following morning, the 
membrane was washed three times for five minutes in PBS-tween. The membrane was 
incubated in the primary antibody (see 5.3.8.4 ) and a milk solution (5% w/v dried milk, 0.6% 
w/v bovine serum albumin (BSA) in distilled water) on a roller for 1 hour. Following three 
more PBS-tween washes, the blot was ready to be developed. 
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Visualisation of proteins 5.3.8.4 
The proteins were visualised using the Amersham ECL Western Blotting Detection Reagent 
according to the manufacturer’s instructions. The membrane was then covered in plastic 
wrap and taped into a film cassette. In the dark room, the membrane was exposed to 
several photographic films, BioMax XAR (Kodak) which was developed at regular time 
intervals until a good quality signal was produced. 
Stripping the antibodies to allow re-probing 5.3.8.5 
The antibodies were stripped from a blot by boiling the membrane in distilled water for 5 
minutes. 
Antibodies 5.3.8.6 
Table 5.18 provides details of the optimal antibody dilution for immunoblotting to obtain 
clear images. 
Table 5.18 Dilution factors for antibodies used 
Antibody Dilution in milk 
Primary 
HA mouse 1 in 10000 
α-tubulin mouse 1 in 10000 
GFP 1 in 10000 
Secondary 
Rabbit anti mouse 1 in 10000 
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5.4 Results 
5.4.1 Variants observed during gene screening analyses  
A total of 75 variants (excluding Class I polymorphisms) were identified during gene 
screening for this research, as detailed in Chapters 3 and 4. The 75 variants included 72 
heterozygous variants (see Table 5.19) and 3 mosaic variants (see Table 5.20). In the context 
of this study, sequence changes were considered to be a Class I polymorphisms if they: 1) 
had been identified in greater than 1% of a super population on either of the large variation 
databases available at the time of analysis (1000 genomes and Exome Sequencing Project); 
and/or 2) been identified in trans with a pathogenic mutation. In addition, variants which 
had been observed in one or more control populations at greater than 1% and were 
recorded in the literature as being putatively disease causing, were also included (n=2). 
A variant was considered pathogenic in a tumour suppressor gene if it: 1) was a nonsense 
mutation, a frameshift mutation, at a splice site (±2 bp of CDS) or large deletion mutation 
(i.e. caused clear loss of function); 2) a missense, synonymous, intronic, 5’UTR or 3’UTR 
mutation with extensive published or local data to confirm pathogenicity. However, there 
were exceptions to these rules, in particular with regard to SDHA (see section 5.5 
Discussion). 
Of the 72 variants described in Table 5.19, 20 had been classified as either pathogenic or 
likely pathogenic and therefore clinically actionable. The remaining 52 had been classified as 
either likely benign or variants of unknown significance (VUS). These can be broken down by 
gene and their location within that gene, see Table 5.21. 
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Table 5.19 Heterozygous sequence variants identified during the analyses for this thesis 
Complete list of the 72 sequence variants identified during gene screening for this thesis, not included those designated to be a Class I 
polymorphism. RCC = Renal Cell Carcinoma; PPH = Phaeochromocytoma / Paraganglioma / Head and neck paraganglioma; VUS = Variant of 
unknown significance. 
No. Panel Gene 
Gene location 
(Exon/Intron) 
Variant type Variant (codingDNA) Variant (protein) 
Times  
observed 
Variant description 
(Variant class) 
1 RCC  FLCN 7 Missense c.[715C>T];[=] p.(Arg239Cys) 2 VUS (III) 
2 RCC  FLCN 11 Frameshift c.[1285dupC];[=] p.(His429Profs*27) 1 Pathogenic (V)  
3 RCC  FLCN 12 Frameshift c.[1333_1337dupGCACG];[=] p.(Ser447Hisfs*23) 1 Pathogenic (V)  
4 RCC  FLCN 12 Missense c.[1333G>A];[=] p.(Ala445Thr) 1 VUS (III) 
5 RCC  FLCN 3'UTR 3'UTR c.[*4A>G];[=]   1 VUS (III) 
6 PPH  MAX 4 Nonsense c.[223C>T];[=] p.(Arg75*) 1 Pathogenic (V)  
7 PPH  MAX 5 Missense c.[425C>T];[=] p.(Ser142Leu) 1 VUS (III) 
8 RCC  MET 17 Missense c.[3356G>C];[=] p.(Gly1119Ala) 1 VUS (III) 
9 PPH  SDHA 2 Missense c.[136A>G];[=] p.(Lys46Glu) 1 VUS (III) 
10 PPH  SDHA 2 Nonsense c.[91C>T];[=] p.(Arg31*) 2 Likely pathogenic (IV)  
11 PPH  SDHA 5 Synonymous c.[549C>T];[=] p.(=) 1 VUS (III) 
12 PPH  SDHA 7 Synonymous c.[822C>T];[=] p.(=) 1 VUS (III) 
13 PPH  SDHA 8 Synonymous c.[1002G>A];[=] p.(=) 1 VUS (III) 
14 PPH  SDHA 8 Missense c.[923C>T];[=] p.(Thr308Met) 1 VUS (III) 
15 PPH  SDHA 10 Missense c.[1273G>A];[=] p.(Val425Met) 1 VUS (III) 
16 PPH  SDHA 10 Frameshift c.[1338delA];[=] p.(His447Metfs*23) 1 VUS (III) 
17 PPH  SDHA 12 Synonymous c.[1623G>A];[=] p.(=) 1 VUS (III) 
18 PPH  SDHA 13 Missense c.[1753C>T];[=] p.(Arg585Trp) 1 Likely pathogenic (IV)  
19 PPH  SDHA 13 Synonymous c.[1776T>C];[=] p.(=) 1 VUS (III) 
20 PPH  SDHAF2 3 Missense c.[319C>T];[=] p.(Arg107Cys) 1 VUS (III) 
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No. Panel Gene 
Gene location 
(Exon/Intron) 
Variant type Variant (codingDNA) Variant (protein) 
Times  
observed 
Variant description 
(Variant class) 
21 PPH  SDHB 1 Deletion c.[-?_200+?del];[=] 
 
1 Pathogenic (V)  
22 RCC  SDHB 1 Missense c.[32G>A];[=] p.(Arg11His) 1 VUS (III) 
23 PPH  SDHB 1 Splicing c.[72+1G>T];[=]   1 Pathogenic (V)  
24 PPH  SDHB 2 Missense c.[118A>G];[=] p.(Lys40Glu) 1 Pathogenic (V)  
25 PPH  SDHB 2 Deletion c.[73-?_200+?del];[=] 
 
1 Pathogenic (V)  
26 PPH  SDHB 2 to 7 Deletion c.[73-?_765+?del];[=] 
 
1 Pathogenic (V)  
27 PPH  SDHB 4 Splicing c.[423+1G>A];[=]   1 Pathogenic (V)  
28 
PPH & 
RCC  
SDHB 5 Missense c.[487T>C];[=] p.(Ser163Pro) 6 VUS (III) 
29 PPH  SDHB 6 Missense c.[587G>A];[=] p.(Cys196Tyr) 1 Pathogenic (V)  
30 RCC  SDHB 7 Missense c.[724C>T];[=] p.(Arg242Cys) 1 Pathogenic (V)  
31 PPH  SDHB 7 Missense c.[725G>A];[=] p.(Arg242His) 1 Pathogenic (V)  
32 PPH  SDHB 8 Frameshift c.[770dupT];[=] p.(Asn258Glufs*17) 1 Likely pathogenic (IV)  
33 PPH  SDHC 5'UTR 5'UTR c.[-118_-117delAG];[=] 
 
1 VUS (III) 
34 PPH  SDHC 2 Splicing c.[77+2dupT];[=]   1 Pathogenic (V)  
35 PPH  SDHC 3 Missense c.[148C>T];[=] p.(Arg50Cys) 1 VUS (III) 
36 PPH  SDHC 4 Missense c.[214C>T];[=] p.(Arg72Cys) 1 VUS (III) 
37 PPH  SDHC 5 Missense c.[380A>G];[=] p.(His127Arg) 1 VUS (III) 
38 PPH  SDHD 1 Missense c.[34G>A];[=] p.(Gly12Ser) 3 VUS (III) 
39 PPH  SDHD 3 Missense c.[242C>T];[=] p.(Pro81Leu) 2 Pathogenic (V)  
40 PPH  SDHD 3 Synonymous c.[312C>T];[=] p.(=) 1 VUS (III) 
41 PPH  TMEM127 3 Missense c.[268G>A];[=] p.(Val90Met) 1 VUS (III) 
42 PPH  TMEM127 3 Frameshift c.[512delTinsGCC];[=] p.(Val171Glyfs*137) 1 Pathogenic (V)  
43 PPH  TMEM127 4 Synonymous c.[411T>A];[=] p.(=) 1 VUS (III) 
44 PPH  TMEM127 4 Synonymous c.[534C>T];[=] p.(=) 1 VUS (III) 
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No. Panel Gene 
Gene location 
(Exon/Intron) 
Variant type Variant (codingDNA) Variant (protein) 
Times  
observed 
Variant description 
(Variant class) 
45 VHL  VHL 5'UTR 5'UTR c.[-3933C>T];[=] 
 
2 VUS (III) 
46 VHL  VHL 5'UTR 5'UTR c.[-3197_-3195delCTC];[=] 
 
1 VUS (III) 
47 VHL  VHL 5'UTR 5'UTR c.[-963G>A];[=] 
 
1 VUS (III) 
48 VHL  VHL 1 Synonymous c.[183C>G];[=] p.(Pro61Pro) 1 VUS (III) 
49 RCC  VHL 1 Missense c.[233A>G];[=] p.(Asn78Ser) 1 Pathogenic (V)  
50 VHL  VHL 1 Missense c.[242C>T];[=] p.(Pro81Leu) 1 VUS (III) 
51 VHL  VHL 1 Missense c.[338G>A];[=] p.(Arg113Gln) 1 VUS (III) 
52 VHL  VHL 1 Intronic c.[340+203G>A];[=] 
 
1 VUS (III) 
53 VHL  VHL 1 Intronic c.[340+280T>G];[=] 
 
1 Likely benign (II) 
54 VHL  VHL 1 Intronic c.[340+376C>A];[=] 
 
1 Likely benign (II) 
55 VHL  VHL 1 Intronic c.[341-123G>T];[=] 
 
1 VUS (III) 
56 VHL  VHL 1 Intronic 
c.[341-21_341-
17delAACCT];[=]  
1 VUS (III) 
57 VHL  VHL 2 Missense c.[361G>C];[=] p.(Asp121His) 1 VUS (III) 
58 VHL  VHL 2 Intronic c.[463+8C>T];[=] 
 
1 VUS (III) 
59 VHL  VHL 2 Intronic c.[464-10G>A];[=] 
 
1 VUS (III) 
60 VHL  VHL 2 Intronic c.[464-1212A>G];[=] 
 
1 Likely benign (II) 
61 VHL  VHL 2 Intronic c.[464-1434C>T];[=] 
 
2 Likely benign (II) 
62 VHL  VHL 2 Intronic c.[464-1530C>T];[=] 
 
1 VUS (III) 
63 RCC  VHL 3 Splice-site c.[464-2A>G];[=]   1 Pathogenic (V)  
64 VHL  VHL 3 Missense c.[554A>G];[=] p.(Tyr185Cys) 1 VUS (III) 
65 RCC  VHL 3 Missense c.[629G>A];[=] p.(Arg210Gln) 1 VUS (III) 
66 VHL  VHL 3 Synonymous c.[639T>C];[=] p.(Asp213Asp) 1 VUS (III) 
67 VHL  VHL 3'UTR 3'UTR c.[*820A>G];[=] 
 
1 Likely benign (II) 
68 VHL  VHL 3'UTR 3'UTR c.[*2511A>G];[=] 
 
1 VUS (III) 
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No. Panel Gene 
Gene location 
(Exon/Intron) 
Variant type Variant (codingDNA) Variant (protein) 
Times  
observed 
Variant description 
(Variant class) 
69 VHL  VHL 3'UTR 3'UTR c.[*3021T>C];[=] 
 
1 VUS (III) 
70 VHL  VHL 3'UTR 3'UTR c.[*3082C>T];[=] 
 
1 VUS (III) 
71 VHL  VHL 3'UTR 3'UTR c.[*3170G>A];[=] 
 
1 VUS (III) 
72 VHL  VHL 3'UTR 3'UTR c.[*3482dupA];[=] 
 
1 Likely benign (II) 
 
Table 5.20 Mosaic sequence variants identified during the analyses for this thesis 
No. Panel 
Gene 
Gene location 
(Exon/Intron) Variant type 
Variant (codingDNA) Variant (protein) 
Times  
observed 
Variant description 
(Variant class) 
1 VHL  VHL 1 Missense c.[277G=/277G>C];[=] p.(Gly93Arg) 1 Likely pathogenic (IV) 
2 VHL  VHL 2 Missense c.[394C=/394C>T];[=] p.(Gln132Ter) 1 Pathogenic (V)  
3 VHL  VHL 3 Missense c.[499C=/499C>T];[=] p.(Arg167Trp) 1 Pathogenic (V) 
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Table 5.21 Summary of genes and types of Class II and III variants identified during full 
gene screening 
  
Variant type 
 
  
Frameshift Missense Synonymous Intronic 5'UTR 3'UTR TOTAL 
G
e
n
e 
FLCN 
 
2 
   
1 3 
MAX 
 
1 
    
1 
MET 
 
1 
    
1 
SDHA 1 3 5 
   
9 
SDHAF2 
 
1 
    
1 
SDHB 
 
2 
    
2 
SDHC 
 
3 
  
1 
 
4 
SDHD 
 
1 1 
   
2 
TMEM127 
 
1 2 
   
3 
VHL 
 
5 2 10 3 6 26 
 
TOTAL 1 20 10 10 4 7 52 
 
5.4.2 Interrogation of variation databases  
All variants designated to be Class II or III during the gene screening chapters were 
compared to the current versions of the 1000 genomes data in Ensembl, Exome Sequencing 
Project (ESP) data and Exome Aggregation Consortium (ExAC) data, as of July 2015 (see 
Table 5.22). 
The interrogation of currently available data has allowed the reclassification of five VUSs to 
Class I - Benign, as a result of new data showing these variants to be present in greater than 
1% of at least one super population of control individuals. The reclassified variants 
comprised four synonymous changes and one deep intronic variant. An additional variant, 
TMEM127 c.534C>T p.(=), was found at 1.02% in the SAS population in 1000 genomes but 
only 0.61% in the ExAC data, which includes the 1000 genomes data. Following the criteria 
given here, this variant should not be downgraded to a benign polymorphism, but it would 
be reasonable to downgrade it to Class II. This left 47 variants for further analysis. 
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In addition, 2 variants, SDHB c.487T>C p.(Ser163Pro) and SDHD c.34G>A p.(Gly12Ser), which 
were both present in more than one population at greater than one percent, were putative 
disease causing mutations, and therefore warranted further investigation (246;247). These 
variants are discussed in depth in section 5.6 . 
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Table 5.22 Updated variation database minor allele frequencies (MAF) as percentages for identified Class II and III variants 
Variants highlighted in purple are those which can be reclassified as a Class I polymorphism as the result of the current MAFs (criteria: found at 
greater than one percent in at least one super population). The three databases examined are: 1) 1000 genomes (super populations: African 
(AFR); Ad-Mixed American (AMR); East Asian (EAS); European (EUR) and South Asian (SAS)); 2) Exome sequencing project (ESP) (populations: 
European Americans (EA) and African Americans (AA)); 3) Exome Aggregation Consortium (ExAC) (populations: African (AFR); Ad-Mixed 
American (AMR); East Asian (EAS); South Asian (SAS); Non-Finnish European (NFE); Finnish European (FIN) and Other (OTH)). 
Gene Variant (codingDNA) Variant (protein) 
Original Variant 
Class 
1000 genomes  
(MAF-%) 
ESP  
(MAF-%) 
ExAC  
(MAF - %) 
G AFR  AMR  EAS  EUR  SAS  AA EA ALL AFR AMR EAS SAS NFE FIN OTH 
FLCN c.715C>T p.(Arg239Cys) VUS (III) 0.06 0.00 0.14 0.00 0.20 0.00 0.02 0.06 0.02 0.02 0.01 0.00 0.01 0.03 0.00 0.22 
FLCN c.1333G>A p.(Ala445Thr) VUS (III) 0.08 0.00 0.14 0.00 0.30 0.00 - - 0.27 0.05 0.13 0.00 0.33 0.37 0.08 0.22 
FLCN c.*4G>A   VUS (III) - - - - - - - - 0.00 0.01 0.00 0.00 0.01 0.00 0.00 0.00 
MAX c.425C>T p.(Ser142Leu) VUS (III) - - - - - - - - 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 
MET c.3356G>C p.(Gly1119Ala) VUS (III) 0.02 0.00 0.14 0.00 0.00 0.00 - - 0.01 0.00 0.01 0.00 0.00 0.01 0.00 0.00 
SDHA c.136A>G p.(Lys46Glu) VUS (III) 0.06 0.23 0.00 0.00 0.00 0.00 0.41 0.00 0.04 0.43 0.01 0.00 0.01 0.00 0.00 0.00 
SDHA c.549C>T p.(=) VUS (III) 0.92 2.87 1.01 0.00 0.10 0.00 2.54 0.07 0.27 2.45 0.30 0.00 0.00 0.06 0.00 0.22 
SDHA c.822C>T p.(=) VUS (III) 1.00 2.95 1.15 0.00 0.30 0.00 2.52 0.36 0.46 2.53 0.38 0.00 0.06 0.36 0.00 0.22 
SDHA c.1002G>A p.(=) VUS (III) 0.04 0.00 0.00 0.00 0.20 0.00 0.02 0.12 0.08 0.02 0.05 0.00 0.01 0.13 0.00 0.00 
SDHA c.923C>T p.(Thr308Met) VUS (III) - - - - - - - - - - - - - - - - 
SDHA c.1273G>A p.(Val425Met) VUS (III) 0.04 0.00 0.29 0.00 0.00 0.00 - - 0.00 0.00 0.02 0.00 0.01 0.00 0.00 0.00 
SDHA c.1338delA p.(His447Metfs*23) VUS (III) - - - - - - - - - - - - - - - - 
SDHA c.1623G>A p.(=) VUS (III) 0.20 0.00 0.14 0.00 0.89 0.00 0.07 0.28 0.21 0.08 0.19 0.00 0.10 0.29 0.12 0.44 
SDHA c.1776T>C p.(=) VUS (III) 1.18 4.01 0.72 0.00 0.10 0.00 4.40 0.08 0.41 4.45 0.12 0.00 0.02 0.02 0.00 0.22 
SDHAF2 c.319C>T p.(Arg107Cys) VUS (III) 0.06 0.23 0.00 0.00 0.00 0.00 0.34 0.00 0.02 0.28 0.00 0.00 0.00 0.00 0.00 0.11 
SDHB c.32G>A p.(Arg11His) VUS (III) 0.14 0.53 0.00 0.00 0.00 0.00 0.68 0.00 0.05 0.55 0.03 0.00 0.00 0.00 0.00 0.13 
SDHB c.487T>C p.(Ser163Pro) VUS (III) 0.94 0.15 0.58 0.00 1.69 2.45 - - 1.25 0.16 0.34 0.00 1.76 1.52 2.33 0.77 
SDHC c.-118_-117delAG   VUS (III) - - - - - - - - - - - - - - - - 
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Gene Variant (codingDNA) Variant (protein) 
Original Variant 
Class 
1000 genomes  
(MAF-%) 
ESP  
(MAF-%) 
ExAC  
(MAF - %) 
G AFR  AMR  EAS  EUR  SAS  AA EA ALL AFR AMR EAS SAS NFE FIN OTH 
SDHC c.148C>T p.(Arg50Cys) VUS (III) - - - - - - - - - - - - - - - - 
SDHC c.214C>T p.(Arg72Cys) VUS (III) - - - - - - - - 0.00 0.00 0.00 0.01 0.00 0.00 0.00 0.00 
SDHC c.380A>G p.(His127Arg) VUS (III) - - - - - - - - - - - - - - - - 
SDHD c.34G>A p.(Gly12Ser) VUS (III) 0.50 0.08 1.59 0.10 0.99 0.20 - - 0.73 0.21 0.81 0.01 0.27 1.02 0.48 1.11 
SDHD c.312C>T p.(=) VUS (III) 0.70 2.57 0.14 0.00 0.00 0.00 1.93 0.01 0.21 2.39 0.10 0.00 0.00 0.00 0.00 0.11 
TMEM127 c.268G>A p.(Val90Met) VUS (III) 0.18 0.68 0.00 0.00 0.00 0.00 0.82 0.00 0.08 0.84 0.05 0.00 0.00 0.00 0.00 0.11 
TMEM127 c.411T>A p.(=) VUS (III) - - - - - - - - 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.11 
TMEM127 c.534C>T p.(=) VUS (III) 0.20 0.00 0.00 0.00 0.00 1.02 - - 0.08 0.00 0.01 0.00 0.61 0.00 0.00 0.00 
VHL c.-3933C>T   VUS (III) 0.04 0.00 0.00 0.00 0.10 0.10 - - - - - - - - - - 
VHL c.-3197_-3195delCTC   VUS (III) - - - - - - - - - - - - - - - - 
VHL c.-963G>A   VUS (III) - - - - - - - - - - - - - - - - 
VHL c.183C>G p.(Pro61Pro) VUS (III) 0.04 0.00 0.00 0.00 0.00 0.20 0.00 0.08 0.25 0.00 0.34 0.15 0.47 0.20 0.00 0.00 
VHL c.242C>T p.(Pro81Leu) VUS (III) - - - - - - - - 0.00 0.00 0.00 0.00 0.01 0.00 0.00 0.00 
VHL c.338G>A p.(Arg113Gln) VUS (III) - - - - - - - - - - - - - - - - 
VHL c.340+203G>A   VUS (III) - - - - - - - - - - - - - - - - 
VHL c.340+280T>G   Likely benign (II) 0.04 0.00 0.00 0.00 0.20 0.00 - - - - - - - - - - 
VHL c.340+376C>A   Likely benign (II) 0.02 0.00 0.00 0.00 0.10 0.00 - - - - - - - - - - 
VHL c.341-123G>T   VUS (III) 0.14 0.00 0.00 0.00 0.00 0.72 - - - - - - - - - - 
VHL 
c.341-21_341-
17delAACCT 
  VUS (III) - - - - - - - - - - - - - - - - 
VHL c.361G>C p.(Asp121His) VUS (III) - - - - - - - - - - - - - - - - 
VHL c.463+8C>T   VUS (III) 0.02 0.00 0.00 0.00 0.10 0.00 0.11 0.07 0.05 0.05 0.00 0.00 0.00 0.08 0.00 0.00 
VHL c.464-10G>A   VUS (III) - - - - - - - - 0.00 0.01 0.00 0.00 0.00 0.00 0.00 0.00 
VHL c.464-1212A>G   Likely benign (II) 0.44 0.00 0.72 0.00 0.60 1.12 - - - - - - - - - - 
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Gene Variant (codingDNA) Variant (protein) 
Original Variant 
Class 
1000 genomes  
(MAF-%) 
ESP  
(MAF-%) 
ExAC  
(MAF - %) 
G AFR  AMR  EAS  EUR  SAS  AA EA ALL AFR AMR EAS SAS NFE FIN OTH 
VHL c.464-1434C>T   Likely benign (II) - - - - - - - - - - - - - - - - 
VHL c.464-1530C>T   VUS (III) - - - - - - - - - - - - - - - - 
VHL c.554A>G p.(Tyr185Cys) VUS (III) 0.02 0.00 0.00 0.00 0.10 0.00 - - 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 
VHL c.629G>A p.(Arg210Gln) VUS (III) 0.02 0.08 0.00 0.00 0.00 0.00 0.00 0.01 0.01 0.01 0.00 0.00 0.00 0.01 0.00 0.00 
VHL c.639T>C p.(Asp213Asp) VUS (III) - - - - - - - - 0.00 0.00 0.00 0.00 0.00 0.01 0.00 0.00 
VHL c.*820A>G   Likely benign (II) 0.08 0.00 0.29 0.00 0.20 0.00 - - - - - - - - - - 
VHL c.*2511A>G   VUS (III) - - - - - - - - - - - - - - - - 
VHL c.*3021T>C   VUS (III) - - - - - - - - - - - - - - - - 
VHL c.*3082C>T   VUS (III) - - - - - - - - - - - - - - - - 
VHL c.*3170G>A   VUS (III) - - - - - - - - - - - - - - - - 
VHL c.*3482dupA   Likely benign (II) - - - - - - - - - - - - - - - - 
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5.4.3 In silico analysis of variants identified 
In silico splicing prediction 5.4.3.1 
In silico prediction of splicing was performed with five different tools for the remaining 47 
Class II and III variants using Alamut as an interface (see Appendix Table 7.4). Four variants 
(8.5%) sat within the splice consensus sequences. Two sat in the 5’ sequence, one exonic 
and one intronic and two in the 3’ sequence, one exonic and one intronic. These variants 
were examined using the pathway (see Figure 5.2) determined by Houdayer et. al. (219), 
which incorporates two of the five programs employed (MES and SSF). The results are given 
in Table 5.23. None of the four variants reached the threshold for RNA analysis. 
Table 5.23 Examination of variants affecting 5’/3’ consensus splice sequences using the 
pathway devised by Houdayer et. al. 
Gene TMEM127 VHL VHL VHL 
Variant  
(coding DNA) 
c.411T>A c.338G>A c.463+8C>T c.464-10G>A 
Variant  
(protein) 
p.(=) p.(Arg113Gln)     
Consensus 
sequence  
affected 
3' 5' 5' 3' 
Consensus 
sequence 
above  
reliability 
threshold? 
Yes Yes Yes Yes 
MES at least 
15% lower than 
WT? 
No (9.8% ↓) No (9.6% ↑) No (No change) No (6.8% ↓) 
SSF at least 5% 
lower than 
WT? 
No (No 
change) 
No (0.9% ↑) No (No change) No (No change) 
RNA analysis 
recommended? 
No No No No 
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All variants were then examined using more permissive criteria (considered to warrant 
further investigation if two or more programs predicted a ≥10% decrease of a true splice site 
or a ≥10% increase for a cryptic splice site). The results are summarised in Table 5.24. Of the 
47 variants examined, one (2%) was predicted to affect an actual splice site and five (11%) 
were predicted to create a cryptic splice site.  
Figure 5.6 shows the data for the sole variant predicted to affect a normally-used splice site, 
VHL c.341-21_341-17delAACCT. The local sequence was examined for any potential cryptic 
splice sites using the data from the splicing prediction algorithms; however, none were 
predicted. Therefore, it is hypothesised that this variant may stop or decrease the use of the 
VHL exon 2 splice acceptor site, leading to skipping of exon 2. 
Of the five variants where two or more programs showed a ≥10% increase in scores for a 
cryptic splice site, four were exonic and one was within the 3’UTR of the gene. None of 
these variants were within the 5’ or 3’ consensus sequences. In order to further investigate 
their potential to affect splicing, the scores for these variants were compared to the average 
scores less two standard deviations for the actual donors or acceptors for that gene, as 
appropriate. A summary of these results is shown in Table 5.25. Of the five variants 
examined, three only equalled or exceeded the threshold (average minus 2SD) for 1 or 2 
programs, but two reached or exceeded the threshold for 4 out of 5 programs. The 
sequence local to the variants was also examined for predicted but unused splice sites. This 
showed that VHL c.[*3082C>T] has a local predicted but unused splice site (see Figure 5.7), 
suggesting that RNA analysis would not be worthwhile, especially given that a mechanism of 
aberrant splicing so far into a 3’UTR has never been reported.  
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Interestingly, TMEM127 c.534C>T p.(=) has a MAF of >1% in the SAS population in the 1000 
genomes study and 0.61% in the same population in the ExAC database. So is unlikely to be 
pathogenic, however confirmation that it does not affect splicing would be worthwhile. 
Given these finding it was concluded that RNA analysis would only be worthwhile for VHL 
c.341-21_341-17delAACCT and TMEM127 c.534C>T p.(=). 
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Table 5.24 Summary of splicing predictions of 5 splicing algorithms for identified variants 
An effect on splicing was considered to be indicated if the score was reduced by greater 
than 10% in more than one program for the actual donor or acceptor, or increased by 
greater than 10% in more than one program for a cryptic splice donor or acceptor. 
Gene Variant (coding DNA) 
Variant 
(protein) 
Actual 
donor/acceptor 
score reduced 
Cryptic 
donor/acceptor 
score increased 
FLCN c.715C>T p.(Arg239Cys) No No 
FLCN c.1333G>A p.(Ala445Thr) No No 
FLCN c.*4G>A 
 
No No 
MAX c.425C>T p.(Ser142Leu) No No 
MET c.3356G>C p.(Gly1119Ala) No No 
SDHA c.136A>G p.(Lys46Glu) No No 
SDHA c.923C>T p.(Thr308Met) No No 
SDHA c.1002G>A p.(=) No No 
SDHA c.1273G>A p.(Val425Met) No No 
SDHA c.1338delA 
p.(His447Metfs
*23) 
No No 
SDHA c.1623G>A p.(=) No No 
SDHAF2 c.319C>T p.(Arg107Cys) No No 
SDHB c.32G>A p.(Arg11His) No No 
SDHB c.487T>C p.(Ser163Pro) No No 
SDHC c.-118_-117delAG 
 
No No 
SDHC c.148C>T p.(Arg50Cys) No No 
SDHC c.214C>T p.(Arg72Cys) No No 
SDHC c.380A>G p.(His127Arg) No No 
SDHD c.34G>A p.(Gly12Ser) No Yes 
TMEM127 c.268G>A p.(Val90Met) No No 
TMEM127 c.411T>A p.(=) No No 
TMEM127 c.534C>T p.(=) No Yes 
VHL c.-3933C>T 
 
Not available Not available 
VHL c.-3197_-3195delCTC 
 
Not available Not available 
VHL c.-963G>A 
 
No No 
VHL c.183C>G p.(Pro61Pro) No Yes 
VHL c.242C>T p.(Pro81Leu) No No 
VHL c.338G>A p.(Arg113Gln) No No 
VHL c.340+203G>A 
 
No No 
VHL c.340+280T>G 
 
No No 
VHL c.340+376C>A 
 
No No 
VHL c.341-123G>T 
 
No No 
VHL c.341-21_341-17delAACCT 
 
Yes No 
VHL c.361G>C p.(Asp121His) No No 
VHL c.463+8C>T 
 
No No 
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Gene Variant (coding DNA) 
Variant 
(protein) 
Actual 
donor/acceptor 
score reduced 
Cryptic 
donor/acceptor 
score increased 
VHL c.464-10G>A 
 
No No 
VHL c.464-1434C>T 
 
No No 
VHL c.464-1530C>T 
 
No No 
VHL c.554A>G p.(Tyr185Cys) No No 
VHL c.629G>A p.(Arg210Gln) No Yes 
VHL c.639T>C p.(Asp213Asp) No No 
VHL c.*820A>G 
 
No No 
VHL c.*2511A>G 
 
No No 
VHL c.*3021T>C 
 
No No 
VHL c.*3082C>T 
 
No Yes 
VHL c.*3170G>A 
 
No No 
VHL c.*3482dupA 
 
No No 
 
 
 
Figure 5.6 Alamut splicing prediction for the VHL variant c.341-21_341-17delAACCT 
Four programs identified the splice acceptor. Half of the programs predicted a small drop in 
the score given to the sequence; the MaxEntScan score decreased by 16% and the NNSplice 
score by 10%. In addition, 2 predicted branch points were removed by the deletion but 
these were not the best predicted sites. 
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Table 5.25 Summary of comparison of predicted cryptic splice sites caused by variant with 
true splice sites for the same gene 
The number of programs was recorded (maximum 5) for which the score for potential 
cryptic splice sites is equal to or exceeds the average scores minus two standard deviations 
for the comparable true splice sites, 5’ or 3’ considered as appropriate (full calculations 
available in Appendix Table 7.5). 
Gene Variant  
(coding DNA) 
Variant  
(protein) 
Prediction Number of algorithms 
for which variant score 
is equal to or greater 
than the average scores 
less 2SDs of the real 
splice sites for that gene 
SDHD c.34G>A p.(Gly12Ser) 3' Acceptor created 1 of 5 
TMEM127 c.534C>T p.(=) 3' Acceptor created 4 of 5 
VHL c.183C>G; p.(Pro61Pro) 5' Donor created 2 of 5 
VHL c.629G>A p.(Arg210Gln) 3' Acceptor created 1 of 5 
VHL c.*3082C>T   5' Donor created 4 of 5 
 
 
Figure 5.7 Predicted splice sites local to VHL c.*3082C>T 
VHL c.*3082C>T is predicted to create a splice donor site (red box), however another splice 
donor site (blue box) is predicted at a similar level in both the wildtype and variant 
sequences, which is unused in normal splicing of the gene. 
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In silico missense analysis 5.4.3.2 
Twenty sequence variants caused missense changes in their respective proteins. One 
occurred in a proto-oncogene, MET c.3356G>C p.(Gly1119Ala), and therefore use of in silico 
analysis programs, which look for deleterious changes, was not considered worthwhile and 
it was excluded, leaving 19 variants for analysis. 
5.4.3.2.1 In silico missense analysis - tools commonly used by diagnostic 
genetics laboratories 
The three in silico tools most commonly used by UK diagnostic genetics laboratories were 
used to interrogate the variants (see Table 5.26). 7/19 variants showed concordant results 
for these programs, with 5 variants predicted to be benign and 2 predicted to be 
pathogenic. The remaining 12 variants gave conflicting results. 
5.4.3.2.2  In silico missense analysis - additional in silico missense variant 
prediction tools 
First, five sequence and evolutionary conservation-based prediction tools were run (see 
Table 5.27), including Align-GVGD and SIFT which were included in analyses in the section 
above. 11/19 variants gave concordant results for all tools for which a result was returned, 
with seven variants predicted to be benign and four variants predicted to be pathogenic. An 
additional six variants were concordant for greater than 75% of the tools for which a result 
was returned, with three variants predicted to be benign and three predicted to be 
pathogenic. 
Next, eight machine learning tools were run (see Table 5.28). Only 4/19 gave 100% 
concordant results for all tools for which a result was returned. An additional 3/19 gave 
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concordant results for greater than 75% of tools which returned a result, with an additional 
one variant predicted to be benign and two predicted to be pathogenic. 
5.4.3.2.3 In silico missense analysis – meta-analysis tools 
Three meta-analysis tools were interrogated (see Table 5.29). 11/19 variants gave 
concordant results for these programs, with four variants predicted to be benign and seven 
variants predicted to be pathogenic, the remaining eight gave conflicting results. 
5.4.3.2.4 In silico missense analysis – concordance between sub-groups of 
prediction tools 
The concordance between subgroups of tools was then examined (see Table 5.30). A variant 
was considered to be concordant between all sub-groups if ≥75% of the tools examined for 
each category gave the same result. If <75% of tools were concordant for a category of tool 
then that category was excluded. Using this method, 5 variants were assigned as benign, 5 
as pathogenic and 9 as unknown. 
5.4.3.2.5 In silico missense analysis – comparison between amalgamated 
predictions for all tools and tools used by diagnostic laboratories. 
Finally the amalgamated results for all the 17 different in silico tools were compared to the 
amalgamated results of the three in silico tools used by diagnostic labs (see Table 5.31). All 
seven predictions by the three diagnostically used tools (100% concordance) were matched 
by the amalgamated results (using ≥75% concordance within a program type). An additional 
three predictions were made by the amalgamated tools. 
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Table 5.26 In silico predictions using programs commonly in use in UK diagnostic laboratories 
Red writing indicates the variant is considered to be damaging, yellow indicates the effect is unclear and green indicates the variant is 
predicted to be benign. Concordance between the programs is demonstrated in the last column. 
Gene Exon Variant  
(coding DNA) 
Variant  
(protein) 
AlignGVGD Polyphen-2  
(HumDiv) 
Polyphen-2  
(HumVar) 
SIFT 100% 
Concordant? 
FLCN 7 c.715C>T p.(Arg239Cys) Class C65 (GV: 0.00 - GD: 179.53) PROBABLY DAMAGING: 1.000 PROBABLY DAMAGING: 0.999 Deleterious (score: 0) YES (Pathogenic) 
FLCN 12 c.1333G>A p.(Ala445Thr) Class C0 (GV: 171.88 - GD: 0.00) BENIGN: 0.000 BENIGN: 0.000 Tolerated (score: 1) YES (Benign) 
MAX 5 c.425C>T p.(Ser142Leu) Class C0 (GV: 181.93 - GD: 0.00) PROBABLY DAMAGING: 0.999 PROBABLY DAMAGING: 0.984 Tolerated (score: 0.33) NO 
SDHA 2 c.136A>G p.(Lys46Glu) Class C0 (GV: 126.89 - GD: 43.63) BENIGN: 0.010 BENIGN: 0.005 Tolerated (score: 0.11) YES (Benign) 
SDHA 8 c.923C>T p.(Thr308Met) Class C65 (GV: 0.00 - GD: 81.04) PROBABLY DAMAGING: 1.000 PROBABLY DAMAGING: 1.000 Deleterious (score: 0) YES (Pathogenic) 
SDHA 10 c.1273G>A p.(Val425Met) Class C0 (GV: 251.13 - GD: 20.52) POSSIBLY DAMAGING: 0.819 POSSIBLY DAMAGING: 0.516 Tolerated (score: 0.05) NO 
SDHAF2 3 c.319C>T p.(Arg107Cys) Class C15 (GV: 124.29 - GD: 109.21) POSSIBLY DAMAGING: 0.641 BENIGN: 0.165 Deleterious (score: 0) NO 
SDHB 1 c.32G>A p.(Arg11His) Class C0 (GV: 241.31 - GD: 1.62) POSSIBLY DAMAGING: 0.874 BENIGN: 0.165 Deleterious (score: 0) NO 
SDHB 5 c.487T>C p.(Ser163Pro) Class C0 (GV: 144.64 - GD: 0.00) BENIGN: 0.000 BENIGN: 0.000 Tolerated (score: 0.3) YES (Benign) 
SDHC 3 c.148C>T p.(Arg50Cys) Class C25 (GV: 85.11 - GD: 126.72) PROBABLY DAMAGING: 1.000 PROBABLY DAMAGING: 0.996 Deleterious (score: 0) NO 
SDHC 4 c.214C>T p.(Arg72Cys) Class C65 (GV: 0.00 - GD: 179.53) PROBABLY DAMAGING: 0.995 POSSIBLY DAMAGING: 0.815 Deleterious (score: 0) NO 
SDHC 5 c.380A>G p.(His127Arg) Class C0 (GV: 227.83 - GD: 28.42) PROBABLY DAMAGING: 1.000 PROBABLY DAMAGING: 1.000 Deleterious (score: 0) NO 
SDHD 1 c.34G>A p.(Gly12Ser) Class C0 (GV: 353.86 - GD: 0.00) BENIGN: 0.005 BENIGN: 0.003 Tolerated (score: 0.6) YES (Benign) 
TMEM127 3 c.268G>A p.(Val90Met) Class C0 (GV: 28.68 - GD: 0.00) POSSIBLY DAMAGING: 0.739 POSSIBLY DAMAGING: 0.530 Deleterious (score: 0.02) NO 
VHL 1 c.242C>T p.(Pro81Leu) Class C25 (GV: 37.56 - GD: 76.16) PROBABLY DAMAGING: 0.997 POSSIBLY DAMAGING: 0.64 Deleterious (score: 0.02) NO 
VHL 1 c.338G>A p.(Arg113Gln) Class C0 (GV: 108.48 - GD: 16.48) POSSIBLY DAMAGING: 0.520 BENIGN: 0.012 Tolerated (score: 0.25) NO 
VHL 2 c.361G>C p.(Asp121His) Class C0 (GV: 95.81 - GD: 5.07) PROBABLY DAMAGING: 1.000 PROBABLY DAMAGING: 0.995 Deleterious (score: 0.04) NO 
VHL 3 c.554A>G p.(Tyr185Cys) Class C0 (GV: 257.44 - GD: 11.33) BENIGN: 0.372 BENIGN: 0.276 Deleterious (score: 0.03) NO 
VHL 3 c.629G>A p.(Arg210Gln) Class C0 (GV: 238.02 - GD: 0.00) BENIGN: 0.002 BENIGN: 0.001 Tolerated (score: 0.61) YES (Benign) 
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Table 5.27 In silico predictions using programs categorised as sequence and evolutionary conservation-based 
Red text indicates the variant is considered to be damaging, yellow indicates the effect is unclear and green indicates the variant is predicted 
to be benign. Concordance between the programs is demonstrated in the last column. 
Gene Exon Variant  
(codingDNA) 
Variant 
(protein) 
AlignGVGD SIFT  Mutation 
Assessor 
PANTHER PROVEAN 100% 
Concordant? 
≥75% 
Concordant? 
FLCN 7 c.715C>T p.(Arg239Cys) Class C65  Deleterious  medium (2.765) Error (-) Deleterious (-5.68) Yes (Pathogenic) - 
FLCN 12 c.1333G>A p.(Ala445Thr) Class C0  Tolerated  neutral (-1.1) Error (-) Neutral (0.19) Yes (Benign) - 
MAX 5 c.425C>T p.(Ser142Leu) Class C0  Tolerated  low (1.59) Not significant (-1.68274) Deleterious (-2.57) No Yes (Benign) 
SDHA 2 c.136A>G p.(Lys46Glu) Class C0  Tolerated  low (1.21) Not significant (-0.31746) Neutral (-0.47) Yes (Benign) - 
SDHA 8 c.923C>T p.(Thr308Met) Class C65  Deleterious  high (4.725) Significant (-4.7476) Deleterious (-5.61) Yes (Pathogenic) - 
SDHA 10 c.1273G>A p.(Val425Met) Class C0  Tolerated  low (1.15) Error (-) Neutral (-0.33) Yes (Benign) - 
SDHAF2 3 c.319C>T p.(Arg107Cys) Class C15  Deleterious  medium (3.025) Significant (-4.19036) Deleterious (-5.53) Yes (Pathogenic) - 
SDHB 1 c.32G>A p.(Arg11His) Class C0  Deleterious  neutral (0) Error (-) Neutral (-0.5) No Yes (Benign) 
SDHB 5 c.487T>C p.(Ser163Pro) Class C0  Tolerated  neutral (0) Not significant (-2.04801) Neutral (0.44) Yes (Benign) - 
SDHC 3 c.148C>T p.(Arg50Cys) Class C25  Deleterious  high (4.11) Significant (-6.25127) Deleterious (-6.19) No Yes (Pathogenic) 
SDHC 4 c.214C>T p.(Arg72Cys) Class C65  Deleterious  high (3.86) Significant (-6.82403) Deleterious (-7.07) Yes (Pathogenic) - 
SDHC 5 c.380A>G p.(His127Arg) Class C0  Deleterious  high (4.24) Significant (-5.71111) Deleterious (-7.47) No Yes (Pathogenic) 
SDHD 1 c.34G>A p.(Gly12Ser) Class C0  Tolerated  neutral (0.145) Not significant (-1.27688) Neutral (0.21) Yes (Benign) - 
TMEM127 3 c.268G>A p.(Val90Met) Class C0  Deleterious  neutral (0.345) Error (-) Neutral (-1.43) No Yes (Benign) 
VHL 1 c.242C>T p.(Pro81Leu) Class C25  Deleterious  low (1.445) Significant (-3.63422) Deleterious (-4.31) No No 
VHL 1 c.338G>A p.(Arg113Gln) Class C0  Tolerated  low (0.895) Not significant (-2.84052) Neutral (-0.53) Yes (Benign) - 
VHL 2 c.361G>C p.(Asp121His) Class C0  Deleterious  medium (2.435) Significant (-3.39572) Deleterious (-5.32) No Yes (Pathogenic) 
VHL 3 c.554A>G p.(Tyr185Cys) Class C0  Deleterious  low (1.39) Significant (-4.0583) Deleterious (-4.59) No No 
VHL 3 c.629G>A p.(Arg210Gln) Class C0  Tolerated  neutral (0) Not significant (-1.21391) Neutral (-0.44) Yes (Benign) - 
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Table 5.28 In silico predictions using programs categorised as machine learning-based 
Red text indicates the variant is considered to be damaging and green indicates the variant is predicted to be benign. Concordance between 
the programs is demonstrated in the last two columns. RI = reliability index, Prob of Path = probability of pathogenicity. 
Gene Exon Variant  
(codingDNA) 
Variant 
(protein) 
I-Mutant 
(RI) 
 Mutation Taster 
(p-value) 
MutPred 
(Prob of Path) 
nsSNP 
Analyzer  
PON-P2 
(Prob of Path) 
PhD-SNP 
(RI) 
SNAP 
(RI) 
SNPs&GO 
(RI) 
100% 
Concordant 
≥75% 
Concordant 
FLCN 7 c.715C>T p.(Arg239Cys) Disease 
(4) 
Disease causing (1) Disease 
(0.916) 
UNKNOWN Pathogenic (0.912) Neutral 
(3) 
Non-neutral 
(6) 
Neutral 
(5) 
No No 
FLCN 12 c.1333G>A p.(Ala445Thr) Disease 
(3) 
Polymorphism (1) Neutral 
(0.281) 
UNKNOWN Neutral (0.058) Neutral 
(6) 
Non-neutral 
(1) 
Neutral 
(7) 
No No 
MAX 5 c.425C>T p.(Ser142Leu) Neutral 
(8) 
Disease causing (1) Neutral 
(0.304) 
UNKNOWN Unknown (0.607) Neutral 
(6) 
Non-neutral 
(2) 
Neutral 
(9) 
No No 
SDHA 2 c.136A>G p.(Lys46Glu) Disease 
(3) 
Disease causing (1) Neutral 
(0.425) 
NEUTRAL Unknown (0.594) Disease 
(0) 
Neutral (1) Neutral 
(2) 
No No 
SDHA 8 c.923C>T p.(Thr308Met) Disease 
(4) 
Disease causing (1) Disease (0.86) DELETERIOUS Pathogenic (0.994) Disease 
(0) 
Non-neutral 
(5) 
Disease 
(9) 
Yes 
(Pathogenic) 
- 
SDHA 10 c.1273G>A p.(Val425Met) Disease 
(4) 
Polymorphism (0.73) Neutral 
(0.292) 
NEUTRAL Unknown (0.529) Neutral 
(2) 
Neutral (4) Neutral 
(3) 
No Yes (Benign) 
SDHAF2 3 c.319C>T p.(Arg107Cys) Disease 
(6) 
Disease causing (1) Neutral 
(0.488) 
UNKNOWN Unknown (0.843) Disease 
(3) 
Neutral (2) Disease 
(0) 
No No 
SDHB 1 c.32G>A p.(Arg11His) Disease 
(3) 
Disease causing (0.99) Disease 
(0.775) 
UNKNOWN Neutral (0.193) Neutral 
(3) 
Non-neutral 
(0) 
Disease 
(3) 
No No 
SDHB 5 c.487T>C p.(Ser163Pro) Disease 
(3) 
Disease causing (1) Neutral (0.14) UNKNOWN Unknown (0.666) Disease 
(0) 
Neutral (2) Neutral 
(5) 
No No 
SDHC 3 c.148C>T p.(Arg50Cys) Disease 
(5) 
Disease causing (1) Disease 
(0.971) 
UNKNOWN Pathogenic (0.878) Disease 
(9) 
Non-neutral 
(6) 
Disease 
(9) 
Yes 
(Pathogenic) 
- 
SDHC 4 c.214C>T p.(Arg72Cys) Disease 
(6) 
Disease causing (1) Disease 
(0.984) 
UNKNOWN Pathogenic (0.93) Disease 
(9) 
Non-neutral 
(6) 
Disease 
(8) 
Yes 
(Pathogenic) 
- 
SDHC 5 c.380A>G p.(His127Arg) Disease 
(6) 
Disease causing (1) Disease (0.91) UNKNOWN Pathogenic (0.952) Disease 
(9) 
Non-neutral 
(6) 
Disease 
(9) 
Yes 
(Pathogenic) 
- 
SDHD 1 c.34G>A p.(Gly12Ser) Disease 
(4) 
Disease causing (0) Neutral 
(0.127) 
UNKNOWN Neutral (0.036) Neutral 
(8) 
Neutral (2) Neutral 
(6) 
No No 
TMEM127 3 c.268G>A p.(Val90Met) Disease 
(2) 
Disease causing (0.99) Neutral 
(0.743) 
UNKNOWN Unknown (0.434) Neutral 
(8) 
Non-neutral 
(3) 
Neutral 
(7) 
No No 
VHL 1 c.242C>T p.(Pro81Leu) Disease 
(8) 
Disease causing (0.98) Neutral 
(0.708) 
NEUTRAL Unknown (0.744) Disease 
(4) 
Neutral (0) Disease 
(9) 
No No 
VHL 1 c.338G>A p.(Arg113Gln) Disease Polymorphism (0.99) Neutral NEUTRAL Pathogenic (0.838) Neutral Neutral (2) Disease No No 
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Gene Exon Variant  
(codingDNA) 
Variant 
(protein) 
I-Mutant 
(RI) 
 Mutation Taster 
(p-value) 
MutPred 
(Prob of Path) 
nsSNP 
Analyzer  
PON-P2 
(Prob of Path) 
PhD-SNP 
(RI) 
SNAP 
(RI) 
SNPs&GO 
(RI) 
100% 
Concordant 
≥75% 
Concordant 
(2) (0.715) (7) (8) 
VHL 2 c.361G>C p.(Asp121His) Disease 
(5) 
Disease causing (1) Disease 
(0.842) 
NEUTRAL Pathogenic (0.867) Disease 
(4) 
Non-neutral 
(4) 
Disease 
(9) 
No Yes 
(Pathogenic) 
VHL 3 c.554A>G p.(Tyr185Cys) Disease 
(5) 
Disease causing (0.96) Neutral 
(0.689) 
DELETERIOUS Pathogenic (0.89) Disease 
(2) 
Non-neutral 
(0) 
Disease 
(9) 
No Yes 
(Pathogenic) 
VHL 3 c.629G>A p.(Arg210Gln) Neutral 
(4) 
Polymorphism (1) Neutral 
(0.525) 
UNKNOWN Unknown (0.285) Neutral 
(9) 
Non-neutral 
(0) 
Disease 
(0) 
No No 
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Table 5.29 In silico predictions from 3 meta-predictors 
Red text indicates the variant is considered to be damaging and green indicates the variant is predicted to be benign. Concordance between 
the programs is demonstrated in the last column. 
Gene Exon Variant  
(codingDNA) 
Variant 
(protein) 
CONDEL Meta-SNP PredictSNP 100% 
Concordant? 
FLCN 7 c.715C>T p.(Arg239Cys) D (0.63) Disease (0.743, 5) DELETERIOUS (0.76) Yes (Pathogenic) 
FLCN 12 c.1333G>A p.(Ala445Thr) N (0.4) Neutral (0.063, 9) NEUTRAL (0.83) Yes (Benign) 
MAX 5 c.425C>T p.(Ser142Leu) D (0.57) Neutral (0.165, 7) DELETERIOUS (0.55) No 
SDHA 2 c.136A>G p.(Lys46Glu) D (0.52) Neutral (0.297, 4) NEUTRAL (0.75) No 
SDHA 8 c.923C>T p.(Thr308Met) D (0.77) Disease (0.82, 6) DELETERIOUS (0.87) Yes (Pathogenic) 
SDHA 10 c.1273G>A p.(Val425Met) N (0.51) Neutral (0.242, 5) NEUTRAL (0.61) Yes (Benign) 
SDHAF2 3 c.319C>T p.(Arg107Cys) D (0.69) Disease (0.614, 2) NEUTRAL (0.6) No 
SDHB 1 c.32G>A p.(Arg11His) D (0.53) Neutral (0.401, 2) NEUTRAL (0.68) No 
SDHB 5 c.487T>C p.(Ser163Pro) N (0.5) Neutral (0.433, 1) NEUTRAL (0.74) Yes (Benign) 
SDHC 3 c.148C>T p.(Arg50Cys) D (0.73) Disease (0.854, 7) DELETERIOUS (0.87) Yes (Pathogenic) 
SDHC 4 c.214C>T p.(Arg72Cys) D (0.72) Disease (0.823, 6) DELETERIOUS (0.87) Yes (Pathogenic) 
SDHC 5 c.380A>G p.(His127Arg) D (0.79) Disease (0.888, 8) DELETERIOUS (0.87) Yes (Pathogenic) 
SDHD 1 c.34G>A p.(Gly12Ser) N (0.51) Neutral (0.1, 8) NEUTRAL (0.83) Yes (Benign) 
TMEM127 3 c.268G>A p.(Val90Met) N (0.48) Neutral (0.166, 7) DELETERIOUS (0.55) No 
VHL 1 c.242C>T p.(Pro81Leu) D (0.64) Neutral (0.378, 2) DELETERIOUS (0.51) No 
VHL 1 c.338G>A p.(Arg113Gln) D (0.62) Neutral (0.198, 6) NEUTRAL (0.83) No 
VHL 2 c.361G>C p.(Asp121His) D (0.67) Disease (0.73, 5) DELETERIOUS (0.87) Yes (Pathogenic) 
VHL 3 c.554A>G p.(Tyr185Cys) D (0.64) Disease (0.605, 2) DELETERIOUS (0.76) Yes (Pathogenic) 
VHL 3 c.629G>A p.(Arg210Gln) D (0.57) Neutral (0.168, 7) NEUTRAL (0.75) No 
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Table 5.30 Concordance between types of in silico prediction tools 
Red text indicates the variant is considered to be damaging, yellow indicates the effect is unclear and green indicates the variant is predicted 
to be benign. Concordance between all sub-groups of program is demonstrated in the last column with subgroups without concordance 
excluded. 
    
Sequence and evolutionary conservation Protein sequence and structure Machine learning Meta-tools 
 Gene Exon Variant  
(codingDNA) 
Variant 
(protein) 
≥75% concordant Polyphen-2 Concordant ≥75% Concordant 100% Concordant SUBGROUPS 
CONCORDANT? 
FLCN 7 c.715C>T p.(Arg239Cys) Yes (Pathogenic) Yes (Pathogenic) No Yes (Pathogenic) Yes (Pathogenic) 
FLCN 12 c.1333G>A p.(Ala445Thr) Yes (Benign) Yes (Benign) No Yes (Benign) Yes (Benign) 
MAX 5 c.425C>T p.(Ser142Leu) Yes (Benign) Yes (Pathogenic) No No No 
SDHA 2 c.136A>G p.(Lys46Glu) Yes (Benign) Yes (Benign) No No Yes (Benign) 
SDHA 8 c.923C>T p.(Thr308Met) Yes (Pathogenic) Yes (Pathogenic) Yes (Pathogenic) Yes (Pathogenic) Yes (Pathogenic) 
SDHA 10 c.1273G>A p.(Val425Met) Yes (Benign) Yes (Poss. path) Yes (Benign) Yes (Benign) No 
SDHAF2 3 c.319C>T p.(Arg107Cys) Yes (Pathogenic) No No No No 
SDHB 1 c.32G>A p.(Arg11His) Yes (Benign) No No No No 
SDHB 5 c.487T>C p.(Ser163Pro) Yes (Benign) Yes (Benign) No Yes (Benign) Yes (Benign) 
SDHC 3 c.148C>T p.(Arg50Cys) Yes (Pathogenic) Yes (Pathogenic) Yes (Pathogenic) Yes (Pathogenic) Yes (Pathogenic) 
SDHC 4 c.214C>T p.(Arg72Cys) Yes (Pathogenic) No Yes (Pathogenic) Yes (Pathogenic) No 
SDHC 5 c.380A>G p.(His127Arg) Yes (Pathogenic) Yes (Pathogenic) Yes (Pathogenic) Yes (Pathogenic) Yes (Pathogenic) 
SDHD 1 c.34G>A p.(Gly12Ser) Yes (Benign) Yes (Benign) No Yes (Benign) Yes (Benign) 
TMEM127 3 c.268G>A p.(Val90Met) Yes (Benign) Yes (Poss. path) No No No 
VHL 1 c.242C>T p.(Pro81Leu) No No No No No 
VHL 1 c.338G>A p.(Arg113Gln) Yes (Benign) No No No No 
VHL 2 c.361G>C p.(Asp121His) Yes (Pathogenic) Yes (Pathogenic) Yes (Pathogenic) Yes (Pathogenic) Yes (Pathogenic) 
VHL 3 c.554A>G p.(Tyr185Cys) No Yes (Benign) Yes (Pathogenic) Yes (Pathogenic) No 
VHL 3 c.629G>A p.(Arg210Gln) Yes (Benign) Yes (Benign) No No Yes (Benign) 
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Table 5.31 Comparison of concordance between amalgamated results of all programs and the amalgamated results of the three programs 
used by diagnostic laboratories 
Gene Exon 
Variant  Variant 
Amalgamation of results for 
all tools (n=19) 
Amalgamated diagnostic tools (n=3) - 
100% concordant only 
(coding 
DNA) 
(protein) 
From Table 5.30 From Table 5.26 
FLCN 7 c.715C>T p.(Arg239Cys) Yes (Pathogenic) YES (Pathogenic) 
FLCN 12 c.1333G>A p.(Ala445Thr) Yes (Benign) YES (Benign) 
MAX 5 c.425C>T p.(Ser142Leu) NO NO 
SDHA 2 c.136A>G p.(Lys46Glu) Yes (Benign) YES (Benign) 
SDHA 8 c.923C>T p.(Thr308Met) Yes (Pathogenic) YES (Pathogenic) 
SDHA 10 c.1273G>A p.(Val425Met) NO NO 
SDHAF2 3 c.319C>T p.(Arg107Cys) NO NO 
SDHB 1 c.32G>A p.(Arg11His) NO NO 
SDHB 5 c.487T>C p.(Ser163Pro) Yes (Benign) YES (Benign) 
SDHC 3 c.148C>T p.(Arg50Cys) Yes (Pathogenic) NO 
SDHC 4 c.214C>T p.(Arg72Cys) NO NO 
SDHC 5 c.380A>G p.(His127Arg) Yes (Pathogenic) NO 
SDHD 1 c.34G>A p.(Gly12Ser) Yes (Benign) YES (Benign) 
TMEM127 3 c.268G>A p.(Val90Met) NO NO 
VHL 1 c.242C>T p.(Pro81Leu) NO NO 
VHL 1 c.338G>A p.(Arg113Gln) NO NO 
VHL 2 c.361G>C p.(Asp121His) Yes (Pathogenic) NO 
VHL 3 c.554A>G p.(Tyr185Cys) NO NO 
VHL 3 c.629G>A p.(Arg210Gln) Yes (Benign) YES (Benign) 
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5.4.4 RNA analysis for VHL 
Analysis of the effect variants may have upon the correct splicing of VHL mRNA is 
complicated by the isoforms normally produced. VHL is a small gene consisting of only three 
exons. There are two mRNA isoforms: 1) NM_000551, which includes all 3 exons 
(designated here as ‘VHL full’) and 2) NM_198156, which lacks exon 2, an inframe coding 
exon (designated here as ‘VHL Δ2’) (135-137). Given that exon 2 deletions are pathogenic 
mutations leading to VHL type 1, the isoform lacking exon 2 cannot be sufficient for VHL 
protein function. Mutations that affect the consensus splice sites of exons 1, 2 and 3, again 
causing skipping of exon 2, are also known to be pathogenic (137;144). Analysis of the RNA 
is further hindered by the paucity of coding polymorphic variants, which does not allow 
discernment of allele-specific expression. 
Fresh blood samples for RNA extraction were obtained from a patient with a clinical 
diagnosis of VHL with an intronic deletion of 5 base pairs, c.[341-21_341-17delAACCT];[=]. In 
silico prediction software only showed minimally reduced scores as a result of this variant 
(see Figure 5.6). Full gene sequencing was carried out (see Chapter 3) but no additional 
likely causative variants were identified. Given the phenotype, and the fact that the intronic 
deletion had not been reported on any of the variation databases, it was felt that further 
analysis was warranted. The potential splicing effects that this variant could have were 
postulated in section 5.3.3.1 . 
A number of assays were designed that could be used on this patient and other patients 
with potential splicing mutations in the VHL gene. Initially a set of assays combining RT-PCR, 
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gel electrophoresis and Sanger sequencing were designed and performed, followed by an 
assay using droplet digital RT-PCR. 
 
VHL RNA analysis using RT-PCR, gel electrophoresis and Sanger 5.4.4.1 
sequencing 
The first assay was designed to amplify cDNA for both VHL isoforms. All cDNAs analysed 
showed bands at the expected sizes for the two isoforms, which differ in size by 123 bp (see 
Figure 5.8 and Figure 5.9). The intensity of the upper band encoding ‘VHL full’ appeared 
higher than that of the ‘VHL Δ2’ isoform band for the 4 control cDNAs, despite variability in 
amplification efficiency. Meanwhile, the respective intensity of the bands appeared 
reversed for the VHL c.[341-21_341-17delAACCT];[=] patient’s cDNA bands (see Figure 5.9). 
This was confirmed upon Sanger sequencing because the relative abundance of the two 
isoforms could be observed on the electropherograms (see Figure 5.10). The ‘VHL full’ was 
the predominant isoform in the normal control samples and the ‘VHL Δ2 ‘isoform was 
predominant in the cDNA from the patient with the intronic 5 bp deletion. 
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Figure 5.8 Schematic comparing the two transcribed isoforms of VHL 
‘VHL full’ (NM_000552) which encodes the functional protein and ‘VHL Δ2’ (NM_198156) 
which lacks exon two and doesn’t produce a functional protein. 
 
 
1000 bp 
 
300 bp 
 
 
 
Figure 5.9 Amplification of coding region of VHL from cDNA to include both isoforms 
Lanes: 1) Hyperladder II; 2&3) c.[341-21_341-17delAACCT];[=] cDNAs; 4-7) Normal control 
cDNAs; 8) Negative control from cDNA preparation; 9) Assay water control.   
 1        2        3        4        5        6        7       8      9 
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a) 
Full  ATGCCCCGGAGGGCGGAGAACTGGGACGAGGCCGAGGTAGGCGCGGAGGAGGCAGGCGTC 
Δ2   ATGCCCCGGAGGGCGGAGAACTGGGACGAGGCCGAGGTAGGCGCGGAGGAGGCAGGCGTC 
Full  GAAGAGTACGGCCCTGAAGAAGACGGCGGGGAGGAGTCGGGCGCCGAGGAGTCCGGCCCG 
Δ2   GAAGAGTACGGCCCTGAAGAAGACGGCGGGGAGGAGTCGGGCGCCGAGGAGTCCGGCCCG 
Full  GAAGAGTCCGGCCCGGAGGAACTGGGCGCCGAGGAGGAGATGGAGGCCGGGCGGCCGCGG 
Δ2   GAAGAGTCCGGCCCGGAGGAACTGGGCGCCGAGGAGGAGATGGAGGCCGGGCGGCCGCGG 
Full  CCCGTGCTGCGCTCGGTGAACTCGCGCGAGCCCTCCCAGGTCATCTTCTGCAATCGCAGT 
Δ2   CCCGTGCTGCGCTCGGTGAACTCGCGCGAGCCCTCCCAGGTCATCTTCTGCAATCGCAGT 
Full  CCGCGCGTCGTGCTGCCCGTATGGCTCAACTTCGACGGCGAGCCGCAGCCCTACCCAACG 
Δ2   CCGCGCGTCGTGCTGCCCGTATGGCTCAACTTCGACGGCGAGCCGCAGCCCTACCCAACG 
Full  CTGCCGCCTGGCACGGGCCGCCGCATCCACAGCTACCGAGGTCACCTTTGGCTCTTCAGA 
Δ2   CTGCCGCCTGGCACGGGCCGCCGCATCCACAGCTACCGAGTGTATACTCTGAAAGAGCGA 
Full  GATGCAGGGACACACGATGGGCTTCTGGTTAACCAAACTGAATTATTTGTGCCATCTCTC 
Δ2   TGCCTCCAGGTTGTCCGGAGCCTAGTCAAGCCTGAGAATTACAGGAGACTGGACATCGTC 
Full  AATGTTGACGGACAGCCTATTTTTGCCAATATCACACTGCCAGTGTATACTCTGAAAGAG 
Δ2   AGGTCGCTCTACGAAGATCTGGAAGACCACCCAAATGTGCAGAAAGACCTGGAGCGGCTG 
Full  CGATGCCTCCAGGTTGTCCGGAGCCTAGTCAAGCCTGAGAATTACAGGAGACTGGACATC 
Δ2   ACACAGGAGCGCATTGCACATCAACGGATGGGAGATTGA 
Full  GTCAGGTCGCTCTACGAAGATCTGGAAGACCACCCAAATGTGCAGAAAGACCTGGAGCGG 
Δ2    
Full  CTGACACAGGAGCGCATTGCACATCAACGGATGGGAGATTGA.................. 
Δ2    
 
b) 
 
c) 
 
Figure 5.10 Expected sequence and Sanger sequencing of amplification product of coding 
region of VHL to include both isoforms 
a) Alignment of the two cDNA isoforms to show the expected sequence in the forward 
direction following Sanger sequencing, exon 1 in purple, exon 2 in blue and exon 3 in green; 
b) Example of electropherogram of Sanger sequencing of amplification of c.[341-21_341-
17delAACCT];[=] cDNA, commencing after the last base of exon 1; c) Example 
electropherogram of Sanger sequencing of a normal control. 
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The second assay was designed to amplify only the VHL Δ2 isoform by placing a primer over 
the junction of exon 1 and exon 3. As expected, all cDNAs amplified the VHL Δ2 isoform (see 
Figure 5.11). During the full VHL gene NGS analysis performed in Chapter 4, a common Class 
I polymorphism was identified heterozygously in the 3’UTR, c.[*294G>A];[=] for the patient 
with the 5 bp deletion. Sanger sequencing was used to determine if both alleles were found 
in the mRNA by examining this polymorphic base. Figure 5.12 shows that the polymorphism 
was present heterozygously, indicating both alleles were present.  
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Figure 5.11 Amplification of the coding region of VHL from cDNA for only the VHL Δ2 
isoform 
Lanes: 1) Hyperladder II; 2&3) c.[341-21_341-17delAACCT];[=] cDNAs; 4-7) Normal control 
cDNAs; 8) Negative control from cDNA preparation; 9) Assay water control.  
 
 
 
Figure 5.12 Sanger sequencing of cDNA for VHL Δ2 isoform only for intronic deletion 
patient 
The c.*294G>A polymorphism, marked with box, is identified heterozygously in the cDNA. 
 
 
Figure 5.13 Sanger sequencing of cDNA for VHL full isoform only for intronic deletion 
patient 
The c.*294G>A polymorphism, marked with a box, is identified homozygously in the cDNA. 
The third assay was a replica of the second, but the primer was designed to bind over the 
exon 1 to exon 2 junction, so only the ‘VHL full’ isoform would be amplified. Again all 
 1        2       3      4       5      6        7       8      9 
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samples produced an amplicon but upon sequencing of the cDNA, the polymorphism was 
observed homozygously, indicating only one allele was present and thus that no mRNA was 
present from one allele for the ‘VHL full’ isoform.  
VHL RNA analysis using droplet digital RT-PCR 5.4.4.2 
A droplet digital RT-PCR assay was designed to confirm semi-quantitatively that the two 
isoforms were abnormally represented in the cDNA of the patient with c.[341-21_341-
17delAACCT];[=], designated patient A for this assay.  
Primers and probes were designed to amplify and specifically detect each of the two 
isoforms. The concentration (copies/µl) of each isoform was determined for the patient 
sample and eight normal control cDNA samples. Then the relative abundance of the ‘VHL 
full’ isoform was compared to the ‘VHL Δ2’ isoform for each sample. This was performed in 
duplicate and the average relative abundance plotted (see Figure 5.14). The difference 
between the patient data and the normal control data was considered extremely 
statistically significant using the unpaired t-test giving a two-tailed P value of less than 
0.0001.  
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Figure 5.14 Graph showing the average relative abundance of the VHL Δ2 isoform 
compared to the VHL full isoform for the intronic deletion patient compared to eight 
normal controls 
 
A very limited number of additional RNAs were also available from other patients who had 
been analysed using the VHL NGS full gene assay. These five cDNAs were also input into the 
assay and the statistical significance of the results considered (see Table 5.32 and Figure 
5.15). While the difference in the average relative abundance of the isoforms for Patient C 
was considered statistically significant, this was not the case for any of the other patients as 
compared with normal controls. VHL c.[463+8C>T];[=] was not predicted in silico to affect 
the normal splicing of the VHL gene either by decreasing the score of the true donor site or 
creation of a cryptic splice site, however the result was of interest given the variant’s 
location within the splice donor consensus sequence. Analysis of the RNA by PCR and 
sequencing did not identify an aberrant splicing event, however there were no heterozygous 
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variants in the sequence analysed and therefore loss of an aberrant transcript by NMD 
cannot be discounted (RT-PCR and sequence analysis of cDNA for this patient performed by 
WMRGL). 
Table 5.32 Statistical significance of difference of relative abundance of isoforms for six 
patients examined using the digital droplet PCR method 
Patient VHL variant identified Predicted to affect 
normal splicing of 
VHL exon 2 
Statistically 
significant isoform 
difference  
A c.[341-21_341-17delAACCT];[=] YES YES (P = >0.0001) 
B c.[463+8C>T];[=] NO NO 
C c.[394C=/394C>T];[=] 
p.(Gln132Ter)a 
YESb YES (P = >0.0001) 
D c.[*3082C>T];[=] NO NO 
E No mutation identified NO NO 
F No mutation identified NO NO 
a Variant observed at a mosaic level of approximately 7% in lymphocyte DNA. b This 
mutation sits within exon 2, it creates a stop codon at amino acid 132 and the transcript 
would be expected to undergo nonsense mediated decay (NMD).  
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Figure 5.15 Graph showing the average relative abundance of the ‘VHL Δ2’ isoform 
compared to the ‘VHL full’ isoform for six patients compared to the average of eight 
normal controls  
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5.4.5 FFPE tumour analysis 
Analysis of FFPE tumour material from patients with a number of variants was performed. 
Unfortunately tumour material was not available for the majority of patients in whom the 
Class II and III variants had been identified. However it was available for some and additional 
tumour material was available from some patients with variants which had been identified 
previously by the WMRGL. For all variants where tumour material was available, loss of 
heterozygosity analysis was performed by direct Sanger sequencing of the tumour tissue 
and comparison with the Sanger sequencing for the lymphocyte DNA from that patient. 
Additionally, if it was possible to do so, immunohistochemistry (IHC) was performed for any 
variant in SDHB, SDHC and SDHD using immunohistochemistry for SDHB. The IHC was 
performed in collaboration with the Department of Molecular Pathology, University Hospital 
Birmingham NHS Trust. 
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Table 5.33 Summary of direct tumour analysis using loss of heterozygosity (LOH) analysis and immunohistochemistry 
In silico prediction is the consensus of the three diagnostically used splicing algorithms. The results for patient 1 can be seen in Figure 5.19. 
Patient Gene coding DNA Protein LOH IHC result In silico prediction Identified by 
1 SDHB c.220G>A p.(Asp74Asn) Yes - Partial loss of WT allele - Discordant Other research 
2 SDHB c.269G>A p.(Arg90Gln) Yes - Total loss of WT allele SDHB - Patchy (? Fixation artefact) Discordant WMRGL 
3 SDHB c.296G>A p.(Gly99Asp) Yes - Partial loss of WT allele SDHB - Loss of staining Pathogenic WMRGL 
4 SDHB c.298T>C p.(Ser100Pro) Yes - Total loss of WT allele - Pathogenic WMRGL 
5 SDHB c.326A>G p.(Asn109Ser) Yes - Total loss of WT allele SDHB - Normal staining Discordant WMRGL 
6 SDHB c.487T>C p.(Ser163Pro) No - Benign WMRGL/Thesis/ 
Other research No SDHB - Normal staining 
No SDHB - Normal staining 
No SDHB - Normal staining 
Yes - Partial loss of variant allele - 
No - 
No - 
7 SDHB c.529C>G p.(Arg177Gly) Yes - Total loss of WT allele - Discordant WMRGL 
8* SDHB c.587G>A p.(Cys196Tyr) Yes - Partial loss of WT allele SDHB - Weak diffuse staining Pathogenic WMRGL 
9* SDHB c.590C>G p.(Pro197Arg) Yes - Total loss of WT allele - Pathogenic WMRGL 
10 SDHB c.801G>T p.(Lys267Asn) Yes - Partial loss of WT allele SDHB - Patchy (? Fixation artefact) Pathogenic WMRGL/Thesis 
11 SDHC c.148C>T p.(Arg50Cys) No - Discordant WMRGL/Thesis 
12 SDHC c.380A>G p.(His127Arg) Failed SDHB - Normal staining Discordant Thesis 
13 SDHD c.116C>T p.(Pro39Leu) No SDHB - Normal staining Benign WMRGL 
14 SDHD c.34G>A p.(Gly12Ser) No - Benign WMRGL/Thesis 
No - 
No - 
15 SDHD c.149A>G p.(His50Arg) No - Discordant WMRGL 
* Pathogenic mutations, included as seen in patient who also has variant    
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5.4.6 Functional analysis of VHL protein stability 
A simple functional assay was designed to investigate the stability of VHL proteins when the 
VHL gene had been mutated. A similar assay had been used successfully in Prof E Maher’s 
research group to investigate the stability of the folliculin protein when the FLCN gene had 
been mutated (248). The VHL assay comprised modelling the VHL variants in a pcDNA3.1 
plasmid containing wild type HA tagged VHL using site directed mutagenesis, transforming 
them into a bicistronic vector which also expressed green fluorescent protein (GFP) and 
transiently transfecting them into HEK293T cells. The level of VHL protein expression was 
measured using densitometry of western blotted protein lysate by dividing the amount of 
HA, as a measurement of VHL protein expression, by GFP protein, as an indicator of the level 
of transfection for each variant. 
Previous work 5.4.6.1 
Site directed mutagenesis and transformation had already been performed by Prof Maher’s 
group for several VHL sequence variants. The variants were in the pcDNA3.1 plasmid as 
human influenza hemagglutinin (HA) tagged-VHL; the cDNA included codons 1-53 which 
allowed translation of both protein isoforms. These variants included examples of various 
different classes of VHL pathogenic mutations which could be used as controls in the 
functional experiments (see Table 5.34). 
Table 5.34 List of available VHL variants to use as controls 
Variant Variant type VHL type 
c.74C>T; p.(Pro25Leu) Missense Polymorphism 
c.194C>G; p.(Ser65Trp) Missense VHL type 1 
c.250G>T; p.(Val84Leu) Missense VHL type 2C 
c.361_362insC; p.(Asp121Alafs*11) Premature truncation VHL type 1 
c.499G>C; p.Arg167Gly Missense VHL type 2B/C 
c.562C>G; p.Leu188Val Missense VHL type 2C (few reports of 
RCC) 
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Additional variant selection 5.4.6.2 
A number of additional VHL variants were selected to be included in the assay. These 
compromised VUSs identified during routing diagnostic testing by the West Midlands 
Regional Genetics Laboratory (WMRGL), some of which were also identified during this 
study (Table 5.35). 
Table 5.35 VHL variants of unknown significance selected for inclusion in VHL protein 
stability assay 
Gene Exon cDNA 
change 
Protein 
change 
Protein 
shorthand 
Identified by 
VHL 1 c.154G>A p.(Glu52Lys) E52K WMRGL 
VHL 1 c.242C>T p.(Pro81Leu) P81L WMRGL/Thesis 
VHL 1 c.245G>T p.(Arg82Leu) R82L WMRGL 
VHL 1 c.284C>G p.(Pro95Arg) P95R WMRGL 
VHL 1 c.326T>G p.(Ile109Ser) I109S WMRGL 
VHL 2 c.361G>C p.(Asp121His) D121H WMRGL/Thesis 
VHL 2 c.391A>C p.(Asn131His) N131H WMRGL 
VHL 3 c.605C>T p.(Thr202Ile) T202I WMRGL 
 
Site directed mutagenesis (SDM) 5.4.6.3 
SDM was used to model the variants in full length VHL in pcDNA3.1. Following SDM, plasmid 
DNA was grown up and extracted by mini-prep from several individual colonies for each 
VUS. Then the complete coding region of VHL was Sanger sequenced to rule out the 
introduction of additional mutations during the mutagenesis process. This had occurred in 
several plasmids and ranged from additional single base changes to large deletions. 
However, 6/8 of the VUSs were modelled without additional mutations (see Figure 5.16). 
Two VUSs were not modelled despite repeated attempts. (see Figure 5.16).  
Once the VUSs had been introduced into VHL by SDM, both the VUSs and the control 
mutation inserts were subcloned into the bicistronic vector, pIRES2-AcGFP1, by digestion, 
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gel extraction, ligation and transformation. Again the complete coding region of VHL was 
sequenced to rule out the introduction of mutations during this process. 
 
Transient transfection and immunoblotting 5.4.6.4 
All the constructs (VUSs and controls) were transiently transfected into HEK293T cells. The 
cells were then lysed and the protein extracted. The protein was visualised by 
immunoblotting using optimised antibody concentrations. The HA tag of VHL was probed as 
the cell line used produces pVHL protein. An example of the results achieved is shown in 
Figure 5.17. 
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Figure 5.16 Results of site directed mutagenesis 
The altered base is highlighted with a red box for each successful assay. 
 
 
 
 
200 
 
 
Figure 5.17 Example immunoblot for HA tag of the VHL construct, GFP and α-tubulin 
VHL expression was variable across the 3 variants examined here. However the variation 
was not reproducible between experiments. The controls of the empty vector and the 
frameshift both behaved as expected with no pVHL-HA detected. 
 
Dosimetry to compare stability of VUSs in VHL 5.4.6.5 
The strength of each band was determined using densitometry (GeneTools, SyncGene). Each 
transfection was repeated 3 times and the average stabilities were calculated and plotted 
graphically. Unfortunately, as Figure 5.18 shows, VHL stability was not reproducible 
between experiments for the 19kDa isoform. The larger isoform also gave inconsistent 
results and therefore this was not considered to be a good method to functionally assess 
the pathogenicity of VHL VUSs. 
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Figure 5.18 Graphical representation of the stability of variants in the 19kDa isoform of 
VHL-HA as a ratio of the stability of wildtype VHL-HA from three separate experiments 
As expected, no HA was detected for the frameshift mutation as it would remove the HA 
tag. Stability was not reproducible between experiments.  
 
5.4.7 Variant assessment summary 
Fifty two variants were put through pathogenicity assessment using a number of laboratory 
based methods. 17.3% of these variants had their pathogenicity reclassified following these 
analyses. The majority of reclassifications resulted from additional variation data due to the 
release of the ExAC database, which allowed five variants to be reclassified as benign (I) and 
one as likely benign (II). One variant was classified as pathogenic following extensive RNA 
analysis. Two variants were reclassified as benign (I) following examination of multiple lines 
of evidence and are discussed in detail in section 5.6 . 
 
0.00
0.50
1.00
1.50
2.00
2.50
3.00
P25L E52K R82L I109S D121fsX N131H T202I S65W V84L R167Q L188V L188Q
Variants
S
ta
b
il
it
y
 (
V
a
ri
a
n
t/
W
il
d
 t
y
p
e
 V
H
L
)
Repeat 1
Repeat 2
Repeat 3
202 
 
Table 5.36 Summary of variant analysis and variants where their Class could be updated 
Gene Variant type Variant (codingDNA) Variant (protein) Times  
observed 
Original 
variant class 
Seen at 
>1% in 
variation 
database 
RNA 
analysis 
warranted? 
RNA analysis 
performed 
In silico missense 
predicted 
pathogenic (overall) 
LOH IHC (SDHB) Updated 
variant class 
FLCN Missense c.715C>T p.(Arg239Cys) 2 VUS (III) No No   Pathogenic     No 
FLCN Missense c.1333G>A p.(Ala445Thr) 1 VUS (III) No No   Predicted benign     No 
FLCN 3'UTR c.*4A>G   1 VUS (III) No No   N/A     No 
MAX Missense c.425C>T p.(Ser142Leu) 1 VUS (III) No No   Discordant results     No 
MET Missense c.3356G>C p.(Gly1119Ala) 1 VUS (III) No No   N/A     No 
SDHA Missense c.136A>G p.(Lys46Glu) 1 VUS (III) No No   Predicted benign     No 
SDHA Synonymous c.549C>T p.(=) 1 VUS (III) Yes           Benign (I) 
SDHA Synonymous c.822C>T p.(=) 1 VUS (III) Yes           Benign (I) 
SDHA Synonymous c.1002G>A p.(=) 1 VUS (III) No No   N/A     No 
SDHA Missense c.923C>T p.(Thr308Met) 1 VUS (III) No No   Pathogenic     No 
SDHA Missense c.1273G>A p.(Val425Met) 1 VUS (III) No No   Discordant results     No 
SDHA Frameshift c.1338delA p.(His447Metfs*23) 1 VUS (III) No No   N/A     No 
SDHA Synonymous c.1623G>A p.(=) 1 VUS (III) No No   N/A     No 
SDHA Synonymous c.1776T>C p.(=) 1 VUS (III) Yes           Benign (I) 
SDHAF2 Missense c.319C>T p.(Arg107Cys) 1 VUS (III) No No   Discordant results     No 
SDHB Missense c.32G>A p.(Arg11His) 1 VUS (III) No No   Discordant results     No 
SDHB Missense c.487T>C p.(Ser163Pro) 6 VUS (III) Yes* No   Predicted benign No LOH No loss Benign (I)* 
SDHC 5'UTR c.-118_-117delAG  1 VUS (III) No No   N/A     No 
SDHC Missense c.148C>T p.(Arg50Cys) 1 VUS (III) No No   Pathogenic No LOH   No 
SDHC Missense c.214C>T p.(Arg72Cys) 1 VUS (III) No No   Discordant results     No 
SDHC Missense c.380A>G p.(His127Arg) 1 VUS (III) No No   Pathogenic Failed No loss No 
SDHD Missense c.34G>A p.(Gly12Ser) 3 VUS (III) Yes* No   Predicted benign No LOH No loss Benign (I)* 
SDHD Synonymous c.312C>T p.(=) 1 VUS (III) Yes           No 
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Gene Variant type Variant (codingDNA) Variant (protein) Times  
observed 
Original 
variant class 
Seen at 
>1% in 
variation 
database 
RNA 
analysis 
warranted? 
RNA analysis 
performed 
In silico missense 
predicted 
pathogenic (overall) 
LOH IHC (SDHB) Updated 
variant class 
TMEM127 Missense c.268G>A p.(Val90Met) 1 VUS (III) No No   Discordant results     No 
TMEM127 Synonymous c.411T>A p.(=) 1 VUS (III) No No   N/A     No 
TMEM127 Synonymous c.534C>T p.(=) 1 VUS (III) No** Yes Not available N/A     Likely benign 
(II)No 
VHL 5'UTR c.-3933C>T  2 VUS (III) No No   N/A     No 
VHL 5'UTR c.-3197_-3195delCTC  1 VUS (III) No No   N/A     No 
VHL 5'UTR c.-963G>A  1 VUS (III) No No   N/A     No 
VHL Synonymous c.183C>G p.(Pro61Pro) 1 VUS (III) No No   N/A     No 
VHL Missense c.242C>T p.(Pro81Leu) 1 VUS (III) No No   Discordant results     No 
VHL Missense c.338G>A p.(Arg113Gln) 1 VUS (III) No No   Discordant results     No 
VHL Intronic c.340+203G>A  1 VUS (III) No No   N/A     No 
VHL Intronic c.340+280T>G  1 Likely benign 
(II) 
No No   N/A     No 
VHL Intronic c.340+376C>A  1 Likely benign 
(II) 
No No   N/A     No 
VHL Intronic c.341-123G>T  1 VUS (III) No No   N/A     No 
VHL Intronic c.341-21_341-
17delAACCT 
 1 VUS (III) No Yes Aberrant 
splicing 
N/A     Pathogenic 
(V) 
VHL Missense c.361G>C p.(Asp121His) 1 VUS (III) No No   Pathogenic     No 
VHL Intronic c.463+8C>T  1 VUS (III) No No Normal 
splicing 
N/A     Likely benign 
(II) 
VHL Intronic c.464-10G>A  1 VUS (III) No No   N/A     No 
VHL Intronic c.464-1212A>G  1 Likely benign 
(II) 
Yes           Benign (I) 
VHL Intronic c.464-1434C>T  2 Likely benign 
(II) 
No No   N/A     No 
VHL Intronic c.464-1530C>T  1 VUS (III) No No   N/A     No 
VHL Missense c.554A>G p.(Tyr185Cys) 1 VUS (III) No No   Discordant results     No 
VHL Missense c.629G>A p.(Arg210Gln) 1 VUS (III) No No   Predicted benign     No 
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Gene Variant type Variant (codingDNA) Variant (protein) Times  
observed 
Original 
variant class 
Seen at 
>1% in 
variation 
database 
RNA 
analysis 
warranted? 
RNA analysis 
performed 
In silico missense 
predicted 
pathogenic (overall) 
LOH IHC (SDHB) Updated 
variant class 
VHL Synonymous c.639T>C p.(Asp213Asp) 1 VUS (III) No No   N/A     No 
VHL 3'UTR c.*820A>G  1 Likely benign 
(II) 
No No   N/A     No 
VHL 3'UTR c.*2511A>G  1 VUS (III) No No   N/A     No 
VHL 3'UTR c.*3021T>C  1 VUS (III) No No   N/A     No 
VHL 3'UTR c.*3082C>T  1 VUS (III) No No   N/A     No 
VHL 3'UTR c.*3170G>A  1 VUS (III) No No   N/A     No 
VHL 3'UTR c.*3482dupA  1 Likely benign 
(II) 
No No   N/A     No 
* There is further discussion regarding the pathogenicity of these variants in section 5.6 ;**Only reaches 1% population frequency in the GBR 
subpopulation. 
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5.5 Discussion 
During the course of the gene screening performed as part of this research, 72 heterozygous 
variants were identified, excluding Class I benign polymorphisms. An additional three 
variants were detected at a mosaic level. Of these variants, 20/72 heterozygous variants and 
3/3 mosaic level variants were considered to be Class IV - Likely pathogenic or Class V - 
Pathogenic and therefore clinically actionable. The remaining 52 variants were considered 
to be Class III VUS or Class II likely benign. 
Of the variants listed there are some that sit outside standard practice, for example those 
variants identified in SDHA, discussed below, and those variants at ≥1% frequency in the 
population but considered in the literature to be putatively disease causing (discussed in 
section 5.6 ). 
Multiple variant assessment techniques were used for the 52 variants of unclear 
significance. The first technique was reanalysis of the variants using the most up to date 
variation databases. This was the most successful method of variant reclassification. Any 
variant that was in ≥1% of alleles in any ‘super population’ was determined to be a Class I 
benign polymorphism. It could be argued that, given the incidence of disease related to all 
of the genes included is less than 1 in 10, 000, this threshold could be lowered further. 
However because at least one of the databases used is known to contain a cancer cohort 1% 
was considered appropriately cautious. 
Next in silico splicing analysis was performed. Whilst it is recognised that in silico analysis 
can never be used to assign pathogenicity, it is a very helpful indicator of where RNA 
analysis is worthwhile. In this cohort of patients all predictions of altered splicing were 
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subtle and comparison of predicted cryptic splice site scores to the scores of the true splice 
sites for a given gene was a useful method of establishing if splicing analysis might be 
worthwhile. Only two variants were deemed to be worthwhile candidates for direct RNA 
analysis and RNA could only be obtained from one of these, VHL c.341-21_341-17delAACCT. 
RNA analysis allowed reclassification of VHL c.341-21_341-17delAACCT from Class III - VUS 
to Class V - Pathogenic. This was not a simple task as it was predicted to cause skipping of 
exon 2 of VHL, which is also a known alternative mRNA isoform of VHL. Thus it was 
necessary to demonstrate that exon 2 skipping was occurring in a pathogenic manner. It was 
shown, through RT-PCR and sequencing, that only one allele was producing any of the 
functional full VHL mRNA isoform and, through semi-quantitative PCR, that the level of the 
VHL mRNA lacking exon two was disproportionate to level of normally spliced VHL mRNA, 
when compared to normal controls.  
The semi-quantitative assay was also used to analyse three other VHL variants, from which 
patient RNA could be obtained. Neither VHL c.463+8C>T nor VHL c.*3082C>T showed any 
evidence of abnormal levels of exon 2 skipping. This is especially interesting for the intronic 
variant because, combined with the evidence of lack an alternatively splice product, it 
confirms the in silico finding that splicing would not be affected. The only caveat is that the 
presence of an aberrant mRNA, that has undergone NMD, cannot be discounted by this 
method. VHL c.[394C=/394C>T] p.(Gln132Ter) was considered to show a statistically 
significant difference (P = >0.0001) in the proportion of the two isoforms, with the non-
functional isoform lacking exon two being overrepresented. This is likely to be the result of 
NMD of the nonsense transcript (since the nonsense mutation sits in exon 2, only transcripts 
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containing exon 2 can be affected). The proportional difference in transcript abundance is 
smaller as the mutation is present at a mosaic level in the blood, shown to be in 7% of reads 
by NGS rather than 50% for a heterozygous change, such as VHL c.341-21_341-17delAACCT.  
In silico missense variant analysis was also performed for 19 variants in TSGs. Again, it is 
recognised that in silico analysis can never be used to definitively assign pathogenicity but 
rather to identify likely benign or pathogenic variants and distinguish those where further 
investigation is most warranted. The programs that used sequence and evolutionary 
conservation to predict pathogenicity were most concordant (58% totally concordant). The 
machine learning tools were least concordant (21% totally concordant), which is likely due 
to the different data sets used to train the algorithms. The results of the different program 
categories were combined and used to assign an overall prediction, since it was considered 
that the more sources used to predict pathogenicity where the data concurred (≥75% 
concordance within a category) the more accurate the prediction was likely to be. Finally 
the amalgamated predictions of the 17 programs were compared to the predictions using 
only the three tools routinely used in diagnostic laboratories. Interestingly there were no 
discrepant predictions. There were three additional predictions for the amalgamated set, 
likely to be the result of the more permissive concordance threshold set. These data suggest 
that the three diagnostically used prediction tools provide similar results to those produced 
using a much greater number of programs but their use is vastly less time consuming. Given 
that in silico analysis alone cannot be used for pathogenicity prediction, this work only 
enabled a group of variants to be identified for which additional pathogenicity investigations 
may be more or less fruitful. 
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Tumour analysis was performed for a number of variants. Not all variants analysed were 
those identified during this research since additional VUS were included that had been 
identified during previous Sanger analysis by the WMRGL. Interestingly, loss of 
heterozygosity (LOH) did not mean that loss of staining was observed by IHC analysis and 
these are conflicting results with regard to pathogenicity assessment. However, the 
mechanism of pathogenicity of a missense mutation in a TSG does not always have to be 
destabilisation of the protein (249), and so it is conceivable that LOH and retention of 
protein staining could coexist. Either LOH alone or LOH and loss of staining by IHC are 
supporting evidence for the pathogenicity of the applicable variants. Reassuringly, in all of 
the eight cases with concordant in silico predictions for a variant and LOH results, both 
results were congruent, five variants were predicted to be pathogenic and showed LOH with 
the variant allele retained and three cases were predicted to be benign and either no LOH 
was observed or LOH was observed with the variant allele lost.  
In an attempt to functionally classify some of these variants, a protein stability assay for 
pVHL was attempted. Unfortunately, this failed to produce reproducible results. The 
attempt at this assay was time consuming and required specialised equipment not routinely 
available in the diagnostic setting, exemplifying why missense variant classification remains 
such a difficult procedure within the diagnostic laboratory. 
The SDHA gene provided both analysis and variant interpretation challenges. It is a complex 
gene to analyse as it has 3 highly homologous pseudogenes. Additionally the clinical 
significance of the variants observed in the genes was not always clear cut. The c.91C>T 
p.(Arg31Ter) mutation was observed in 2/692 (0.3%) Dutch controls (73) and was reported 
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on the TCA Cycle Gene Mutation Database as ‘Probably pathogenic’ but ‘probably very low 
penetrance’ (250). Given that this is a nonsense mutation in the second exon of the gene its 
lack of penetrance casts a level of suspicion on the pathogenicity of this variant. Various 
analyses undertaken to prove the pathogenicity of this mutation are reported in the 
literature, such as identification of the second hit in the tumour. In the Kopershoek paper, 
SDHA c.91C>T p.(Arg31Ter) was identified in two individuals who both showed loss of the 
wild type allele in the tumours as the result of loss of heterozygosity (LOH) and 
immunohistochemistry (IHC) also showed loss of protein expression in the tumours (73). In 
addition, in the ExAC database (release October 2013), it was observed at an average MAF 
of only 0.02%, whilst Europeans demonstrated the highest MAF at 0.03% (18/66740) (207), 
much lower than the 0.3% in the original publication. 
A frameshift mutation in SDHA was designated to be Class III in Chapter 3. At the time, it 
was considered that that the published evidence regarding SDHA pathogenicity was not 
conclusive enough to allow clinical decisions to be made on the basis of the finding. 
Therefore, it was felt that tumour studies to confirm loss of SDHA protein expression and 
identify the second hit should be performed prior to offering predictive testing to family 
members. However, during the course of this study the additional material to perform these 
analyses were not received. 
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5.6 Pathogenicity assessment of variants putatively associated with 
another independent cancer predisposition syndrome 
There were two variants which were categorised as Class III - VUS, as a result of being 
putatively disease causing, despite having a known incidence in population studies of 
greater than 1%. These variants were SDHB c.487T>C p.(Ser163Pro) and SDHD c.34G>A 
p.(Gly12Ser). Both variants were classed as benign by the WMRGL, as a result of their 
population frequency, until a series of papers were published which associated them and 
other variants in the succinate dehydrogenase complex genes with an increased risk of 
Cowden syndrome, see Table 5.37 (246;247). As a result of these papers, further 
investigation of these variants has been undertaken to establish their pathogenicity.  
The work performed comprises a brief literature review, examination of the frequency of 
identification of these variants during local diagnostic testing, and review of in silico and 
tumour analyses performed. 
5.6.1 Literature review 
Cowden syndrome (CS) is an autosomal dominant cancer predisposition syndrome, which is 
characterised by benign and malignant breast, thyroid and endometrial neoplasia, as well as 
macrocephaly and skin abnormalities (246). Up to 85% of patients have a germline mutation 
in PTEN (246). Cowden syndrome-like (CSL) describes individuals who have disease with 
Cowden syndrome features, but do not meet the strict International Cowden Consortium’s 
criteria for the disease (247). Only about 5% of individuals with CSL have a germline 
mutation in PTEN (247).  
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In 2008, five variants in SDHB and SDHD were reported to be associated with the CS/CSL 
phenotype, see Table 5.37 (246). Functional studies using cell lysates from patient 
lymphoblastoid cell lines with these variants showed a combination of mitochondrial 
dysfunction exhibited by increased expression of manganese super oxide dismutase and/or 
reactive oxygen species (ROS) and activation of the MAPK and/or AKT pathways, which 
mimic PTEN dysfunction (246). The authors acknowledged that three of the variants (SDHB 
c.487T>C p.(Ser163Pro); SDHD c.34G>A p.(Gly12Ser); SDHD c.149A>G p.(His50Arg)) had 
been reported in specific population controls at between 1.1% and 3%, despite not being 
found in their 700 population controls, described as ‘normal white populational controls of 
Northern and Western European origin’. Their explanation for this was that the individuals 
in the populations with known variant alleles may have had unrecognised or partial 
phenotypes (246). Notably, the tumour spectrum in the patients with an SDH variant was 
different to that of the patients with a PTEN mutation, with increased frequencies of breast, 
thyroid and renal cancers in the SDH variant set (246). The authors concluded that, whilst 
the data require validation in a larger study, PTEN-negative patients with CS/CSL should be 
offered SDH mutation analysis (246). 
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Table 5.37 Succinate dehydrogenase complex gene variants associated with Cowden 
disease 
*variants identified in the course of this research in patients who are not known to have a 
Cowden syndrome like phenotype (Adapted from (247)). 
Gene codingDNA variation Protein variation Initially reported 
SDHB c.8C>G p.(Ala3Gly) 2008 (246) 
SDHB c.9C>G p.(Arg27Gly) 2012 (247) 
SDHB c.158G>A p.(Gly53Glu) 2012 (247) 
SDHB c.170A>G p.(His57Arg) 2012 (247) 
SDHB c.359A>G p.(Asn120Ser) 2012 (247) 
SDHB* c.487T>C p.(Ser163Pro) 2008 (246) 
SDHB c.643G>A p.(Ala215Thr) 2012 (247) 
SDHC c.197C>T p.(Ala66Val) 2012 (247) 
SDHD* c.34G>A p.(Gly12Ser) 2008 (246) 
SDHD c.149A>G p.(His50Arg) 2008 (246) 
SDHD c.433C>A p.(His145Asn) 2008 (246) 
 
In a letter to the editor of the American Journal of Human Genetics, Bayley examined the 
validity of some of the findings of the above paper (251). He questioned what normal 
controls had been used for the functional assays and stated that, given the frequency of 
some of the variants had been demonstrated to be as high as 1 in 20 in certain populations, 
the prevalence of the disease should be much higher in those populations (251). He 
commented that ‘in light of the high frequency of these variants in many populations, 
adequate comprehension of their clinical significance and thus appropriate counselling will 
be very challenging’ (251). 
In 2012, Ni et. al. published a more extensive analysis of SDH complex gene variants in 
patients with CS/CSL (247). They identified variants in 8% (49/608) of PTEN mutation 
negative CS/CSL patients but also in 6% (26/444) of PTEN mutation positive CS/CSL patients, 
stating that an SDH variant modified PTEN cancer risks (247). This second study identified an 
additional five SDH variants, the majority of which had not been recorded previously on 
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dbSNP or in the SDH genes LSDBs but two had been reported in African American 
populations on dbSNP (247). Ni et. al. identified that their patient group had increased risk 
of breast cancer if they had both a PTEN mutation and an SDH variant compared to having 
either alone, and again found that SDH variants without PTEN mutation conferred an 
increased risk of breast cancer and epithelial thyroid cancer (247). The authors went on to 
perform various functional analyses on patient lymphoblastoid cell lines (247). They 
identified that SDH variant cell lines had increased cellular ROS, which was highest when 
there was also a PTEN mutation (247). SDH variant cell lines also showed stabilised HIF1α 
signalling and the majority showed loss of steady state p53 (247). 
Interestingly, another paper was published in 2012 by Lendvai et. al. entitled ‘Over-
representation of the G12S polymorphism in patients with MEN2A syndrome’(252). This 
observed that 15.5% (8/55) patients with MEN2A had the SDHD c.34G>A p.(Gly12Ser) 
variant compared to 1% (1/100) of controls (252). Both the patients and controls were of 
Hungarian descent (252). No difference was detected in phenotype between the groups 
with and without the variant (252). Furthermore, upon review of the published literature a 
paper by Montani et. al. was identified where SDHB c.487T>C p.(Ser163Pro), SDHD c.34G>A 
p.(Gly12Ser) and SDHD c.149A>G p.(His50Arg) had been found more commonly in a 
population with medullary thyroid cancer (17.1% (6/35) combined) than in the control 
population (1.2% (1/83) combined) (253). 
5.6.2 Local cohort frequency analysis 
Of the list of variants implicated in CS/CSL, two were identified in NGS prospective patient 
analysis. In the PHEO/PGL/HNPGL cohort, SDHB c.487T>C p.(Ser163Pro) was identified 
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heterozygously in 7 of 239 patients, an allele frequency of 1.5% and SDHD c.34G>A 
p.(Gly12Ser) was identified heterozygously in 3 of 120 patients, an allele frequency of 1.3%. 
None of the other variants were identified. 
The frequency of the CS/CSL associated variants was established for the patients referred to 
the WMRGL for diagnostic analysis of these genes, in order to more thoroughly determine 
the frequency in a similar patient group (see Table 5.38). The cumulative incidence of the 
CS/CSL-associated variants in the local cohort was most similar to the ExAC control 
population cohort. 
Additionally, 29% (n=51) of patients identified with CS/CSL-associated variants had an 
additional variant identified during diagnostic genetic analysis (see Table 5.39). 9/15 were 
known pathogenic mutations and 6/15 were initially classed as VUSs.  
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Table 5.38 Frequency of variants associated with CS/CSL in cohort of patients referred to WMRGL for testing following diagnosis of 
PHEO/PGL/HNPGL and/or RCC compared to frequency reported in CS/CSL patients and on a variation database (ExAC) 
Local PHEO / PGL/ HNPGL patients referred from the commencement of diagnostic testing in 2004 until September 2011. (SDHB – n=870; 
SDHC – n= 233; SDHD - n=705) 
Gene 
coding 
DNA 
variation 
Protein 
variation 
Local PHEO / 
PGL/ HNPGL 
MAF 
CS/CSL 2008 
Paper (246) 
MAF (n=74) 
CS/CSL 2012 
Paper (247) 
PTEN Negative 
MAF (n=608) 
CS/CSL 2012 
Paper (247) 
PTEN Positive 
MAF (n=444) 
ExAC 
ALL 
ExAC 
NFE 
ExAC Homozygotes 
observed 
SDHB c.8C>G p.(Ala3Gly) 0.057% 1.351% 0.164% 0.225% 0.436% 0.019% Yes (AFR) 
SDHB c.9C>G p.(Arg27Gly) 0.000% 0.000% 0.164% 0.000% 0.004% 0.008% No 
SDHB c.158G>A p.(Gly53Glu) 0.000% 0.000% 0.000% 0.225% 0.084% 0.046% Yes (NFE) 
SDHB c.170A>G p.(His57Arg) 0.056% 0.000% 0.164% 0.000% 0.072% 0.001% No 
SDHB c.359A>G p.(Asn120Ser) 0.000% 0.000% 0.164% 0.000% 0.000% 0.000% No 
SDHB c.487T>C p.(Ser163Pro) 1.445% 2.703% 2.138% 2.027% 1.250% 1.520% Yes (FIN, NFE, AFR) 
SDHB c.643G>A p.(Ala215Thr) 0.000% 0.000% 0.000% 0.225% 0.000% 0.000% No 
SDHC c.197C>T p.(Ala66Val) 0.000% 0.000% 0.164% 0.000% 0.002% 0.000% No 
SDHD c.34G>A p.(Gly12Ser) 0.861% 5.405% 2.961% 0.676% 0.730% 1.020% Yes (NFE) 
SDHD c.149A>G p.(His50Arg) 0.780% 2.703% 1.974% 2.477% 0.651% 0.928% Yes (NFE) 
SDHD c.433C>A p.(His145Asn) 0.000% 1.351% 0.164% 0.000% 0.000% 0.000% No 
  
SUM 3.200% 13.514% 8.059% 5.856% 3.230% 3.541% 
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Table 5.39 Summary of patients identified with a CS/CSL and another variant or mutation during this thesis and by the WMRGL since 2004 
All patients identified with a CS/CSL-associated variant and another variant are tabulated. LOH analysis is also recorded where appropriate 
Number CS/CSL associated variant 
identified 
LOH analysis performed? Additional variant identified Class LOH performed? 
1 SDHB c.170A>G p.(His57Arg) No SDHB c.380T>G p.(Ile127Ser) Pathogenic (V) No 
2 SDHB c.487T>C p.(Ser163Pro) No SDHB Exon 1 and 2 duplication VUS (III) No 
3 SDHB c.487T>C p.(Ser163Pro) No SDHD c.191_192delTC 
p.(Leu64Profs*4) 
Pathogenic (V) No 
4 SDHB c.487T>C p.(Ser163Pro) No SDHB c.379dupA 
p.(Ile127Asnfs*28) 
Pathogenic (V) No 
5 SDHB c.487T>C p.(Ser163Pro) Yes - No LOH SDHC c.380A>G p.(His127Arg) VUS (III) Yes - Failed 
6 SDHB c.487T>C p.(Ser163Pro) Yes - Variant allele is lost (partial) SDHB c.220G>A p.(Asp74Asn) VUS (III) Yes - WT allele is lost 
(partial) 
7 SDHD c.34G>A p.(Gly12Ser) No SDHB c.287-1G>C Pathogenic (V) No 
8 SDHD c.34G>A p.(Gly12Ser) No SDHB c.137G>A p.(Arg46Gln) Pathogenic (V) No 
9 SDHD c.34G>A p.(Gly12Ser) No SDHB c.79C>T p.(Arg27*) Pathogenic (V) No 
10 SDHD c.34G>A p.(Gly12Ser) Yes - No LOH SDHB c.298T>C p.(Ser100Pro) VUS (III) Yes - WT allele is lost 
(total) 
11 SDHD c.34G>A p.(Gly12Ser) Yes - No LOH SDHB c.529C>G p.(Arg177Gly) VUS (III) Yes - WT allele is lost 
(total) 
12 SDHD c.149A>G p.(His50Arg) Yes - No LOH SDHB c.587G>A p.(Cys196Tyr) Pathogenic (V) Yes - WT allele is lost 
(partial) 
13 SDHD c.149A>G p.(His50Arg) No RET c.1826G>A p.(Cys609Tyr) Pathogenic (V) No 
14 SDHD c.149A>G p.(His50Arg) Yes - No LOH SDHB c.590C>G p.(Pro197Arg) Pathogenic (V) Yes - WT allele is lost 
(total) 
15 SDHD c.149A>G p.(His50Arg) No SDHB c.689G>A p.(Arg230His) VUS (III) No 
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5.6.3 Tumour analysis of higher frequency variants 
Tumour analysis was performed in all the cases where material could be obtained. For SDHB 
c.487T>C p.(Ser163Pro), 7 FFPE tumour samples were identified. 5/7 patients only had SDHB 
c.487T>C p.(Ser163Pro) and none of the samples showed evidence of loss of heterozygosity 
(LOH). IHC was performed for three of the samples and all showed preserved expression of 
SDHB. One patient also had a variant in SDHC and, whilst no LOH was observed for SDHB 
c.487T>C p.(Ser163Pro), the SDHC analysis failed to produce a result despite repeated 
attempts (see Table 5.39). The final patient identified also had a VUS in the same gene, 
SDHB c.220G>A p.(Asp74Asn). That sample showed partial loss of heterozygosity with 
retention of variant allele for SDHB c.220G>A p.(Asp74Asn) and reciprocal loss of the variant 
allele for SDHB c.487T>C p.(Ser163Pro) (see Figure 5.19), showing that they were on 
opposite alleles and that SDHB c.487T>C p.(Ser163Pro) was unlikely to be driving 
tumourigenesis .  
For SDHD c.34G>A p.(Gly12Ser), 3 FFPE tumour samples were identified. 1/3 patients only 
had SDHD c.34G>A p.(Gly12Ser). Two also had a Class III VUS in SDHB, SDHB c.298T>C 
p.(Ser100Pro) and SDHB c.529C>G p.(Arg177Gly). None of the samples showed LOH for 
SDHD c.34G>A p.(Gly12Ser). Both additional VUSs showed LOH, with loss of the normal 
allele.  
For SDHD c.149A>G p.(His50Arg), two FFPE tumours were identified. Both patients also had 
a pathogenic mutation SDHB c.587G>A p.(Cys196Tyr) and SDHB c.590C>G p.(Pro197Arg). 
Both samples showed LOH for the pathogenic mutation but not for SDHD c.149A>G 
p.(His50Arg). 
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a) 
 
b) 
 
c) 
  
d) 
 
Figure 5.19 LOH analysis for patient with two variants in SDHB c.220G>A p.(Asp74Asn) and 
c.487T>C p.(Ser163Pro) 
a) SDHB c.220G>A p.(Asp74Asn) in lymphocyte DNA, b) SDHB c.220G>A p.(Asp74Asn) in 
FFPE tumour, c) SDHB c.487T>C p.(Ser163Pro) in lymphocyte DNA and d) SDHB c.487T>C 
p.(Ser163Pro) FFPE tumour. The FFPE tumour sequences show that the variants are on 
opposite alleles as the variant allele is retained for SDHB c.220G>A p.(Asp74Asn) and lost for 
SDHB c.487T>C p.(Ser163Pro), indicating that SDHB c.220G>A p.(Asp74Asn) is more likely to 
be involved in tumourigenesis. 
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5.6.4 Conclusions regarding pathogenicity of these variants 
The decision regarding the pathogenicity of the variants discussed in section 5.6 is highly 
complex. The evidence from the functional analyses performed by Ni et. al. together with 
the increased frequency of certain tumours in the CS/CSL patients with these variants is 
apparently compelling. However the identification of these variants in patients with PTEN 
mutations suggests that they could be modifiers rather than initiators of disease and that 
the PTEN mutation negative cases may have a yet undiscovered germline initiator mutation. 
The increased frequency of some of the variants (those at already relatively high frequency) 
in cohorts with MEN2A and MTC supports the theory that these variants could increase 
disease penetrance for certain tumour types.  
Whilst it was difficult to know how best to report these variants in a patient with symptoms 
of CS, it had become impossible to know how to report them in patients with 
PHEO/PGL/HNPGL. This is of particular importance for those variants which are seen at 
greater than 1% allele frequency, as inherently greater than 1% of patients tested will be 
found to have them.  
The cumulative evidence provided above supports the view that the higher frequency 
variants are not pathogenic with regard to familial paraganglioma (PHEO/PGL/HNPGL/RCC) 
tumorigenesis, in the context of causing high risk of cancer: 
 The variants are not enriched for in the familial paraganglioma cohort tested at the 
WMRGL, suggesting they are unlikely to be drivers or indeed modifiers of disease; 
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 None of the variants were on the retained allele in any patient when LOH analysis 
was performed. There was either no LOH observed or the variant was on the lost 
allele; 
 IHC analysis of SDHB c.487T>C p.(Ser163Pro) found normal staining; 
 On nine occasions, a CS/CSL-associated variant was identified with a pathogenic 
mutation in the same gene, one of the other genes in the SDH complex or another 
gene which explains the phenotype; 
 A CS/CSL-associated variant was identified with a VUS in the same gene or another 
gene in the SDH complex on six occasions and in all cases where LOH analysis was 
successfully performed (n=3) LOH was observed with the non-CS/CSL associated 
variant allele being retained in the tumour, increasing its likelihood of pathogenicity. 
Additionally, whilst full phenotype data is not available for the cohort, only 1/51 patients in 
which one of these variants was identified was reported to have any Cowden syndrome like 
features. Ni et. al. state that the penetrance is low for these variants (246) but likely 
penetrance of only 2% doesn’t fulfil Rahman’s criteria for assigning tumour suppressor gene 
status to a gene (with regard to the CS/CSL phenotype) (2). 
From the evidence available it seems appropriate that SDHB c.487T>C p.(Ser163Pro), SDHD 
c.34G>A p.(Gly12Ser) and SDHD c.149A>G p.(His50Arg) now be reported back to clinicians as 
not associated with a familial paraganglioma phenotype and that their relevance regarding 
CS/CSL be reported as remaining uncertain. 
  
221 
 
 
5.7 Conclusion 
This chapter exemplifies the vast workload that is associated with the classification of 
variants identified in the course of genetic analysis. Variation databases play a huge role in 
the classification of variants and even within the comparatively short time between the 
completion of the gene screening portion of this work and the variant analysis section, the 
release of the ExAC database allowed reclassification of a number of variants. A set of RNA 
assays for use with the VHL gene were established which allowed a variant to be reclassified 
into a clinically actionable category. 
In addition, the chapter has demonstrated that functional assays are difficult and labour-
intensive to set up and, as shown by the CS/CSL data, even when they show a variant to be 
associated with altered function, the data must be assessed in context, e.g. the phenotype 
of all individuals with the variant. 
In total, 9/52 (17.3%) variants were reclassified. 
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Chapter 6 Discussion 
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6.1 Summary of thesis 
Genetics plays a fundamental role in healthcare. One particular aspect of that role is the use 
of genetics in the context of familial cancer syndromes, specifically in the diagnosis and 
management of individuals (and their families) who have inherited a mutation in a cancer 
predisposition gene. Genetic techniques are rapidly advancing and the application of these 
advancements to the healthcare setting allows more individuals to be diagnosed as having a 
genetic illness, and hence for better care to be provided for both them and their relatives. 
Chapter 3 describes the optimisation, validation and prospective use of Next Generation 
Sequencing (NGS) for genetic diagnosis of patients with phaeochromocytoma/parganglioma 
and renal cell carcinoma. These two overlapping assays allowed increased detection of 
germline mutations at a lower cost per gene and reduced processing time compared to 
previous methods of analysis. 
As is well known, routine diagnostic genetic analysis can miss pathogenic mutations since it 
is almost always limited to identifying heterozygous mutations in the coding region of the 
gene. Chapter 4 describes the optimisation, validation and prospective use of Next 
Generation Sequencing (NGS) to look for mutations in the full VHL gene region and for 
mutations occurring at a mosaic level in the tissue that the patient DNA was extracted from. 
Eighteen percent of clinically diagnosed VHL patients screened using this assay had a 
clinically actionable mosaic mutation identified. 
Unfortunately, the analysis of more genes and fuller analysis of gene regions inherently 
increases the identification of variants of unknown significance (VUSs). The classification of 
these VUSs as either benign or pathogenic is very important for the appropriate clinical 
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management of the individuals that carry them. Chapter 5 describes the attempt to classify 
the VUSs identified during the course of Chapters 3 and 4 of this thesis, with the addition of 
some other VUSs identified in the genes studied during previous routine Sanger-based 
diagnostic analysis by the WMRGL. The chapter demonstrates the many difficulties in 
variant classification, however, it was possible to reclassify 17.3% of VUSs identified in 
Chapters 3 and 4 and additional evidence was gathered about those which could not be 
reclassified. 
6.2  The current landscape of genetic medicine 
Even in the short time since the commencement of this project there have been significant 
advances in the field of diagnostic genetics. All British NHS diagnostic genetics laboratories 
have implemented NGS into routine practice, mainly in the form of gene panel tests such as 
those described in Chapter 3. Furthermore, exome sequencing is now available from a select 
set of British diagnostic genetics laboratories with the findings used in the clinic. 
There are two ways in which exome sequencing has been implemented. In the first the 
exome is sequenced but a list of genes that are of relevance to the patient’s phenotype is 
curated and data analysis is restricted to the genes identified, creating a virtual gene panel. 
This method allows numerous different virtual gene panel tests (more than one gene 
analysed simultaneously) to be performed using a single technical workflow (254;255). 
Currently the vast majority of NGS gene panel tests are performed using a specific target 
enrichment designed in a bespoke manner to a single panel of genes related to a single 
phenotype or set of overlapping phenotypes, such as the panels in Chapter 3. The new 
model can be implemented either with whole exome enrichment or with smaller 
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enrichment limited to those genes in the exome already known to be associated with 
genetic disease (sometimes referred to as the ‘Mendeliome’). Whilst this model has little 
scope for novel disease gene identification, it is a cost effective and streamlined method of 
gene panel analysis. Additional benefits are that the genes in a panel can be easily updated 
and that the exome data for a patient can be stored and analysed for additional genes or 
using a new gene list for a different phenotype, should the need arise (254). One limitation 
of this method is that the exome enrichment may not fully cover the coding region of all of 
the genes of interest, thus decreasing the clinical sensitivity of the test compared to a 
specifically designed panel. In a study using this model, with the Agilent Sure Select All 
Human Exon Kit for target enrichment, it was estimated that only ~90% of genes were 
reliably covered (255). Another limitation is that a laboratory routinely performing a specific 
panel test becomes expert in the interpretation of its results and, given that interpretation 
of VUSs is central to diagnostic genetics, a movement away from centres with expert 
knowledge could hinder VUS interpretation. 
The second way in which exome sequencing has been implemented is following the model 
used in research for novel gene identification first demonstrated by Ng et. al. (256). In this 
approach, all variants identified within the exome enrichment used are reported and then 
prioritised using a locally validated protocol. An example of a flowchart depicting one such 
protocol published by Baylor College of Medicine, USA is shown in Figure 6.1 (257). A 
number of publications have demonstrated how this approach can work in the diagnostic 
setting (257-260). For example, the Canadian Finding Of Rare Disease Genes study showed 
how exome sequencing could be used for both novel gene identification and genetic 
diagnosis in patients who have mutations in previously characterised genes, but where the 
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causative mutation(s) had not been identified by previous analysis (260), with the latter 
being the more likely scenario in a diagnostic setting in the short term. That study identified 
a mutation in a known gene in 105/362 families analysed (260). The lack of previous 
identification of the pathogenic change(s) was most commonly the result of either a high 
level of genetic heterogeneity related to the patient’s condition or an atypical presentation 
(260). One of the disadvantages of whole exome sequencing is the increased burden of 
variant interpretation. It has been established that each sequenced exome has 20, 000 to 
50, 000 variants identified and that following variant prioritisation methods, such as that in 
Figure 6.1, there are still between 150 and 500 private non-synonymous or splice-site 
variants requiring further analysis and interpretation in the context of the phenotype (261). 
It should also be noted that the pathogenic mutation could have been filtered out during 
the prioritisation process (261). 
The majority of the published studies in this area are for patients with childhood-onset 
disorders and do not include cancer patients. In one study where cancer patients were 
included and which used the first model (virtual panel), a diagnostic yield of only 3% was 
achieved when the authors looked at a group of patients with microsatellite stable 
colorectal cancer, in comparison to a diagnostic yield of 52% in their blindness cohort (255). 
However, it is hoped that the use of clinical whole exome analysis could identify some 
currently unknown cancer predisposition genes (CPGs) and additional tumour types 
associated with known CPGs. In addition, CPG-specific enrichments are available, such as 
the Illumina TruSight Cancer enrichment. This means a patient with inherited cancer can be 
analysed for the vast majority of known CPGs, thus identifying patients with atypical 
presentation of disease. 
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Figure 6.1 Example variant prioritisation and interpretation protocol published by Yang et. al. 
ESP = ESP5400 data from the National Heart, Lung, and Blood Institute GO Exome Sequencing Project, HGMD = Human Gene Mutation 
Database, MAF = minor allele frequency, TG = the 1000 Genomes Project and VUS = variants of unknown clinical significance. (Adapted from 
(257)). 
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The use of exome sequencing brings with it the issue of incidental findings (IFs). Green et. al. 
defined IFs as ‘results that are not related to the indication for ordering the sequencing but 
that may nonetheless be of medical value or utility to the ordering physician and the 
patient’ (262). There has been much discussion in the literature regarding the ethics and the 
utility of reporting such findings. In 2013, the American College of Medical Genetics and 
Genomics (ACMG) released their recommendations for dealing with IFs (262). In brief, they 
recommended that mutations in a defined list of 57 genes should not only be reported but 
the data be sought if it was available from the analyses performed (262), e.g. exome 
sequencing. The list mainly comprised genes in which pathogenic mutations could be life-
limiting, such as genes related to cardiovascular diseases and cancer predisposition (262) 
and included the majority of the genes studied during this research. The recommendations 
included that those being tested would be obliged to have any incidental findings reported 
to them (262).  
There was a flurry of responses to the recommendations, with critics suggesting the ACMG 
guidelines ignored the patient’s right for autonomy (263). Various other internationally 
recognised bodies released their versions but none proposed such definite ideas as the 
American group (264-267). In fact, a 2014 report from the European Society for Human 
Genetics recounted that during their annual conference debate there was no audience 
consensus regarding whether incidental findings should be reported back to patients or not 
(268), let alone actively sought as suggested by the ACMG (262). The debate over incidental 
findings is further complicated by VUSs and how and when they should be reported to 
patients if identified in genes such as those highlighted by the ACMG. 
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Another difficulty with the rapid technological advancement in genetic medicine is deciding 
which test(s) will be most useful for which patients, whilst achieving a diagnosis at the 
lowest cost possible. There is still much value in traditional genetic analysis, such as single 
gene analysis and chromosome analysis. A retrospective study of the genetic diagnosis of 
500 patients at Duke University Medical Center, USA found that 46% of patients were 
diagnosed using these traditional methods and that it therefore was not necessary or cost 
effective to request complex tests in these cases (269). The advantages and disadvantages 
of each type of test must be recognised, see Table 6.1, and related back to the patient and 
their phenotype. Xue et. al. have proposed a general algorithm to aid in the clinician’s 
decision making process, see Figure 6.2 (270). 
Table 6.1 Factors to consider when selecting a sequencing based diagnostic test. 
CDS = coding sequence, VUS = variant of unknown significance, IF = incidental finding. 
(Based on (270)). 
Test  Coverage of CDS 
for gene(s) of 
interest 
Chance of VUS 
identification 
Chance of IF 
identification 
Cost Additional test(s) required 
Single 
gene 
test 
Comprehensive Minimal Minimal Low None 
Gene 
panel 
test 
Moderate to 
comprehensive 
Moderate Low Moderate 
to high 
Sanger sequencing required to 
confirm variants. May also be 
used to fill coverage gaps 
Exome 
test 
Variable High High High Sanger sequencing required to 
confirm variants 
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Figure 6.2 Molecular genetic testing algorithm 
(Adapted from (270)). 
In terms of the cancer predisposition diseases examined in this research, the current 
optimum testing strategy is highly dependent on the specific patient. For example a patient 
with a clinical diagnosis of VHL disease Type 1 would still currently be best served by either 
single gene analysis or a comprehensive NGS panel depending upon cost, followed by a test 
allowing mosaic level examination if no mutation was identified. In contrast, a patient with 
inherited paraganglioma would be best served by a comprehensive NGS panel, followed by 
exome analysis for novel gene identification, if required. 
 
6.3 The future of genetic medicine 
Whole genome sequencing is considered likely to become the test of choice in coming years 
(271). The British government has recognised this and has commissioned the 100, 000 
genomes project to be run by a Department of Health owned company called Genomics 
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England (272). This project aims to perform whole genome sequencing on 100, 000 NHS 
patients by 2017, focussing on patients with rare diseases and cancer (272). For patients 
with rare diseases they plan to sequence trios (patient and both parents), whilst for cancer 
patients they plan to sequence germline and tumour DNA samples (272). Genomics England 
recognises that there are three main challenges involved with a project of this magnitude, 
sequencing, data and security (272). The sequencing challenge concerns ensuring the quality 
of the amount of sequencing to be performed; initially all findings will be confirmed in a 
diagnostic laboratory (272). Data refers to both bioinformatic processing and the clinical 
interpretation of the variants identified (272). Security refers to the appropriate storage of 
the data obtained (272). In particular recognition of the data interpretation challenges, a 
number of Genomics England Clinical Interpretation Partnership (GeCIP) domains have been 
created (272). These GeCIPs are described as having three main aims: 
‘1. To optimise clinical data and sample collection, clinical reporting and data validation and 
interpretation. 
2. To improve understanding of the implications of genomic findings and improve the 
accuracy and reliability of information fed back to patients. To add to knowledge of the 
genetic basis of disease. 
3. To provide a sustainable thriving training environment.’ (272). 
Therefore, Genomics England recognises the vast problems they face with variant 
pathogenicity determination, as exemplified on a smaller scale by Chapter 5 of this research.  
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Interestingly, the 100, 000 genomes project has decided on an ‘opt-in’ policy with regard to 
incidental findings (272). In the context of the project they are referred to as secondary 
findings and defined as ‘an additional looked-for health-related finding that is not pertinent 
to the main condition’ (272). A patient has to opt-in to having secondary findings actively 
sought and reported back from a list of defined genes/conditions known to influence 
healthcare, similar to those included on the ACMG list (262;272). VUS in these genes will not 
be reported, however reanalysis of genes which are later identified to meet these criteria is 
included (272), as, it must assumed, variants will be variant with upgraded pathogenicity 
status, at least within the context of the study. 
 
6.4 Final conclusions 
This thesis describes the identification and assessment of variants in a subset of genes 
involved in familial cancer syndromes. The development of three novel variant identification 
assays has allowed genetic diagnosis in patients who would have otherwise remained 
uncertain of their family’s genetic status. This thesis has also demonstrated the difficulty in 
successful variant pathogenicity determination, both in the context of highly penetrant 
genetic diseases and genetic modifiers. The meteoric rise in both the importance of genetics 
in healthcare and the vast improvements in the technology available to perform genetic 
analyses, mean that variant pathogenicity determination will remain at the centre of 
diagnostic genetics.
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7.1 Chapter 3 Appendices 
Table 7.1 Primer sequences 
Primers were tagged with the Fluidigm CS tags for NGS and the M13 tags for Sanger confirmations and gap-fills. CS forward tag: 
ACACTGACGACATGGTTCTACA, CS reverse tag: TACGGTAGCAGAGACTTGGTCT, M13 forward tag: TGTAAAACGACGGCCAGT, M13 reverse tag: 
CAGGAAACAGCTATGACC. 
Gene_Exon F Primer  R Primer Chromosome  Product size 
FH_1 GGTCATTCACGATTGGTCCT GAATCTCTCCCGCCAAGTC 1 375 
FH_10 TTAAGAGGCCCATATAGCATCAA TCCATCTTAGACCTAGCACATCC 1 422 
FH_2 CAGCTGATAAGATGCGATTACTTT TATTCAAAGCGATGGCTCAA 1 419 
FH_3 TCTTGGTTCATGAATTCCTGTCT TGCCAGAGCATATCGTCATC 1 360 
FH_4 TCTGTGGTTGGAGCAAGTGA AAGAACCATAAGAAGCCTTATCCA 1 434 
FH_5 ACCAGGATGCTGCTTATTTGA ATTGGCCATTTGTACCAAGC 1 419 
FH_6 CCCTCATCCTTCCCTATACTTTG CACAAGAATTCAAGACAGGAACA 1 436 
FH_7 TGTTTCACTTGCTAATGGTAGAAAA TGACCAGAGGACCACAGACA 1 428 
FH_8 CTACCCATCCCACCTTCCTT ACCCAACTACCCAATGTGGA 1 397 
FH_9 GCCTTCAAATGTTCATGCTTT GCTGTTCTCAAACACTGATCCA 1 450 
FLCN_4 GGGAGGTTTCATGGAGTCAA CCTGTCCATCCCACACCTAC 17 390 
FLCN_5 TTCCGAGCTCAGATTTGCAT GCTCAGCAAGTCCAACATGA 17 432 
FLCN_6 TGGTGTCACTAAGCGAGGAA GTGCACTGGCTGTAAGCAGA 17 393 
FLCN_7 GATTGGACTGGTGGCACTTT TGGACAAGCCAACCAATGTA 17 388 
FLCN_8 GTGAGCGTCAGGTTTGCTTT GACAGCCCACCTGTGAATTT 17 412 
FLCN_9 GGCTCAGCCCATGAAGTATC GAAGGTGGAGGGTCCAGAG 17 371 
FLCN_10 CTGAGCCCTGTCTTTGCTCT GCACACGCATCCTTCTGA 17 425 
FLCN_11 ACAAGCTGGTGTGTGACTGG TCCACAACCCATGACAGAGA 17 446 
FLCN_11a CACTGTGGGCTGAGAGTCTG CACCGCTACCTGTGTGAAGA 17 448 
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Gene_Exon F Primer  R Primer Chromosome  Product size 
FLCN_12 CATTGATTTGGGCCAGTCTT CCGCTTCAATCTTATTCAGGA 17 398 
FLCN_13 GAGTTTGCTGTCATCGTGGA TTGGAAACAGCTCCAGGTTT 17 399 
FLCN_14 GGATTGTGCTGTGGTGTCTG CCTGATGGTTTCCCTTCCTT 17 380 
MAX_1 GCCGTCTGTTAGAGGGACAA GAGGGGAAGGGGAAGGAG 14 445 
MAX_2 GCCGGCATTTTCTTTCTTATT GGCATCTGGATCCCCTATCT 14 392 
MAX_3 TGCTGACAGCGTGTACTTCC TGCAGTGATCCTCCAAACAG 14 357 
MAX_4 TTCAGCCTTTTCCCACCTTA CCTCAGGACGGCTCTAACAC 14 416 
MAX_5 CAACAAGCAAGCCCTTAGGA GGAGGATGAGACGATGGAGA 14 348 
MET_16 AATGAAGCTCATAAAGGGTTTGA AGGGCTCTGAGGGATCATTT 7 364 
MET_17 AAACCCTCAGGACAAGATGC AGGGATGGCTGGCTTACAG 7 360 
MET_18 GGCTTGAGCCATTAAGACCA CTGAAAGTCCCACCCACATC 7 413 
MET_19 GGATTTCAAATACTGAAGCCACTT CTGGAATTGGTGGTGTTGAA 7 379 
RET_10 TGGAGGCAGAGTCCTTTGTT TGCTGTTGAGACCTCTGTGG 10 423 
RET_11 ATACGCAGCCTGTACCCAGT CACAGGATGGCCTCTGTCTC 10 419 
RET_13 TGACCTGGTATGGTCATGGA ATGGCAGTGTCACACCAGAG 10 450 
RET_14 AAGACCCAAGCTGCCTGAC GGCTAGAGTGTGGCATGGT 10 383 
RET_15 CTGGTCACACCAGGCTGAG AGAGGCTGAGCGGAGTTCTA 10 386 
RET_16 CATCTCAGCAATCCACAGGA GCTAGCACTGCAGACAGGTG 10 403 
SDHA_1 GACCTCAGCGTTCCCTTAAC GCTCTCTCAGCCCCTTCC 5 450 
SDHA_2 CAAGTCAGGGTGGAAACGAG CCTTACCCCCTAAGCCAAAA 5 362 
SDHA_3 TTGGCATAGTGGAACATGTGA AAGAGGCTCCAGGGAGAGAC 5 374 
SDHA_4 TCTGGAATCTGTCGGGTCTC CCGCCTCAATTGCTTACATT 5 397 
SDHA_5 TTTGGGTTTGCAGATTTGTG CACGCTGCTGTTCTCTGTTG 5 399 
SDHA_6 TGGTCCATTTGGATCAAGTTC CCATCACCCTCACATGGTTA 5 397 
SDHA_7 TGTGCACAGCACTGAGAAGAC CCTGAGAGCTGAGGAAGCTG 5 374 
SDHA_8 TGTCAGCCTTGTCAGTGCTT CGGTGCTGAAACTCACAGAA 5 436 
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Gene_Exon F Primer  R Primer Chromosome  Product size 
SDHA_9 GATTTGATGAGAGGGTGACCA GTCGTCCCAGCCTTCTTTC 5 392 
SDHA_10 GGCACCTTGACATTTCACCT TGGGACTCTGAAGGTTGAGG 5 383 
SDHA_11 TGGCAGTGTGTTAGCTCAGG GACTCCACCACCTCCCAGTA 5 395 
SDHA_12 CAGTTCTTGGTATGGCTGCTT CATGGAGTCACTGGTTGTGG 5 324 
SDHA_13 GTCCTGGCCCACAGCTATAA TTTACTTTTGGGGCAACGAA 5 366 
SDHA_14 CCTGGGCTGAAGTGGAAAT CGAATCTGTCGGGAGTTGAT 5 369 
SDHA_15 AAGGAACACAAGAGATGGCTTT AATGAAGCAAGGGACAAAGG 5 362 
SDHAF2_1 CCGTTACCGGGAATATGG TATCGGGCAGACGAACTCTC 11 379 
SDHAF2_2 CCTGGCCAGCAGTGTAATTT CCTACTCTGGCTCAGGAAGC 11 410 
SDHAF2_3 GCAGAAAGAGGGGAATGTTG GGCAACGAGAGTGAAACTCA 11 433 
SDHAF2_4 GTGGTTCTTGGCCAGTGTTT TGAGGCTCAGAGCTGAACAA 11 439 
SDHB_1 CGGCTAGTGGGTCCTCAGT ACTTGACAGGGATGCTCGAA 1 350 
SDHB_2 TCCAGCGTTACATCTGTTGTG GGCCACATTGGTCTTGAACT 1 447 
SDHB_3 CCGAAGGTGACCTGAGAAGA GCCAGATGCAGTAACCACAG 1 449 
SDHB_4 CAGCAAGGAGGATCCAGAAG CTCTGGCCACACTGTCTCAG 1 448 
SDHB_5 CCTGGCATAGAGTGGACGAG AGGGCTCTAGCTCCTTGGTC 1 445 
SDHB_6 TTAAGAACCCTGGGCAGATG ATGGCAATGAAGGAAACCAG 1 434 
SDHB_7 CCCAGAGCTTTGAGTTGAGC TCCCACAATGTCCCTGTGTA 1 444 
SDHB_8 CACCTTGCTTGGACACTGAA GACTCCTGGCACCTTCACAT 1 397 
SDHC_1 CCGAAATCCTGGCAAATTC CTGCCCAGGCACAGGATA 1 352 
SDHC_2 TTGTCTTGCATTATTTGTGTTTGA CTGGGTGACAGAGCGAGACT 1 368 
SDHC_3 GATTACAGGCCTGAGCAACC TCTACCCTGAAGGGTTCACCT 1 368 
SDHC_4 ACAGGAATGCAAAAGCTGGT TCCCTCTAAATCAAGTGCTGAGT 1 450 
SDHC_5 GGAGACTCGCTTGAACTTGG AGTCTCCCCACTCCCTTCAC 1 447 
SDHC_6 CCTCCTACCATCACCACACA TCCCAGGCTGGAGATAAGAA 1 429 
SDHD_1 ACCTTCCGACAGCTGTGTTT CCTTCGGGTAAACATCTGGA 11 381 
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Gene_Exon F Primer  R Primer Chromosome  Product size 
SDHD_2 ATGCAGATGTTCCCTGGTCT TGTCTGCCCAAAGGTGTAAA 11 450 
SDHD_3 TGCCTGTCAGTTTGGGTTACT GACATTGAATAGGCAGGCAGA 11 415 
SDHD_4 GGAGTGGCAAATGGAGACAT AAGAAGGCTGTCCACCAATG 11 411 
TMEM127_2 TGCTATCCTCCACCGGACT CTGGTCCCTGGCTATCTCTG 2 421 
TMEM127_3 GCTAAGACAGCGTCCTCCAG AAGACTGGAGCTTGGCACAT 2 431 
TMEM127_4 TGCTCACTAATTCCCCTTCTG GGCTGCCGAGGAAGAGAG 2 381 
VHL_1a AGCGCGTTCCATCCTCTA GCGATTGCAGAAGATGACCT 3 370 
VHL_1b GGCAGGCGTCGAAGAGTA GCTTCAGACCGTGCTATCGT 3 345 
VHL_2 GGACGGTCTTGATCTCCTGA TTGAGACACCATAACACCTTTAACA 3 451 
VHL_3 GCAAAGCCTCTTGTTCGTTC AGGAAGGAACCAGTCCTGTATCT 3 338 
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7.2 Chapter 4 Appendices 
Table 7.2 Class I - Benign variants excluded from further analysis during NGS screening of the VHL gene region 
These variants have been classed as benign on the basis of minimum allele frequency (MAF). MAF = Minimum allele frequency; 1000 genomes 
ALL_MAF = MAF of all populations in 1000 genomes phase 1 study; AFR_MAF = MAF of all African individuals in 1000 genomes phase 1 study; 
AMR_MAF = MAF of all American individuals in 1000 genomes phase 1 study; ASN_MAF = MAF of all East Asian individuals 1000 genomes 
phase 1 study; EUR_MAF = MAF individuals of all European individuals 1000 genomes phase 1 study. * Seen repeatedly in West Midlands 
Regional Genetics Laboratory in trans with pathogenic mutations. 
Number Chromosome 
position - 
start 
dbSNP 
reference 
Study 
MAF 
dbSNP MAF 1000 
genomes 
ALL_MAF 
1000 
genomes 
AFR_MAF 
1000 
genomes 
AMR_MAF 
1000 
genomes 
ASN_MAF 
1000 
genomes 
EUR_MAF 
1 10179646 rs3864019 0.0210 0.0268 G:0.0257 G:0.03 G:0.07 G:0.0017 G:0.02 
2 10179778 rs117742184 0.0035 0.0216 T:0.0073 T:0.0020 T:0.0028 T:0.02 - 
3 10179862 rs9879931 0.1538 0.222 T:0.2222 T:0.56 T:0.21 T:0.0035 T:0.18 
4 10179912 rs60650700 0.0070 0.0312 T:0.0248 T:0.09 T:0.02 - T:0.0013 
5 10179924 rs140812048 0.0490 0.0482 T:0.0482 T:0.04 T:0.03 T:0.07 T:0.04 
6 10180041 rs9875667 0.1818 0.2801 C:0.2801 C:0.70 C:0.23 C:0.10 C:0.17 
7 10180062 rs14465863 0.0035 0.0078 T:0.0078 T:0.03 T:0.01 - - 
8 10180088 rs191444064 0.0035 0.0078 A:0.0096 A:0.03 A:0.01 - A:0.01 
9 10180557 rs776517 0.1434 0.1221 G:0.1221 A:0.94 A:0.81 A:0.87 A:0.88 
10 10180659 rs265318 0.1364 0.1203 C:0.1203 A:0.91 A:0.81 A:0.87 A:0.90 
11 10181240 rs713024 0.1294 0.1198 A:0.1198 G:0.94 G:0.81 G:0.87 G:0.88 
12 10181245 rs151107472 0.0035 0.0038 G:0.0073 - - G:0.03 G:0.0013 
13 10181812 rs111860145 0.0035 0.0284 A:0.0220 A:0.08 A:0.02 - - 
14 10181819 rs137893497 0.0035 0.0212 A:0.0073 A:0.0020 A:0.0028 A:0.02 - 
15 10182040 rs199563741 0.0035 0.0319 -:0.0294 -:0.11 -:0.02 - -:0.0026 
16 10182150 rs73024525 0.0105 0.003 C:0.0046 - - - C:0.01 
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Number Chromosome 
position - 
start 
dbSNP 
reference 
Study 
MAF 
dbSNP MAF 1000 
genomes 
ALL_MAF 
1000 
genomes 
AFR_MAF 
1000 
genomes 
AMR_MAF 
1000 
genomes 
ASN_MAF 
1000 
genomes 
EUR_MAF 
17 10182562 rs779803 0.3007 0.3898 G:0.3898 A:0.29 A:0.59 A:0.77 A:0.70 
18 10183002 rs10433558 0.2483 0.3214 C:0.3214 C:0.05 C:0.30 C:0.64 C:0.27 
19 10183274 rs779804 0.3636 0.135 C:0.1350 T:0.90 T:0.80 T:0.87 T:0.86 
20 10183337 rs779805 0.3077 0.4164 G:0.4164 A:0.18 A:0.57 A:0.77 A:0.70 
21 10183605 rs35460768 * 0.0035 0.0004 Not 
available 
Not 
available 
Not 
available 
Not 
available 
Not 
available 
22 10183876 rs61758376 0.0070 0.0214 C:0.0073 C:0020 C:0.0028 C:0.02 - 
23 10184255 rs779806 0.1608 0.1506 G:0.1506 A:0.86 A:0.78 A:0.87 A:0.86 
24 10184519 rs73024533 0.0070 0.0026 C:0.0046 C:0.0020 C:0.0028 - C:0.01 
25 10184865 rs11920834 0.0035 0.0331 G:0.0289 G:0.11 G:0.02 - - 
26 10184956 rs779807 0.2972 0.4366 A:0.4366 T:0.17 T:0.57 T:0.74 T:0.68 
27 10184963 rs191112313 0.0035 0.0212 T:0.0073 T:0.0020 T:0.0028 T:0.02 - 
28 10185021 rs779808 0.2972 0.4164 C:0.4164 T:0.18 T:0.57 T:0.77 T:0.70 
29 10185128 rs73024535 0.0105 0.003 G:0.0046 - - - G:0.01 
30 10185262 rs779809 0.1294 0.1217 A:0.1217 G:0.93 G:0.81 G:0.87 G:0.88 
31 10185354 rs524411 0.0350 0.0638 G:0.0638 G:0.01 G:0.08 G:0.12 G:0.05 
32 10185803 rs146851054 0.0035 0.0212 C:0.0073 C:0.0020 C:0.0028 C:0.02 - 
33 10186216 rs34232505 0.1434 0.1993 A:0.1993 A:0.41 A:0.20 A:0.08 A:0.16 
34 10186268 rs74749021 0.0035 0.007 T:0.0078 T:0.03 T:0.01 - - 
35 10186447 rs1678593 0.3042 0.4192 A:0.4192 T:0.18 T:0.57 T:0.77 T:0.70 
36 10186514 rs779811 0.3042 0.4669 T:0.4669 A:0.16 A:0.54 A:0.70 A:0.65 
37 10187014 rs779812 0.1364 0.1212 A:0.1212 G:0.93 G:0.81 G:0.87 G:0.88 
38 10187112 rs779813 0.1364 0.1212 A:0.1212 G:0.93 G:0.81 G:0.87 G:0.88 
39 10187171 rs374645 0.2063 0.0693 T:0.0693 C:0.95 C:0.89 C:0.97 C:0.91 
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Number Chromosome 
position - 
start 
dbSNP 
reference 
Study 
MAF 
dbSNP MAF 1000 
genomes 
ALL_MAF 
1000 
genomes 
AFR_MAF 
1000 
genomes 
AMR_MAF 
1000 
genomes 
ASN_MAF 
1000 
genomes 
EUR_MAF 
40 10187175 rs113225030 0.0035 0.0034 T:0.0032 T:0.01 - - - 
41 10187369 rs181381146 0.0035 0.0198 C:0.0073 C:0.0020 C:0.0028 C:0.02 - 
42 10187377 rs1642729 0.1993 0.1717 A:0.1717 G:0.87 G:0.76 G:0.83 G:0.83 
43 10187634 rs2543458 0.1364 0.1217 G:0.1217 T:0.93 T:0.81 T:0.87 T:0.88 
44 10187690 rs76843316 0.1608 0.3127 -:0.3127 C:0.57 C:0.68 C:0.74 C:0.73 
45 10187884 rs9819196 0.0105 0.0763 A:0.0666 A:0.25 A:0.03 - A:0.02 
46 10187949 rs371330108 0.0070 0.0194 Not 
available 
Not 
available 
Not 
available 
Not 
available 
Not 
available 
47 10187952 rs149056499 0.0105 0.003 T:0.0051 - - T:0.0017 T:0.01 
48 10187982 rs143057620 0.0490 0.0184 T:0.0184 T:0.01 T:0.02 - T:0.04 
49 10188011 rs35286098 0.1608 0.2544 C:0.2544 -:0.45 -:0.74 -:0.85 -:0.86 
50 10188363 rs34661876 0.0175 0.0048 G:0.0083 - G:0.01 - G:0.02 
51 10188428 rs1678607 0.1364 0.208 T:0.2080 G:0.88 G:0.75 G:0.75 G:0.79 
52 10188494 rs140172229 0.0035 0.0765 -:0.0666 -:0.25 -:0.03 - -:0.02 
53 10188576 rs143659897 0.0035 0.0022 T:0.0023 T:0.01 - - - 
54 10188798 rs1678606 0.1364 0.1244 T:0.1244 C:0.93 C:0.81 C:0.87 C:0.87 
55 10188835 rs62238314 0.2517 0.32 G:0.3200 G:0.05 G:0.29 G:0.64 G:0.27 
56 10188884 rs112248386 0.1434 0.1212 T:0.1212 T:0.09 T:0.16 T:0.08 T:0.16 
57 10189493 rs9829290 0.0035 0.1274 A:0.1010 A:0.36 A:0.04 A:0.02 A:0.02 
58 10189929 rs1681660 0.1434 0.1217 T:0.1217 C:0.93 C:0.81 C:0.87 C:0.88 
59 10189935 rs147654121 0.0035 0.0088 T:0.0055 T:0.01 - T:0.02 - 
60 10190100 rs189742164 0.0035 0.0767 A:0.0579 A:0.19 A:0.03 - A:0.03 
61 10190293 rs112782301 0.0874 0.124 T:0.1240 T:0.10 T:0.16 T:0.08 T:0.16 
62 10190458 rs189039866 0.0070 0.0018 C:0.0018 - - - C:0.01 
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Number Chromosome 
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start 
dbSNP 
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dbSNP MAF 1000 
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ALL_MAF 
1000 
genomes 
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1000 
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ASN_MAF 
1000 
genomes 
EUR_MAF 
63 10190458 rs189039866 0.0035 0.0018 C:0.0018 - - - C:0.01 
64 10190467 rs1642743 0.3601 0.399 C:0.3990 T:0.30 T:0.57 T:0.78 T:0.67 
65 10190577 rs2600006 0.4755 0.3719 A:0.3719 A:0.36 A:0.41 A:0.22 A:0.48 
66 10190661 rs2600005 0.1573 0.2456 A:0.2456 G:0.49 G:0.74 G:0.85 G:0.86 
67 10190753 rs116127341 0.0175 0.0275 A:0.0275 A:0.0020 A:0.04 - A:0.06 
68 10191219 rs1703153 0.3182 0.4077 C:0.4077 G:0.22 G:0.58 G:0.77 G:0.70 
69 10191377 rs116128787 0.0035 0.138 A:0.0115 A:0.04 A:0.01 - - 
70 10191943 rs1642742 0.3182 0.4073 G:0.4073 A:0.22 A:0.58 A:0.77 A:0.70 
71 10192672 rs1681669 0.3182 0.3866 G:0.3866 A:0.31 A:0.58 A:0.77 A:0.70 
72 10192709 rs1681668 0.3182 0.4054 C:0.4054 T:0.22 T:0.59 T:0.77 T:0.71 
73 10192762 rs1642741 0.1503 0.1244 T:0.1244 C:0.92 C:0.81 C:0.87 C:0.88 
74 10193509 rs458106 0.0140 0.0161 A:0.0161 G:0.99 G:0.96 - G:0.98 
75 10193622 rs149248243 0.0035 0.12 Not 
available 
Not 
available 
Not 
available 
Not 
available 
Not 
available 
76 10193683 rs1136249 0.3217 0.4169 T:0.4169 G:0.18 G:0.57 G:0.77 G:0.71 
77 10193789 rs140614750 0.0175 0.1468 T:0.1129 T:0.41 T:0.04 T:0.03 T:0.02 
78 10194243 rs191582744 0.0070 0.0264 A:0.0078 A:0.0020 A:0.0028 A:0.03 - 
79 10194249 rs142728549 0.0245 0.0471 A:0.0482 A:0.01 A:0.15 - A:0.06 
80 10194624 rs801913 0.1469 0.1134 G:0.1134 C:0.97 C:0.81 C:0.87 C:0.88 
81 10195172 rs17610448 0.0210 0.0128 G:0.0184 G:0.0041 G:0.06 - G:0.02 
82 10195252 rs145137834 0.0070 0.002 T:0.0028 - - - T:0.01 
83 11128507 rs11128507 0.0105 0.0771 A:0.0661 A:0.25 A:0.03 - A:0.02 
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Table 7.3 Artefacts excluded from further analysis during NGS screening of the VHL gene region 
Chromosome location, variant call and possible explanation for false call, with reasoning behind exclusion from further analysis. 
Number Chromosome 
position - 
Start 
Nucleotide change Likely cause of 
false call 
Details 
1 10179447 c.[-4085G>T];[=] Artefact Low percentage reads, all samples within 1 or more 
runs 
2 10179534 c.[-3998A>T];[=] Artefact Low percentage reads, all samples within 1 or more 
runs 
3 10179541 c.-3992_-3991insT;c.-3991_-3990delTT Local 
homopolymer 
Internal to homopolymer 
4 10179552 c.-3980_-3979delTT Local 
homopolymer 
Internal to homopolymer 
5 10179554 c.-3979_-3978insT Local 
homopolymer 
Internal to homopolymer 
6 10179860 c.[-3672T>C];[=] Artefact Low percentage reads, all samples within 1 or more 
runs 
7 10179901 c.[-3631T>C];[=] Artefact Low percentage reads, all samples within 1 or more 
runs 
8 10181322 c.[-2210A>T];[=] Artefact Low percentage reads, all samples within 1 or more 
runs 
9 10181331 c.[-2201A>C];[=] Artefact Low percentage reads, all samples within 1 or more 
runs 
10 10181334 c.-2199_-2198insT;c.-2198_-2197delTT Local 
homopolymer 
Internal to homopolymer 
11 10181334 c.-2199_-2198insT;c.-2198delT Local 
homopolymer 
Internal to homopolymer 
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Number Chromosome 
position - 
Start 
Nucleotide change Likely cause of 
false call 
Details 
12 10181345 c.-2187_-2186delTT Local 
homopolymer 
Internal to homopolymer 
13 10181346 c.-2186delT Local 
homopolymer 
Internal to homopolymer 
14 10181347 c.-2186_-2185insT Local 
homopolymer 
Internal to homopolymer 
15 10182231 c.-1301_-1297delTTTTT Local 
homopolymer 
Internal to homopolymer 
16 10182231 c.-1302_-1301insT;c.-1301_-1297delTTTTT Local 
homopolymer 
Internal to homopolymer 
17 10182244 c.-1288_-1283delTTTTTT Local 
homopolymer 
Internal to homopolymer 
18 10182245 c.-1287_-1283delTTTTT Local 
homopolymer 
Internal to homopolymer 
19 10182249 c.-1283_-1282delTG Local 
homopolymer 
Adjacent to homopolymer 
20 10182250 c.-1283_-1282insT Local 
homopolymer 
Internal to homopolymer 
21 10182250 c.-1282delG Local 
homopolymer 
Internal to homopolymer 
22 10182937 c.-595delA Local 
homopolymer 
Internal to homopolymer 
23 10182937 c.-596_-595insA;c.-595delA Artefact Low percentage reads, all samples within 1 or more 
runs 
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Number Chromosome 
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Start 
Nucleotide change Likely cause of 
false call 
Details 
24 10182946 c.-586delA Local 
homopolymer 
Internal to homopolymer 
25 10182947 c.-586_-585insA Local 
homopolymer 
Internal to homopolymer 
26 10183242 c.-291_-290insA;c.-290_-289delAA Local 
homopolymer 
Internal to homopolymer 
27 10183242 c.-291_-290insA;c.-290delA Local 
homopolymer 
Internal to homopolymer 
28 10183242 c.-291_-290insA Local 
homopolymer 
Internal to homopolymer 
29 10183254 c.-278_-277delAA Local 
homopolymer 
Internal to homopolymer 
30 10183255 c.-277delA Local 
homopolymer 
Internal to homopolymer 
31 10183256 c.-277_-276insAA Local 
homopolymer 
Internal to homopolymer 
32 10183256 c.-277_-276insA;c.[-276C>A];[=] Local 
homopolymer 
Adjacent/Internal to homopolymer 
33 10183256 c.-277_-276insAA;c.[-276C>A];[=] Local 
homopolymer 
Adjacent/Internal to homopolymer 
34 10183256 c.-277_-276insA Local 
homopolymer 
Internal to homopolymer 
35 10184026 c.340+154_340+155insT;c.340+155_340+156delTT Local 
homopolymer 
Internal to homopolymer 
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position - 
Start 
Nucleotide change Likely cause of 
false call 
Details 
36 10184026 c.340+154_340+155insTT;c.340+155delT Local 
homopolymer 
Internal to homopolymer 
37 10184026 c.340+154_340+155insT Local 
homopolymer 
Internal to homopolymer 
38 10184026 c.340+154_340+155insTT Local 
homopolymer 
Internal to homopolymer 
39 10184026 c.340+154_340+155insT;c.340+155delT Local 
homopolymer 
Internal to homopolymer 
40 10184026 c.340+154_340+155insT;c.340+155_340+157delTTT Local 
homopolymer 
Internal to homopolymer 
41 10184044 c.340+173_340+174delTT Artefact Low percentage reads, all samples within 1 or more 
runs 
42 10184045 c.340+174delT Local 
homopolymer 
Internal to homopolymer 
43 10184046 c.340+174_340+175insT Local 
homopolymer 
Internal to homopolymer 
44 10184046 c.340+174_340+175insTT Local 
homopolymer 
Internal to homopolymer 
45 10184046 c.340+174_340+175insTT;c.[340+175C>T];[=] Local 
homopolymer 
Adjacent/Internal to homopolymer 
46 10184046 c.340+174_340+175insT;c.[340+175C>T];[=] Local 
homopolymer 
Adjacent/Internal to homopolymer 
47 10184046 c.[340+175C>T];[=]  Artefact Low percentage reads, all samples within 1 or more 
runs 
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Start 
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false call 
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48 10184047 c.[340+176T>G];[=] Artefact Low percentage reads, all samples within 1 or more 
runs 
49 10184049 c.[340+178A>G];[=] Artefact Low percentage reads, all samples within 1 or more 
runs 
50 10184055 c.[340+184A>G];[=] Artefact Low percentage reads, all samples within 1 or more 
runs 
51 10184059 c.[340+188T>C];[=] Artefact Low percentage reads, all samples within 1 or more 
runs 
52 10184063 c.[340+192T>C];[=] Artefact Low percentage reads, all samples within 1 or more 
runs 
53 10184100 c.[340+229A>G];[=] Artefact Low percentage reads, all samples within 1 or more 
runs 
54 10184123 c.[340+252G>T];[=] Artefact Low percentage reads, all samples within 1 or more 
runs 
55 10184126 c.[340+255T>C];[=] Artefact Low percentage reads, all samples within 1 or more 
runs 
56 10184182 c.[340+311A>C];[=] Artefact Low percentage reads, all samples within 1 or more 
runs 
57 10184227 c.[340+356A>C];[=] Artefact Low percentage reads, all samples within 1 or more 
runs 
58 10184259 c.[340+388A>C];[=] Artefact Low percentage reads, all samples within 1 or more 
runs 
59 10184263 c.[340+392C>G];[=] Artefact Low percentage reads, all samples within 1 or more 
runs 
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false call 
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60 10184268 c.[340+397T>C];[=] Artefact Low percentage reads, all samples within 1 or more 
runs 
61 10184802 c.340+930_340+931insT;c.340+931_340+932delTT Local 
homopolymer 
Internal to homopolymer 
62 10184802 c.340+930_340+931insT;c.340+931delT Local 
homopolymer 
Internal to homopolymer 
63 10184815 c.340+944_340+945delTT Local 
homopolymer 
Internal to homopolymer 
64 10184816 c.340+945delT Local 
homopolymer 
Internal to homopolymer 
65 10184817 c.340+945_340+946insT Local 
homopolymer 
Internal to homopolymer 
66 10184982 c.340+1111delT Local 
homopolymer 
Internal to homopolymer 
67 10184982 c.340+1110_340+1111insT;c.340+1111delT Local 
homopolymer 
Internal to homopolymer 
68 10184991 c.340+1120delT Local 
homopolymer 
Internal to homopolymer 
69 10184992 c.340+1120_340+1121insT Local 
homopolymer 
Internal to homopolymer 
70 10185056 c.[340+1185A>C];[=] Artefact Low percentage reads, all samples within 1 or more 
runs 
71 10185990 c.340+2118_340+2119insA;c.340+2119delA Local 
homopolymer 
Internal to homopolymer 
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Nucleotide change Likely cause of 
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72 10185990 c.340+2118_340+2119insA Local 
homopolymer 
Internal to homopolymer 
73 10186003 c.340+2132delA Local 
homopolymer 
Internal to homopolymer 
74 10186004 c.340+2132_340+2133insA Local 
homopolymer 
Internal to homopolymer 
75 10186181 c.341-2018_341-2017insT;c.341-2017_341-2015delTTT Local 
homopolymer 
Internal to homopolymer 
76 10186181 c.341-2018_341-2017insT;c.341-2017_341-2016delTT Local 
homopolymer 
Internal to homopolymer 
77 10186181 c.341-2018_341-2017insT;c.341-2017delT Local 
homopolymer 
Internal to homopolymer 
78 10186197 c.341-2001_341-2000delTT Local 
homopolymer 
Internal to homopolymer 
79 10186198 c.341-2000delT Local 
homopolymer 
Internal to homopolymer 
80 10186199 c.341-2000_341-1999insT Local 
homopolymer 
Internal to homopolymer 
81 10187161 c.[341-1037G>A];[=] Artefact Low percentage reads, all samples within 1 or more 
runs 
82 10187167 c.[341-1031A>G];[=] Artefact Low percentage reads, all samples within 1 or more 
runs 
83 10187172 c.[341-1026A>G];[=] Artefact Low percentage reads, all samples within 1 or more 
runs 
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84 10187175 c.[341-1023A>G];[=] Artefact Low percentage reads, all samples within 1 or more 
runs 
85 10187299 c.[341-899A>G];[=] Artefact Low percentage reads, all samples within 1 or more 
runs 
86 10187346 c.[341-852T>C];[=] Artefact Low percentage reads, all samples within 1 or more 
runs 
87 10187368 c.[341-830C>T];[=] Artefact Low percentage reads, all samples within 1 or more 
runs 
88 10187390 c.341-809_341-808insA;c.341-808_341-807delAA Local 
homopolymer 
Internal to homopolymer 
89 10187390 c.341-809_341-808insA;c.341-808delA Local 
homopolymer 
Internal to homopolymer 
90 10187402 c.341-796_341-795delAA Local 
homopolymer 
Internal to homopolymer 
91 10187403 c.341-795delA Local 
homopolymer 
Internal to homopolymer 
92 10187404 c.341-795_341-794insA Local 
homopolymer 
Internal to homopolymer 
93 10187858 c.341-341_341-340insT;c.341-340_341-339delTT Local 
homopolymer 
Internal to homopolymer 
94 10187858 c.341-341_341-340insT;c.341-340_341-338delTTT Local 
homopolymer 
Internal to homopolymer 
95 10187872 c.341-326_341-324delTTT Local 
homopolymer 
Internal to homopolymer 
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96 10187873 c.341-325_341-324delTT Local 
homopolymer 
Internal to homopolymer 
97 10187875 c.341-324_341-323insT Local 
homopolymer 
Internal to homopolymer 
98 10187883 c.[341-315A>G];[=] Artefact Low percentage reads, all samples within 1 or more 
runs 
99 10187897 c.[341-301A>G];[=] Artefact Low percentage reads, all samples within 1 or more 
runs 
100 10188986 c.[463+666A>C];[=] Artefact Low percentage reads, all samples within 1 or more 
runs 
101 10189013 c.[463+693A>C];[=] Artefact Low percentage reads, all samples within 1 or more 
runs 
102 10189044 c.463+723_463+724insT;c.463+724_463+725delTT Local 
homopolymer 
Internal to homopolymer 
103 10189044 c.463+724delT Local 
homopolymer 
Internal to homopolymer 
104 10189044 c.463+723_463+724insT;c.463+724delT Local 
homopolymer 
Internal to homopolymer 
105 10189056 c.463+736_463+737delTT Local 
homopolymer 
Internal to homopolymer 
106 10189056 c.[463+736T>A];[=] Local 
homopolymer 
Internal to homopolymer 
107 10189057 c.[463+737T>A];[=] Local 
homopolymer 
Adjacent to homopolymer 
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108 10189058 c.463+737_463+738insTA Local 
homopolymer 
Internal to homopolymer 
109 10189058 c.463+737_463+738insA Local 
homopolymer 
Internal to homopolymer 
110 10189059 c.463+738_463+739insA Local 
homopolymer 
Internal to homopolymer 
111 10189296 c.[463+976A>C];[=] Artefact Low percentage reads, all samples within 1 or more 
runs 
112 10189351 c.463+1030_463+1031insT;c.463+1031_463+1032delTT Local 
homopolymer 
Internal to homopolymer 
113 10189364 c.463+1044_463+1045delTT Local 
homopolymer 
Internal to homopolymer 
114 10189366 c.463+1045_463+1046insT Local 
homopolymer 
Internal to homopolymer 
115 10189554 c.[463+1234T>G];[=] Artefact Low percentage reads, all samples within 1 or more 
runs 
116 10189560 c.[463+1240G>T];[=] Artefact Low percentage reads, all samples within 1 or more 
runs 
117 10189566 c.[463+1246A>C];[=] Artefact Low percentage reads, all samples within 1 or more 
runs 
118 10189569 c.[463+1249A>G];[=] Artefact Low percentage reads, all samples within 1 or more 
runs 
119 10189571 c.[463+1251T>G];[=] Artefact Low percentage reads, all samples within 1 or more 
runs 
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120 10189587 c.[463+1267A>G];[=] Artefact Low percentage reads, all samples within 1 or more 
runs 
121 10189611 c.[463+1291A>C];[=] Artefact Low percentage reads, all samples within 1 or more 
runs 
122 10189788 c.463+1467_463+1468insA;c.463+1468delA Local 
homopolymer 
Internal to homopolymer 
123 10189797 c.463+1477delA Local 
homopolymer 
Internal to homopolymer 
124 10189798 c.463+1477_463+1478insA Local 
homopolymer 
Internal to homopolymer 
125 10189999 c.[464-1472C>T];[=] Artefact Low percentage reads, all samples within 1 or more 
runs 
126 10190000 c.464-1472_464-1471insT;c.464-1471_464-1470delTT Local 
homopolymer 
Internal to homopolymer 
127 10190000 c.464-1472_464-1471insT;c.464-1471_464-1469delTTT Local 
homopolymer 
Internal to homopolymer 
128 10190014 c.464-1457_464-1455delTTT Local 
homopolymer 
Internal to homopolymer 
129 10190015 c.464-1456_464-1455delTT Local 
homopolymer 
Internal to homopolymer 
130 10190016 c.464-1455delT Local 
homopolymer 
Internal to homopolymer 
131 10190017 c.464-1455_464-1454insT Local 
homopolymer 
Internal to homopolymer 
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132 10190063 c.[464-1408A>G];[=] Artefact Low percentage reads, all samples within 1 or more 
runs 
133 10190065 c.[464-1406C>T];[=] Artefact Low percentage reads, all samples within 1 or more 
runs 
134 10190073 c.[464-1398A>C];[=] Artefact Low percentage reads, all samples within 1 or more 
runs 
135 10190092 c.[464-1379G>A];[=] Artefact Low percentage reads, all samples within 1 or more 
runs 
136 10190095 c.[464-1376T>G];[=] Artefact Low percentage reads, all samples within 1 or more 
runs 
137 10190099 c.[464-1372C>T];[=] Artefact Low percentage reads, all samples within 1 or more 
runs 
138 10190124 c.[464-1347A>G];[=] Artefact Low percentage reads, all samples within 1 or more 
runs 
139 10190153 c.[464-1318T>C];[=] Artefact Low percentage reads, all samples within 1 or more 
runs 
140 10190153 c.[464-1318T>C];[=] Artefact Low percentage reads, all samples within 1 or more 
runs 
141 10190172 c.[464-1299G>T];[=] Artefact Low percentage reads, all samples within 1 or more 
runs 
142 10190174 c.[464-1297A>T];[=] Artefact Low percentage reads, all samples within 1 or more 
runs 
143 10190179 c.[464-1292T>A];[=] Artefact Low percentage reads, all samples within 1 or more 
runs 
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144 10190187 c.[464-1284A>C];[=] Artefact Low percentage reads, all samples within 1 or more 
runs 
145 10190192 c.[464-1279G>T];[=] Artefact Low percentage reads, all samples within 1 or more 
runs 
146 10190197 c.[464-1274A>C];[=] Artefact Low percentage reads, all samples within 1 or more 
runs 
147 10190200 c.[464-1271G>T];[=] Artefact Low percentage reads, all samples within 1 or more 
runs 
148 10190202 c.[464-1269T>G];[=] Artefact Low percentage reads, all samples within 1 or more 
runs 
149 10190209 c.[464-1262G>A];[=] Artefact Low percentage reads, all samples within 1 or more 
runs 
150 10190224 c.[464-1247T>C];[=] Artefact Low percentage reads, all samples within 1 or more 
runs 
151 10190229 c.[464-1242A>C];[=] Artefact Low percentage reads, all samples within 1 or more 
runs 
152 10190230 c.[464-1241C>G];[=] Artefact Low percentage reads, all samples within 1 or more 
runs 
153 10190234 c.[464-1237G>A];[=] Artefact Low percentage reads, all samples within 1 or more 
runs 
154 10190238 c.[464-1233T>C];[=] Artefact Low percentage reads, all samples within 1 or more 
runs 
155 10190240 c.[464-1231C>T];[=] Artefact Low percentage reads, all samples within 1 or more 
runs 
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Number Chromosome 
position - 
Start 
Nucleotide change Likely cause of 
false call 
Details 
156 10190364 c.[464-1107A>C];[=] Artefact Low percentage reads, all samples within 1 or more 
runs 
157 10190367 c.464-1105_464-1104insT;c.464-1104delT Local 
homopolymer 
Internal to homopolymer 
158 10190367 c.464-1105_464-1104insT;c.464-1104_464-1103delTT Local 
homopolymer 
Internal to homopolymer 
159 10190379 c.464-1092_464-1091delTT Local 
homopolymer 
Internal to homopolymer 
160 10190380 c.464-1091delT Local 
homopolymer 
Internal to homopolymer 
161 10190381 c.464-1091_464-1090insT Local 
homopolymer 
Internal to homopolymer 
162 10190779 c.464-693_464-692insT;c.464-692delT Local 
homopolymer 
Internal to homopolymer 
163 10190779 c.464-693_464-692insT;c.464-692_464-691delTT Local 
homopolymer 
Internal to homopolymer 
164 10190789 c.464-682_464-681delTT Local 
homopolymer 
Internal to homopolymer 
165 10190790 c.464-681delT Local 
homopolymer 
Internal to homopolymer 
166 10190791 c.464-681_464-680insT Local 
homopolymer 
Internal to homopolymer 
167 10193057 c.*1408delT Local 
homopolymer 
Internal to homopolymer 
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Number Chromosome 
position - 
Start 
Nucleotide change Likely cause of 
false call 
Details 
168 10193065 c.*1416delT Local 
homopolymer 
Internal to homopolymer 
169 10193452 c.[*1803C>A];[=] Local 
homopolymer 
Internal to homopolymer 
170 10193745 c.*2096_*2099delAAAA Local 
homopolymer 
Internal to homopolymer 
171 10193745 c.*2096_*2098delAAA Local 
homopolymer 
Internal to homopolymer 
172 10193745 c.*2095_*2096insA;c.*2096_*2098delAAA Local 
homopolymer 
Internal to homopolymer 
173 10193763 c.*2114_*2117delAAAA Local 
homopolymer 
Internal to homopolymer 
174 10193767 c.*2117_*2118insA Local 
homopolymer 
Internal to homopolymer 
175 10193816 c.[*2167T>C];[=] Artefact Low percentage reads, all samples within 1 or more 
runs 
176 10193827 c.[*2178A>G];[=] Artefact Low percentage reads, all samples within 1 or more 
runs 
177 10194054 c.*2404_*2405insA;c.*2405_*2406delAA Local 
homopolymer 
Internal to homopolymer 
178 10194067 c.*2418_*2419delAA Local 
homopolymer 
Internal to homopolymer 
179 10194069 c.*2419_*2420insA Local 
homopolymer 
Internal to homopolymer 
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Number Chromosome 
position - 
Start 
Nucleotide change Likely cause of 
false call 
Details 
180 10194137 c.[*2488C>T];[=] Artefact Low percentage reads, all samples within 1 or more 
runs 
181 10194140 c.[*2491C>T];[=] Artefact Low percentage reads, all samples within 1 or more 
runs 
182 10194151 c.[*2502A>T];[=] Artefact Low percentage reads, all samples within 1 or more 
runs 
183 10194160 c.[*2511A>T];[=] Artefact Low percentage reads, all samples within 1 or more 
runs 
184 10194163 c.[*2514G>T];[=] Local 
homopolymer 
Internal to homopolymer 
185 10194165 c.[*2516C>T];[=] Artefact Low percentage reads, all samples within 1 or more 
runs 
186 10194166 c.*2517_*2521delTTTTT Local 
homopolymer 
Internal to homopolymer 
187 10194166 c.*2517_*2520delTTTT Local 
homopolymer 
Internal to homopolymer 
188 10194166 c.*2517_*2519delTTT Local 
homopolymer 
Internal to homopolymer 
189 10194186 c.*2537_*2545delTTTTTTTTT Local 
homopolymer 
Internal to homopolymer 
190 10194187 c.*2538_*2545delTTTTTTTT Local 
homopolymer 
Internal to homopolymer 
191 10194188 c.*2539_*2545delTTTTTTT Local 
homopolymer 
Internal to homopolymer 
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Number Chromosome 
position - 
Start 
Nucleotide change Likely cause of 
false call 
Details 
192 10194195 c.*2546delG Local 
homopolymer 
Internal to homopolymer 
193 10194197 c.[*2548G>A];[=] Local 
homopolymer 
Internal to homopolymer 
194 10194409 c.[*2760T>C];[=] Artefact Low percentage reads, all samples within 1 or more 
runs 
195 10194726 c.[*3077C>T];[=] Artefact Low percentage reads, all samples within 1 or more 
runs 
196 10194727 c.[*3078T>G];[=] Artefact Low percentage reads, all samples within 1 or more 
runs 
197 10194731 c.[*3082C>T];[=] Artefact Low percentage reads, all samples within 1 or more 
runs 
198 10194735 c.[*3086T>G];[=] Artefact Low percentage reads, all samples within 1 or more 
runs 
199 10194743 c.[*3094G>A];[=] Local 
homopolymer 
Adjacent to homopolymer 
200 10194827 c.[*3178T>G];[=] Artefact Low percentage reads, all samples within 1 or more 
runs 
201 10194830 c.[*3181T>G];[=] Artefact Low percentage reads, all samples within 1 or more 
runs 
202 10194962 c.*3312_*3313insA;c.*3313delA Local 
homopolymer 
Internal to homopolymer 
203 10194972 c.*3323delA Local 
homopolymer 
Internal to homopolymer 
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Number Chromosome 
position - 
Start 
Nucleotide change Likely cause of 
false call 
Details 
204 10194973 c.*3323_*3324insA Local 
homopolymer 
Internal to homopolymer 
205 10195007 c.[*3358C>G];[=] Artefact Low percentage reads, all samples within 1 or more 
runs 
206 10195026 c.[*3377T>A];[=] Artefact Low percentage reads, all samples within 1 or more 
runs 
207 10195032 c.[*3383G>T];[=] Artefact Low percentage reads, all samples within 1 or more 
runs 
208 10195133 c.*3483_*3484insA;c.*3484delA Local 
homopolymer 
Internal to homopolymer 
209 10195142 c.*3493delA Local 
homopolymer 
Internal to homopolymer 
210 10195143 c.*3493_*3494insA Local 
homopolymer 
Internal to homopolymer 
211 10195307 c.*3658_*3659delTT Local 
homopolymer 
Internal to homopolymer 
212 10195309 c.*3659_*3660insT Local 
homopolymer 
Internal to homopolymer 
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7.3 Chapter 5 Appendices 
 
Table 7.4 Tabulated view of splicing images using Alamut as an interface to interrogate 
five splicing algorithms 
FLCN c.715C>T p.(Arg239Cys)
 
FLCN c.1333G>A p.(Ala445Thr)
 
  
261 
 
FLCN c.*4G>A
 
MAX c.425C>T p.(Ser142Leu)
 
MET c.3356G>C p.(Gly1119Ala)
 
  
262 
 
SDHA c.136A>G p.(Lys46Glu)
 
SDHA c.1002G>A p.(=)
 
SDHA c.923C>T p.(Thr308Met)
 
  
263 
 
SDHA c.1273G>A p.(Val425Met)
 
SDHA c.1338delA p.(His447Metfs*23)
 
SDHA c.1623G>A p.(=)
  
264 
 
SDHAF2 c.319C>T p.(Arg107Cys)
 
SDHB c.32G>A p.(Arg11His)
 
SDHB c.487T>C p.(Ser163Pro)
 
  
265 
 
SDHC c.-118_-117delAG
 
SDHC c.148C>T p.(Arg50Cys)
 
SDHC c.214C>T p.(Arg72Cys)
 
  
266 
 
SDHC c.380A>G p.(His127Arg)
 
SDHD c.34G>A p.(Gly12Ser)
 
TMEM127 c.268G>A p.(Val90Met)
 
  
267 
 
TMEM127 c.411T>A p.(=)
 
TMEM127 c.534C>T p.(=)
 
VHL c.-3933C>T  
No prediction available 
 
 
VHL c.-3197_-3195delCTC  
No prediction available 
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VHL c.-963G>A
 
VHL c.183C>G p.(Pro61Pro)
 
VHL c.242C>T p.(Pro81Leu)
 
  
269 
 
VHL c.338G>A p.(Arg113Gln)
 
VHL c.340+203G>A
 
VHL c.340+280T>G
  
270 
 
VHL c.340+376C>A
  
VHL c.341-123G>T
 
VHL c.341-21_341-17delAACCT
  
271 
 
VHL c.361G>C p.(Asp121His)
 
VHL c.463+8C>T
 
VHL c.464-10G>A
  
272 
 
VHL c.464-1434C>T
 
VHL c.464-1530C>T
 
VHL c.554A>G p.(Tyr185Cys)
 
  
273 
 
VHL c.629G>A p.(Arg210Gln)
 
VHL c.639T>C p.(Asp213Asp)
 
VHL c.*820A>G
 
  
274 
 
VHL c.*2511A>G
 
VHL c.*3021T>C
 
VHL c.*3082C>T
 
  
275 
 
VHL c.*3170G>A
  
VHL c.*3482dupA
 
276 
 
Table 7.5 Calculations for comparison of predicted cryptic splice site scores for sequence variants to average true splice site scores 
A summary of these calculations are found in Table 5.31 
Gene SDHD TMEM127 VHL VHL VHL 
Variant (coding DNA) c.[34G>A];[=] c.[534C>T];[=] c.[183C>G];[=] c.[629G>A];[=] c.[*3082C>T];[=] 
Variant (protein) p.(Gly12Ser) p.(=) p.(Pro61Pro) p.(Arg210Gln)   
Prediction 3' Acceptor 
created 
3' Acceptor 
created 
5' Donor 
created 
3' Acceptor 
created 
5' Donor created 
Variant scores SSF 0.0 81.3 0.0 73.7 81.4 
MES 1.9 4.0 1.6 3.7 5.6 
NNS 0.0 0.0 0.0 0.0 0.7 
GS 0.0 2.9 2.2 0.0 0.0 
HSF 85.3 85.1 71.0 80.3 88.5 
Average scores of real 
splice sites (5' or 3' as 
appropriate) 
SSF 84.3 77.7 83.5 76.5 83.5 
MES 7.5 7.8 10.7 9.2 10.7 
NNS 1.0 0.7 0.9 0.9 0.9 
GS 7.2 8.7 9.1 6.7 9.1 
HSF 87.8 84.8 87.7 82.2 87.7 
Average scores less 
two standard 
deviations of real 
splice sites (5' or 3' as 
appropriate) 
SSF 70.5 60.0 63.3 67.5 63.3 
MES 2.3 2.4 8.6 5.4 8.6 
NNS 0.9 -0.5 0.6 0.6 0.6 
GS 3.8 4.2 -10.0 5.1 -10.0 
HSF 79.6 70.8 67.2 80.4 67.2 
Variant score greater 
than average less 2SD 
of real sites 
SSF NO YES NO YES YES 
MES NO YES NO NO NO 
NNS NO YES NO NO YES 
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Gene SDHD TMEM127 VHL VHL VHL 
Variant (coding DNA) c.[34G>A];[=] c.[534C>T];[=] c.[183C>G];[=] c.[629G>A];[=] c.[*3082C>T];[=] 
Variant (protein) p.(Gly12Ser) p.(=) p.(Pro61Pro) p.(Arg210Gln)   
Prediction 3' Acceptor 
created 
3' Acceptor 
created 
5' Donor 
created 
3' Acceptor 
created 
5' Donor created 
GS NO NO YES NO YES 
HSF YES YES YES NO YES 
Number of algorithms for which variant 
score is equal to or greater than the 
average scores less 2SDs of the real 
splice site of that type for that gene 
1 of 5 4 of 5 2 of 5 1 of 5 4 of 5 
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